Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2R)-N4-hydroxy-2-(3-hydroxybenzyl)-N1-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide
-
(2S,3R)-2-[(cyclopropylmethyl)amino]-N1-hydroxy-N4-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-methylbutanediamide
-
(2Z,5E)-2-(1,2-benzothiazol-3-ylimino)-5-(2-methoxybenzylidene)-1,3-thiazolidin-4-one
-
(2Z,5E)-2-(1,2-benzothiazol-3-ylimino)-5-(3-methoxybenzylidene)-1,3-thiazolidin-4-one
-
(3S,3'S)-astaxanthin
i.e. 3S,3S-dihydoxy-beta, beta-carotene-4,4-dione, active metabolite of some soft drugs, binds to enzyme at or near active site
(E)-2-(4-(2-(biphenyl-4-yl)vinyl)-N-isopropoxyphenylsulfonamido)-N-hydroxyacetamide
-
(R)-2-(4'-(4-chlorobenzyloxy)-N-isopropoxybiphenyl-4-ylsulfonamido)-N-hydroxy-3-methylbutanamide
-
2-(4'-(4-chlorobenzyloxy)-N-isopropoxybiphenyl-4-ylsulfonamido)-N-hydroxyacetamide
-
2-(4'-butoxy-N-isopropoxybiphenyl-4-ylsulfonamido)-N-hydroxyacetamide
-
2-(5-((4-butylphenyl)ethynyl)-N-isopropoxythiophene-2-sulfonamido)-N-hydroxyacetamide
-
2-(5-(4-ethylphenyl)-N-isopropoxythiophene-2-sulfonamido)-N-hydroxyacetamide
-
2-(5-(4-fluorophenyl)-N-isopropoxythiophene-2-sulfonamido)-N-hydroxyacetamide
-
2-(benzo[d]isothiazol-3-ylimino)-5-(4-methoxybenzylidene)thiazolidin-4-one
potent and selective MMP-13 inhibitor
4-([(2-([(3-methoxyphenyl)methyl]carbamoyl)-4-oxo-3H,4H-thieno[2,3-d]pyrimidin-5-yl)methoxy]methyl)benzoic acid
highly potent and selective MMP-13 inhibitor. Compound shows shows more than 2600fold selectivity over the other related metalloenzymes. The disodium salt formulation is well absorbed in all species tested at the oral dose of 10-20 mg/kg. Compound is active in in bovine nasal cartilage explants assay
4-([5-[2-(benzylcarbamoyl)-6-methylpyridin-4-yl]-2H-tetrazol-2-yl]methyl)benzoic acid
-
4-([5-[2-(benzylcarbamoyl)-6-methylpyridin-4-yl]-2H-tetrazol-2-yl]methyl)cyclohexanecarboxylic acid
-
4-([6-[(4-methoxybenzyl)carbamoyl]-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl]methyl)benzoic acid
-
4-oxo-N-[[40-([[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]sulfonyl]methyl)biphenyl-3-yl]methyl]-3,4-dihydroquinazoline-2-carboxamide
compound exhibits excellent potency and selectivity (greater than 170fold) over MMP1, 2, 3, 7, 8, 9, 10, 12, and 14 and tumor necrosis factor-alpha converting enzyme
4-[(5-[2-[(3,4-difluorobenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]benzoic acid
-
4-[(5-[2-[(3,4-difluorobenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]cyclohexanecarboxylic acid
-
4-[(5-[2-[(3,4-difluorobenzyl)carbamoyl]pyridin-4-yl]-2H-tetrazol-2-yl)methyl]benzoic acid
-
4-[(5-[2-[(3-chloro-4-fluorobenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]cyclohexanecarboxylic acid
-
4-[(5-[2-[(3-chlorobenzyl)carbamoyl]pyridin-4-yl]-2H-tetrazol-2-yl)methyl]benzoic acid
-
4-[(5-[2-[(3-cyanobenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]cyclohexanecarboxylic acid
-
4-[(5-[2-[(3-fluorobenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]benzoic acid
-
4-[(5-[2-[(3-fluorobenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]cyclohexanecarboxylic acid
-
4-[(5-[2-[(3-fluorobenzyl)carbamoyl]pyridin-4-yl]-2H-tetrazol-2-yl)methyl]benzoic acid
-
4-[(5-[2-[(3-hydroxybenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]cyclohexanecarboxylic acid
-
4-[(5-[2-[(3-methoxybenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]benzoic acid
-
4-[(5-[2-[(3-methoxybenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]cyclohexanecarboxylic acid
-
4-[(5-[2-[(3-methoxybenzyl)carbamoyl]pyridin-4-yl]-2H-tetrazol-2-yl)methyl]benzoic acid
-
4-[(5-[2-[(4-chlorobenzyl)carbamoyl]pyridin-4-yl]-2H-tetrazol-2-yl)methyl]benzoic acid
-
4-[(5-[2-[(4-fluoro-3-hydroxybenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]cyclohexanecarboxylic acid
-
4-[(5-[2-[(4-fluoro-3-methoxybenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]cyclohexanecarboxylic acid
-
4-[(5-[2-[(4-fluoro-3-methylbenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]cyclohexanecarboxylic acid
-
4-[(5-[2-[(4-fluorobenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]benzoic acid
-
4-[(5-[2-[(4-fluorobenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]cyclohexanecarboxylic acid
-
4-[(5-[2-[(4-fluorobenzyl)carbamoyl]pyridin-4-yl]-2H-tetrazol-2-yl)methyl]benzoic acid
-
4-[(5-[2-[(4-methoxybenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]benzoic acid
-
4-[(5-[2-[(4-methoxybenzyl)carbamoyl]-6-methylpyridin-4-yl]-2H-tetrazol-2-yl)methyl]cyclohexanecarboxylic acid
-
4-[(5-[2-[(4-methoxybenzyl)carbamoyl]pyridin-4-yl]-2H-tetrazol-2-yl)methyl]benzoic acid
-
4-[([3-[(3-methoxybenzyl)carbamoyl]benzoyl]amino)methyl]benzoic acid
-
4-[([3-[2-(3-methoxybenzyl)-2H-tetrazol-5-yl]benzoyl]amino)methyl]benzoic acid
-
4-[([3-[2-(4-methoxybenzyl)-2H-tetrazol-5-yl]benzoyl]amino)methyl]benzoic acid
-
4-[2-([6-fluoro-2-[([[3-(methyloxy)phenyl]methyl]amino)-carbonyl]-4-oxo-3,4-dihydroquinazolin-5-yl]oxy)ethyl]-benzoic acid
inhibitor exhibits excellent potency and selectivity for MMP-13 over other MMPs. No overt toxicity is observed in a preliminary repeat dose oral toxicity study of compound in rats. A single oral dose of the monosodium salt significantly reduces degradation products released from articular cartilage into the joint cavity in a rat MIA model in vivo
4-[[1-methyl-2,4-dioxo-6-(3-phenylprop-1-yn-1-yl)-1,4-dihydroquinazolin-3(2H)-yl]methyl]benzoic acid
-
4-[[5-(2-methyl-6-[[3-(propan-2-yloxy)benzyl]carbamoyl]pyridin-4-yl)-2H-tetrazol-2-yl]methyl]cyclohexanecarboxylic acid
-
4-[[5-(2-methyl-6-[[3-(trifluoromethyl)benzyl]carbamoyl]pyridin-4-yl)-2H-tetrazol-2-yl]methyl]benzoic acid
-
4-[[5-(2-[[3-(trifluoromethyl)benzyl]carbamoyl]pyridin-4-yl)-2H-tetrazol-2-yl]methyl]benzoic acid
-
4-[[5-(2-[[4-fluoro-3-(trifluoromethyl)benzyl]carbamoyl]-6-methylpyridin-4-yl)-2H-tetrazol-2-yl]methyl]cyclohexanecarboxylic acid
-
cilostazol
docking-based screening of existing drugs and binding free-energy calculation suggests eltrombopag, cilostazol and domperidone as potential MMP-13 inhibitors
domperidone
docking-based screening of existing drugs and binding free-energy calculation suggests eltrombopag, cilostazol and domperidone as potential MMP-13 inhibitors
eltrombopag
docking-based screening of existing drugs and binding free-energy calculation suggests eltrombopag, cilostazol and domperidone as potential MMP-13 inhibitors
hydroxamic acid inhibitor CGS 27023
hydroxamic acid inhibitor WAY-151693
complex formation with the catalytic fragment of the enzyme
marimastat
the intact peptide backbone scaffold is optimum to fix the inhibitor into the rigid environment of the MMP13 binding site
N,N'-bis(3-methoxybenzyl)benzene-1,3-dicarboxamide
-
N,N'-bis(3-methylbenzyl)pyrimidine-4,6-dicarboxamide
50% inhibition at 72 nM
N,N'-bis(4-fluoro-3-methylbenzyl)pyrimidine-4,6-dicarboxamide
50% inhibition at 8 nM
N,N'-bis(pyridin-3-ylmethyl)pyrimidine-4,6-dicarboxamide
N,N'-dibenzylpyrimidine-4,6-dicarboxamide
50% inhibition at 400 nM
N-(3-methoxybenzyl)-4-oxo-3,4-dihydroquinazoline-2-carboxamide
lead compound for the development of thieno[2,3-d]pyrimidine-2-carboxamide inhibitors
N-hydroxy-2-(N-isopropoxy-4'-(methylthio)biphenyl-4-ylsulfonamido)acetamide
-
N-hydroxy-2-(N-isopropoxy-4'-methoxybiphenyl-4-ylsulfonamido)acetamide
-
N-hydroxy-2-(N-isopropoxy-4-phenoxyphenylsulfonamido)-acetamide
-
N-hydroxy-2-(N-isopropoxy-5-(4-methoxyphenyl)thiophene-2-sulfonamido)acetamide
-
N2,N5-bis(3-methylbenzyl)-6-oxo-1,6-dihydropyrimidine-2,5-dicarboxamide
compound shows about 75fold selectivity over metalloproteases MMP3, MMP12
N2,N5-bis(4-fluoro-3-methylbenzyl)-6-oxo-1,6-dihydropyrimidine-2,5-dicarboxamide
compound shows about 65fold and 47fold selectivity over metalloproteases MMP3, MMP12, respectively
N2-(biphenyl-4-ylsulfonyl)-N-hydroxy-N2-(2-methylpropyl)glycinamide
-
N2-(biphenyl-4-ylsulfonyl)-N-hydroxy-N2-(propan-2-yloxy)-L-valinamide
-
N2-(biphenyl-4-ylsulfonyl)-N-hydroxy-N2-(propan-2-yloxy)glycinamide
-
N2-(biphenyl-4-ylsulfonyl)-N-hydroxyglycinamide
-
N2-({4'-[(4-chlorobenzyl)oxy]biphenyl-4-yl}sulfonyl)-N-hydroxy-N2-(propan-2-yloxy)glycinamide
-
(2R)-N,3-dihydroxy-2-[(3-methylbutyl)(naphthalen-2-ylsulfonyl)amino]propanamide
-
-
(2R)-N-hydroxy-2-[(3-methylbutyl)(naphthalen-2-ylsulfonyl)amino]-2-(tetrahydro-2H-pyran-4-yl)ethanamide
-
-
(2R)-N-hydroxy-3-methyl-2-[(naphthalen-2-ylsulfonyl)amino]butanamide
-
-
(2R)-N-hydroxy-3-methyl-2-[methyl(naphthalen-2-ylsulfonyl)amino]butanamide
-
-
(2R)-N-hydroxy-4-(4-hydroxyphenyl)-2-[(3-methylbutyl)(naphthalen-2-ylsulfonyl)amino]butanamide
-
-
(2R)-[1-(tert-butoxycarbonyl)piperidin-4-yl][([5-[4-(dimethylamino)phenyl]thiophen-2-yl]sulfonyl)amino]ethanoic acid
-
-
(2R,3R)-4-[[4-(2-chloro-4-fluorophenoxy)phenyl]sulfonyl]-N,2-dihydroxy-2-methylmorpholine-3-carboxamide
-
-
(2R,4S)-1-((4-[(2-chlorobenzyl)oxy]phenyl)sulfonyl)-N,4-dihydroxypiperidine-2-carboxamide
-
i.e. rTACE, 50% inhibition at 12 nM
(2S,3R)-1-acetyl-N-hydroxy-2-methyl-4-[[4-(2-methylbenzyl)phenyl]sulfonyl]piperidine-3-carboxamide
-
-
(3S)-N,3-dihydroxy-4-[(3'-methylbiphenyl-4-yl)sulfonyl]tetrahydro-2H-pyran-3-carboxamide
-
50% inhibition at 0.43 nM, not inhibitory to aggrecanase
(3S)-N,3-dihydroxy-4-[(4'-methylbiphenyl-4-yl)sulfonyl]tetrahydro-2H-pyran-3-carboxamide
-
50% inhibition at 0.39 nM, not inhibitory to aggrecanase
(3S)-N,3-dihydroxy-4-[(4-(2,4-dichlorobenzoxy)phenyl)sulfonyl]tetrahydro-2H-pyran-3-carboxamide
-
50% inhibition of enzyme at 0.95 nM, 50% inhibition of aggrecanase at 8.1 nM
(3S)-N,3-dihydroxy-4-[(4-(2-chlorobenzoxy)phenyl)sulfonyl]tetrahydro-2H-pyran-3-carboxamide
-
50% inhibition at 2.7 nM
(3S)-N,3-dihydroxy-4-[(4-(3-chlorobenzoxy)phenyl)sulfonyl]tetrahydro-2H-pyran-3-carboxamide
-
50% inhibition at 2.4 nM
(3S)-N,3-dihydroxy-4-[(4-(3-methylbenzoxy)phenyl)sulfonyl]tetrahydro-2H-pyran-3-carboxamide
-
50% inhibition at 5 nM
(3S)-N,3-dihydroxy-4-[(4-(4-chlorobenzoxy)phenyl)sulfonyl]tetrahydro-2H-pyran-3-carboxamide
-
50% inhibition at 0.88 nM, selective for enzyme
(3S)-N,3-dihydroxy-4-[(4-(4-methylbenzoxy)phenyl)sulfonyl]tetrahydro-2H-pyran-3-carboxamide
-
50% inhibition at 1.3 nM
(4-[[([5-[2-(ethoxycarbonyl)-1H-indol-5-yl]-1-methyl-1H-pyrazol-3-yl]carbonyl)amino]methyl]phenyl)acetic acid
-
-
(4R)-1-[4-(4-fluorophenoxy)benzyl]-N-hydroxy-2-oxoimidazolidine-4-carboxamide
-
-
(4S)-4-[4-(4-fluorophenoxy)phenyl]-N-hydroxy-5-oxo-D-prolinamide
-
-
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-(1-cyclohexanecarbonyl-piperidin-4-yl)-acetic acid
-
-
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-(1-iso-propylcarbamoyl-piperidin-4-yl)-acetic acid
-
-
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(2,2-dimethylpropionyl)-piperidin-4-yl]-acetic acid
-
-
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(2,2-dimethylpropyl)-piperidin-4-yl]-acetic acid
-
-
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(2-methylpropane-1-sulfonyl)-piperidin-4-yl]-acetic acid
-
-
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(3,3-dimethylbutyryl)-piperidin-4-yl]-acetic acid
-
-
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(benzenesulfonyl)-piperidin-4-yl]-acetic acid
-
-
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(methane-1-sulfonyl)-piperidin-4-yl]-acetic acid
-
-
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(phenylmethanesulfonyl)-piperidin-4-yl]-acetic acid
-
-
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(propane-1-sulfonyl)-piperidin-4-yl]-acetic acid
-
-
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(propane-2-sulfonyl)-piperidin-4-yl]-acetic acid
-
-
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(tetrahydropyran-4-carbonyl)-piperidin-4-yl]-acetic acid
-
-
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-benzylpiperidin-4-yl]-acetic acid
-
-
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-iso-butylpiperidin-4-yl]-acetic acid
-
-
(R)-[5-(4'-methoxyphenyl)-thiophene-2-sulfonylamino]-(1-diethylcarbamoylpiperidin-4-yl)-acetic acid
-
-
(R)-[5-(4'-methoxyphenyl)-thiophene-2-sulfonylamino]-(1-iso-butyl-piperidin-4-yl)-acetic acid
-
-
(R)-[5-(4'-methoxyphenyl)-thiophene-2-sulfonylamino]-(1-isopropylcarbamoyl-piperidin-4-yl)-acetic acid
-
-
(R)-[5-(4'-methoxyphenyl)-thiophene-2-sulfonylamino]-(1-tertbutylcarbamoyl-piperidin-4-yl)-acetic acid
-
-
(R)-[5-(4'-methoxyphenyl)-thiophene-2-sulfonylamino]-[1-(benzenesulfonyl)-piperidin-4-yl]-acetic acid
-
-
(R)-[5-(4'-methoxyphenyl)-thiophene-2-sulfonylamino]-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-acetic acid
-
-
(R)-[5-(4-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(butane-1-sulfonyl)-piperidin-4-yl]-acetic acid
-
-
1,5-anhydro-2,3-dideoxy-3-[[4-(2,4-dichlorophenoxy)phenyl]sulfonyl]-4-C-(hydroxycarbamoyl)-D-threo-pentitol
-
-
1-(4-amino-2-methylquinolin-6-yl)-3-(4-methoxyphenyl)urea
-
-
1-(4-phenoxyphenyl)-1,7,9-triazaspiro[4.5]decane-2,6,8,10-tetrone
1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)-N,N-bis[4-(1-hydroxyethyl)piperazin-1-yl]piperidine-4-carboxamide
-
-
1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)-N,N-bis[4-(1-methoxyethyl)piperazin-1-yl]piperidine-4-carboxamide
-
-
1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)-N,N-bis[4-(2-methoxyphenyl)piperazin-1-yl]piperidine-4-carboxamide
-
-
1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)-N,N-bis[4-(2-phenylethyl)piperazin-1-yl]piperidine-4-carboxamide
-
-
1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)-N,N-bis[4-(propan-2-yl)piperazin-1-yl]piperidine-4-carboxamide
-
-
1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)-N,N-bis[4-(pyrazin-2-yl)piperazin-1-yl]piperidine-4-carboxamide
-
-
1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)-N,N-bis[4-(pyridin-2-yl)piperazin-1-yl]piperidine-4-carboxamide
-
-
1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)-N,N-bis[4-(pyridin-4-yl)piperazin-1-yl]piperidine-4-carboxamide
-
-
1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)-N,N-bis[4-(pyrimidin-4-yl)piperazin-1-yl]piperidine-4-carboxamide
-
-
1-(6-[4-[4-(4-fluorophenyl)-1,3-oxazol-2-yl]phenoxy]pyridin-3-yl)-1,7,9-triazaspiro[4.5]decane-6,8,10-trione
-
-
1-acetyl-4-hydroxypyrrolidine-2-carboxylic acid
-
binding structure, modelling, overview
1-cyclopropyl-4-[(4-[4-[(1,3-dibenzyl-1,3-dimethyltriazan-2-yl)carbonyl]piperidin-1-yl]phenyl)sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
1-cyclopropyl-4-[[4-(4-[[4-(2,3-dimethylphenyl)piperazin-1-yl]carbonyl]piperidin-1-yl)phenyl]sulfonyl]-N-hydroxypiperidine-4-carboxamide
-
-
1-cyclopropyl-N-hydroxy-4-([4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]sulfonyl)piperidine-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
1-cyclopropyl-N-hydroxy-4-[(4-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]phenyl)sulfonyl]piperidine-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
1-cyclopropyl-N-hydroxy-4-[[4-(4-phenylpiperazin-1-yl)phenyl]sulfonyl]piperidine-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
1-[4-((4-phenoxy)phenoxy)phenyl]-1,7,9-triazaspiro[4.5]decane-2,6,8,10-tetrone
-
comparison of selectivity with other matrix metalloproteinases
1-[4-(1,3-benzodioxol-5-yloxy)phenyl]-1,7,9-triazaspiro[4.5]decane-2,6,8,10-tetrone
-
comparison of selectivity with other matrix metalloproteinases
1-[4-(3-methoxyphenoxy)phenyl]-1,7,9-triazaspiro[4.5]decane-2,6,8,10-tetrone
-
comparison of selectivity with other matrix metalloproteinases
1-[4-(4-chlorophenoxy)phenyl]-1,7,9-triazaspiro[4.5]decane-2,6,8,10-tetrone
-
comparison of selectivity with other matrix metalloproteinases
2,3-dihydro-1,4-benzodioxine-2-carboxylic acid
-
binding structure, modelling, overview
2,3-dihydro-1,4-benzodioxine-5-carboxylic acid
-
binding structure, modelling, overview
2-(2-[(2-chlorobenzoyl)amino]-1,3-thiazol-4-yl)acetic acid
-
binding structure, modelling, overview
2-(ethyl[[4-(prop-1-yn-1-yloxy)phenyl]sulfonyl]amino)-5-phenylpentane(thioperox)ic O-acid
-
-
2-butanoyl-1H-indole-5-carboxamide
-
-
2-chloro-N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]pyridine-4-carboxamide
-
-
2-chloro-N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]pyrimidine-4-carboxamide
-
-
2-fluoro-N-hydroxy-6-([4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]sulfonyl)benzamide
-
-
2-fluoroisophthalic acid
-
binding structure, modelling, overview
2-[(4-chlorobenzyl)sulfanyl]-6-methylpyrimidin-4-ol
-
competitive
2-[benzyl[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3,5-dimethylbenzamide
-
WAY- 152177
2-[[(4'-chlorobiphenyl-4-yl)oxy]methyl]-N-hydroxy-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanamide
-
-
2-[[(4'-cyanobiphenyl-4-yl)oxy]methyl]-N-hydroxy-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanamide
-
-
2-[[(4'-[[(5-bromo-4-methoxy-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]methyl]-3-methylbutanoic acid
-
-
2-[[[4-(4-chlorophenoxy)phenyl]sulfonyl](methyl)amino]-N-hydroxy-3-[(4-methylpiperazin-1-yl)methyl]benzamide
-
-
3-(carboxymethyl)-2-methylenepentanedioic acid
-
binding structure, modelling, overview
3-[(4-methoxyphenyl)sulfonyl]propane-1-thiol
-
-
3-[(4-phenoxyphenyl)sulfonyl]cyclohexanethiol
-
-
3-[[4-(phenylsulfanyl)phenyl]sulfonyl]cyclohexanethiol
-
-
4'-aminobiphenyl-4-sulfonamide
-
competitive
4-((R)-carboxy-[5-[4'-(2-methoxyethoxy)-phenyl]-thiophene-2-sulfonylamino]-methyl)-piperidine-1-carboxylic acid iso-propyl ester
-
-
4-(2-cyanophenoxy)-N-(pyridin-4-ylmethyl)benzamide
-
-
4-(2-phenylethoxy)-N-(pyridin-4-ylmethyl)benzamide
-
-
4-(3-methoxy-4-nitrophenoxy)-N-(pyridin-4-ylmethyl)benzamide
-
-
4-(3-[3-[3-(3,4-difluorobenzyl)-4-oxo-3,4-dihydroquinazolin-6-yl]prop-2-yn-1-yl]phenyl)butanoic acid
-
-
4-(4-methylphenoxy)-N-(pyridin-3-ylmethyl)benzamide
-
-
4-(4-methylphenoxy)-N-(pyridin-4-ylmethyl)benzamide
-
-
4-(4-methylphenoxy)-N-[2-(pyridin-4-yl)ethyl]benzamide
-
-
4-(4-nitrophenoxy)-N-(pyridin-4-ylmethyl)benzamide
-
-
4-(4-[[(3R)-3-hydroxy-1-azabicyclo[2.2.2]oct-3-yl]ethynyl]phenoxy)-N-(pyridin-4-ylmethyl)benzamide
-
-
4-(4-[[(3R)-3-hydroxy-1-azabicyclo[2.2.2]oct-3-yl]ethynyl]phenoxy)-N-(pyrimidin-4-ylmethyl)benzamide
-
-
4-(4-[[(3S)-3-hydroxy-1-azabicyclo[2.2.2]oct-3-yl]ethynyl]phenoxy)-N-(pyridin-4-ylmethyl)benzamide
-
-
4-(4-[[(3S)-3-hydroxy-1-azabicyclo[2.2.2]oct-3-yl]ethynyl]phenoxy)-N-(pyrimidin-4-ylmethyl)benzamide
-
-
4-(benzyloxy)-N-(pyridin-4-ylmethyl)benzamide
-
-
4-([4-[(5-[[4-(dimethylamino)phenyl]amino]-5-oxopentyl)oxy]phenyl]sulfonyl)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
4-([4-[4-(2,4-dimethylphenyl)piperazin-1-yl]phenyl]sulfonyl)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
4-([4-[4-(2-chlorophenyl)piperazin-1-yl]phenyl]sulfonyl)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
4-([4-[4-(2-chlorophenyl)piperidin-1-yl]phenyl]sulfonyl)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
4-([4-[4-(2-ethoxyphenyl)piperidin-1-yl]phenyl]sulfonyl)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
4-([4-[4-(2-fluorophenyl)piperazin-1-yl]phenyl]sulfonyl)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
4-([4-[4-(4'-fluorobiphenyl-2-yl)piperidin-1-yl]phenyl]sulfonyl)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
4-([4-[4-(4-chlorophenyl)piperazin-1-yl]phenyl]sulfonyl)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
4-([4-[4-(4-chlorophenyl)piperidin-1-yl]phenyl]sulfonyl)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
4-([6-[(4-methoxybenzyl)carbamoyl]-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl]methyl)benzoic acid
-
a less potent MMP13 inhibitor
4-([[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
4-([[4-(4-fluorophenoxy)phenyl]sulfonyl]amino)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
4-methoxy-N,N'-bis(pyridin-3-ylmethyl)benzene-1,3-dicarboxamide
-
competitive
4-methoxy-N-(pyridin-4-ylmethyl)benzamide
-
-
4-phenoxy-N-(pyridin-4-ylmethyl)benzamide
-
-
4-[(4-[3-[(2,2-dimethylpentanoyl)amino]propoxy]phenyl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
4-[(4-[3-[(2,4-dimethylbenzoyl)amino]propoxy]phenyl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
4-[(4-[3-[(cyclohexylcarbonyl)amino]propoxy]phenyl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
4-[(4-[3-[4-(dimethylamino)phenyl]-3-oxopropoxy]phenyl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
4-[(4-[4-[(1,3-diethenyl-1,3-dimethyltriazan-2-yl)carbonyl]piperidin-1-yl]phenyl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
4-[(4-[4-[4-(dimethylamino)benzoyl]piperidin-1-yl]phenyl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
MMP-13 selective
4-[(4-[4-[4-(dimethylamino)phenyl]-4-oxobutoxy]phenyl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
4-[(4-[4-[bis(3,5-dimethylpiperidin-1-yl)carbamoyl]piperidin-1-yl]phenyl)sulfonyl]-N-hydroxy-1-(2-methoxyethyl)piperidine-4-carboxamide
-
-
4-[(R)-(benzofuran-2-sulfonylamino)-carboxy-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-(benzo[b]thiophene-2-sulfonylamino)-carboxy-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-(4'-dimethylamino-biphenyl-4-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-(4'-ethoxybiphenyl-4-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-(4'-fluorobiphenyl-4-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-(4'-methoxybiphenyl-4-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-(4'-methylbiphenyl-4-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-(5-phenylthiophene-2-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-(5-pyridin-2-yl-thiophene-2-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-(5-pyridin-4-yl-thiophene-2-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-[5-(3',4'-difluorophenyl)-furan-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-[5-(3',4'-methylenedioxyphenyl)-furan-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-[5-(3,4-dimethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-[5-(3-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid 1-ethyl-propyl ester
-
-
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid 4-tetrahydropyranyl ester
-
-
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid butyl ester
-
-
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid cyclohexyl ester
-
-
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid ethyl ester
-
-
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-butyl ester
-
-
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-propyl ester
-
inhibitor of MMP-13 having no activity against MMP-1 (collagenase-1) or tumor necrosis factor-R converting enzyme
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid methyl ester
-
-
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid neopentyl ester
-
-
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid propyl ester
-
-
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-[5-(4'-hydroxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-propyl ester
-
-
4-[(R)-carboxy-[5-(4'-iso-propoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-propyl ester
-
-
4-[(R)-carboxy-[5-(4'-methoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-propyl ester
-
-
4-[(R)-carboxy-[5-(4'-methylphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-propyl ester
-
-
4-[(R)-carboxy-[5-(4'-N,N-dimethylaminophenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid
-
-
4-[(R)-carboxy-[5-(4'-n-propoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid
-
-
4-[(R)-carboxy-[5-(4'-piperidin-1-yl-phenyl)-thiophene-2-sulfonylamino]-methyl]piperidine-1-carboxylic acid iso-propyl ester
-
-
4-[(R)-carboxy-[5-(4'-piperidin-1-yl-phenyl)-thiophene-2-sulfonylamino]-methyl]piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-[5-(4'-trifluoromethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-propyl ester
-
-
4-[(R)-carboxy-[5-(4'-trifluoromethylphenyl)-furan-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[(R)-carboxy-[5-(4'-trifluoromethylphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-propyl ester
-
-
4-[(R)-carboxy-[5-phenylthiophene-2-sulfonylamino]-methyl]piperidine-1-carboxylic acid iso-propyl ester
-
-
4-[([[5-(1H-indol-5-yl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino)methyl]benzoic acid
-
-
4-[2-[4-(4-[[5-(2-ethoxyethyl)-2,4,6-trioxohexahydropyrimidin-5-yl]oxy]phenoxy)phenyl]-1,3-oxazol-4-yl]benzonitrile
-
-
4-[4-(2,6,8,10-tetraoxo-1,7,9-triazaspiro[4.5]dec-1-yl)phenoxy]benzoic acid
-
comparison of selectivity with other matrix metalloproteinases
4-[4-(methylcarbamoyl)phenoxy]-N-(pyridin-4-ylmethyl)benzamide
-
-
4-[4-[(3-hydroxy-1-azabicyclo[2.2.2]oct-3-yl)ethynyl]phenoxy]-N-(pyridin-4-ylmethyl)benzamide
-
-
4-[4-[(3-methoxy-1-azabicyclo[2.2.2]oct-3-yl)ethynyl]phenoxy]-N-(pyrimidin-4-ylmethyl)benzamide
-
-
4-[4-[(E)-2-(1-azabicyclo[2.2.2]oct-2-en-3-yl)ethenyl]phenoxy]-N-(pyridin-4-ylmethyl)benzamide
-
-
4-[4-[(E)-2-(1-azabicyclo[2.2.2]oct-2-en-3-yl)ethenyl]phenoxy]-N-(pyrimidin-4-ylmethyl)benzamide
-
-
4-[4-[(E)-2-(3-hydroxy-1-azabicyclo[2.2.2]oct-3-yl)ethenyl]phenoxy]-N-(pyrimidin-4-ylmethyl)benzamide
-
-
4-[4-[2-(3-hydroxy-1-azabicyclo[2.2.2]oct-3-yl)ethyl]phenoxy]-N-(pyrimidin-4-ylmethyl)benzamide
-
-
4-[carboxy-[5-(4-N,N-dimethylaminophenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[carboxy-[5-(6-methoxy-pyridin-3-yl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
-
4-[[([5-[2-(ethoxycarbonyl)-1H-indol-5-yl]-1-methyl-1H-pyrazol-3-yl]carbonyl)amino]methyl]benzoic acid
-
-
4-[[([5-[2-(ethoxymethyl)-1H-indol-5-yl]-1-methyl-1H-pyrazol-3-yl]carbonyl)amino]methyl]benzoic acid
-
-
4-[[1-methyl-2,4-dioxo-6-(3-phenylprop-1-yn-1-yl)-1,4-dihydroquinazolin-3(2H)-yl]methyl]benzoic acid
4-[[4-(3-[[4-(dimethylamino)benzoyl]amino]propoxy)phenyl]sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
4-[[4-(4-[[1-ethynyl-1,3-dimethyl-3-(prop-2-yn-1-yl)triazan-2-yl]carbonyl]piperidin-1-yl)phenyl]sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
4-[[4-(4-[[4-(2,3-dimethylphenyl)piperazin-1-yl]carbonyl]piperidin-1-yl)phenyl]sulfonyl]-N-hydroxy-1-(2-methoxyethyl)piperidine-4-carboxamide
-
-
4-[[4-(4-[[4-(2,3-dimethylphenyl)piperazin-1-yl]carbonyl]piperidin-1-yl)phenyl]sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
4-[[4-(4-[[4-(dimethylamino)phenyl]amino]-4-oxobutoxy)phenyl]sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
-
4-[[4-([5-[4-(dimethylamino)phenyl]-5-oxopentyl]oxy)phenyl]sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
-
MMP-13 selective
4-[[4-oxo-6-(3-phenylprop-1-yn-1-yl)quinazolin-3(4H)-yl]methyl]benzoic acid
-
-
4-[[6-(2-[3-[3-(hydroxyamino)-3-oxopropoxy]phenyl]-1,3-oxazol-5-yl)-4-oxoquinazolin-3(4H)-yl]methyl]benzoic acid
-
-
5-(2-ethoxyethyl)-5-[4-[4-(1,3,4-oxadiazol-2-yl)phenoxy]phenoxy]pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-(3,4-difluorobenzyl)-7-methyl-4,6-dioxo-N-[[2-(3-sulfanylpropoxy)pyridin-4-yl]methyl]-3a,4,5,6-tetrahydrothieno[3,2-c]pyridine-2-carboxamide
-
-
5-(4-chlorophenoxy)-5-methylpyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-(4-chlorophenyl)-N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]furan-2-carboxamide
5-(5-chloropyridin-2-yl)-N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]furan-2-carboxamide
-
-
5-hexyl-5-(4-phenoxyphenoxy)pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-methyl-5-(4-phenoxyphenoxy)pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-[3-[(4-carboxybenzyl)carbamoyl]-1-methyl-1H-pyrazol-5-yl]-1H-indole-2-carboxylic acid
-
-
5-[3-[(acetylamino)methyl]phenyl]-N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]furan-2-carboxamide
-
-
5-[4-(1-benzofuran-2-ylmethoxy)phenyl]-N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]furan-2-carboxamide
-
-
5-[4-(1H-imidazol-1-yl)phenyl]-4-methyl-1,2-dihydro-3H-pyrazol-3-one
-
-
5-[4-(acetylamino)phenyl]-N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]furan-2-carboxamide
-
-
6-hydroxy-2-(methylsulfanyl)-4-pyrimidinecarboxylic acid
-
binding structure, modelling, overview
alendronate
-
inhibits the in vitro invasion and random cell migration, 99% inhibition at 0.4 mM and physiological Ca2+-concentration, 67% inhibition at 0.4 mM and high Ca2+-concentration
ALS 1-0635
-
noncompetitive
-
benzyl 6-benzyl-5,7-dioxo-6,7-dihydro-5H-[1,3]thiazolo[3,2-c]pyrimidine-2-carboxylate
-
competitive, does not ligate the catalytic zinc, zinc binding is unnecessary to achieve nanomolar affinity, extremely selective for inhibition of MMP13 over all other MMPs
bone morphogenetic protein 2
-
down-regulation of enzyme expression in osteoblasts, can be overcome by noggin
-
bone morphogenetic protein 4
-
down-regulation of enzyme expression in osteoblasts, can be overcome by noggin
-
bone morphogenetic protein 6
-
down-regulation of enzyme expression in osteoblasts, can be overcome by noggin
-
CL 82198
-
specific inhibitor
CL-82198
-
a specific MMP-13 inhibitor, inhibits also the metastatic activity of chloramphenicol-treated cells
clodronate
-
77% inhibition at 0.4 mM and physiological Ca2+-concentration, 35.7% inhibition at 0.4 mM and high Ca2+-concentration
ethyl 5-(1-methyl-1H-imidazol-5-yl)-1H-indole-2-carboxylate
-
-
ethyl 5-(1-methyl-3-[[(6-oxo-1,6-dihydropyridin-3-yl)methyl]carbamoyl]-1H-pyrazol-5-yl)-1H-indole-2-carboxylate
-
-
ethyl 5-(3-methylpyridin-4-yl)-1H-indole-2-carboxylate
-
-
ethyl 5-(acetylamino)-1H-indole-2-carboxylate
-
-
ethyl 5-(pyridin-2-yl)-1H-indole-2-carboxylate
-
-
ethyl 5-(pyridin-3-yl)-1H-indole-2-carboxylate
-
-
ethyl 5-(pyridin-4-yl)-1H-indole-2-carboxylate
-
-
ethyl 5-carbamoyl-1H-indole-2-carboxylate
-
-
ethyl 5-phenyl-1H-indole-2-carboxylate
-
-
ethyl 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylate
-
-
ethyl 5-[1-methyl-3-[(pyridin-4-ylmethyl)carbamoyl]-1H-pyrazol-5-yl]-1H-indole-2-carboxylate
-
-
ethyl 5-[3-(methoxycarbonyl)-1-methyl-1H-pyrazol-5-yl]-1H-indole-2-carboxylate
-
-
ethyl 5-[5-methyl-2-[(pyridin-4-ylmethyl)carbamoyl]pyridin-4-yl]-1H-indole-2-carboxylate
-
-
furin
-
inhibition of enzyme induction by TGFbeta1 in chondrocytes
-
hydroxamic acid-based inhibitor CT1399
-
-
-
hydroxamic acid-based inhibitor CT1847
-
-
-
ilomastat
-
a broad-spectrum MMP inhibitor
mannose-6-phosphate/insulin-like growth factor 2 receptor
-
inhibition of enzyme induction by TGFbeta1 in chondrocytes
-
matrix metalloprotease inhibitor GW9471
-
broad spectrum
methyl 3-[4-(1H-imidazol-1-yl)phenyl]propanoate
-
-
methyl 4-[4-(2,6,8,10-tetraoxo-1,7,9-triazaspiro[4.5]dec-1-yl)phenoxy]benzoate
-
comparison of selectivity with other matrix metalloproteinases
minocycline
-
inhibits MMP-13 activity in synoviocytes
N,N'-bis(3-methylbenzyl)pyrimidine-4,6-dicarboxamide
-
extremely selective for inhibition of MMP13 over all other MMPs
N,N'-bis(pyridin-3-ylmethyl)pyrimidine-4,6-dicarboxamide
-
-
N,N-bis(2,6-dimethylmorpholin-4-yl)-1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)piperidine-4-carboxamide
-
-
N,N-bis(3,5-dimethylpiperidin-1-yl)-1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)piperidine-4-carboxamide
-
-
N,N-bis(4-acetylpiperazin-1-yl)-1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)piperidine-4-carboxamide
-
-
N,N-bis(7,8-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)piperidine-4-carboxamide
-
-
N,N-bis[4-(2,4-dimethylphenyl)piperazin-1-yl]-1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)piperidine-4-carboxamide
-
-
N,N-bis[4-(2-fluorophenyl)piperazin-1-yl]-1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)piperidine-4-carboxamide
-
-
N,N-bis[4-(4-acetylphenyl)piperazin-1-yl]-1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)piperidine-4-carboxamide
-
-
N,N-bis[4-(4-fluorophenyl)piperazin-1-yl]-1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)piperidine-4-carboxamide
-
-
N,N-bis[4-[1-(dimethylamino)ethyl]piperazin-1-yl]-1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)piperidine-4-carboxamide
-
-
N,N-di(3,4-dihydroisoquinolin-2(1H)-yl)-1-(4-[[4-(hydroxycarbamoyl)tetrahydro-2H-pyran-4-yl]sulfonyl]phenyl)piperidine-4-carboxamide
-
-
N-(2-hydroxyethyl)-4-(4-methylphenoxy)benzamide
-
-
N-(3-methoxybenzyl)-4-(4-methylphenoxy)benzamide
-
-
N-(4-fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
-
i.e. PF152, a non-hydroxamic acid and a potent and highly selective MMP-13 inhibitor, that binds the S1' active site pocket of the enzyme and is not a ligand to the catalytic zinc atom
N-(cyclohexylmethyl)-4-(4-methylphenoxy)benzamide
-
-
N-(pyridin-4-ylmethyl)biphenyl-4-carboxamide
-
-
N-([4'-[(1-benzofuran-2-ylcarbonyl)amino]biphenyl-4-yl]sulfonyl)valine
-
-
N-([4'-[([3-methyl-4-[(methylsulfonyl)amino]-1-benzofuran-2-yl]carbonyl)amino]biphenyl-4-yl]sulfonyl)-L-threonine
-
-
N-([4'-[([3-methyl-4-[(methylsulfonyl)amino]-1-benzofuran-2-yl]carbonyl)amino]biphenyl-4-yl]sulfonyl)-L-valine
-
-
N-([4'-[([4-[(1-methoxy-2-methyl-1-oxopropan-2-yl)oxy]-3-methyl-1-benzofuran-2-yl]carbonyl)amino]biphenyl-4-yl]sulfonyl)-L-valine
-
-
N-([4'-[([4-[(2-carboxypropan-2-yl)oxy]-1-benzofuran-2-yl]carbonyl)amino]biphenyl-4-yl]sulfonyl)-L-valine
-
-
N-benzyl-4-(4-methylphenoxy)benzamide
-
-
N-hydroxy-1-(2-methoxyethyl)-4-([4-[4-(phenylcarbamoyl)piperidin-1-yl]phenyl]sulfonyl)piperidine-4-carboxamide
-
-
N-hydroxy-2,2-dimethyl-4-[[4-(pyridin-4-yloxy)phenyl]sulfonyl]thiomorpholine-3-carboxamide
-
-
N-hydroxy-2,6-dimethoxy-3-[[(4-methoxyphenyl)sulfonyl](pyridin-3-ylmethyl)amino]pyridine-4-carboxamide
-
-
N-hydroxy-2-[(2-methylpropyl)(naphthalen-2-ylsulfonyl)amino]acetamide
-
-
N-hydroxy-2-[(naphthalen-2-ylsulfonyl)amino]acetamide
-
-
N-hydroxy-2-[[(4-methoxyphenyl)sulfonyl](pyridin-3-ylmethyl)amino]-3-methylbenzamide
-
-
N-hydroxy-3-methyl-2-(methyl[[4-(pyridin-4-yloxy)phenyl]sulfonyl]amino)benzamide
-
-
N-hydroxy-3-methyl-N2-(3-methylbutyl)-N2-(naphthalen-2-ylsulfonyl)-D-valinamide
-
-
N-hydroxy-4-([4-[(4-hydroxybut-2-yn-1-yl)oxy]phenyl]sulfonyl)-2,2-dimethylthiomorpholine-3-carboxamide
-
-
N-hydroxy-4-([4-[4-(2-hydroxyphenyl)piperidin-1-yl]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-([4-[4-(2-methoxyphenyl)piperazin-1-yl]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-([4-[4-(2-methoxyphenyl)piperidin-1-yl]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-([4-[4-(2-methylphenyl)piperazin-1-yl]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-([4-[4-(2-methylphenyl)piperidin-1-yl]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-([4-[4-(3,3,6-trimethoxycyclohexa-1,5-dien-1-yl)piperidin-1-yl]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-([4-[4-(3-methoxyphenyl)piperazin-1-yl]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-([4-[4-(4,4,6-trimethoxycyclohexa-1,5-dien-1-yl)piperidin-1-yl]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-([4-[4-(4-methoxy-2-methylphenyl)piperidin-1-yl]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-([4-[4-(4-methoxyphenoxy)butoxy]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
-
-
N-hydroxy-4-([4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-([4-[4-(4-methylphenyl)piperazin-1-yl]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-([4-[4-(naphthalen-1-yl)piperidin-1-yl]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-([4-[4-oxo-4-(piperidin-1-yl)butoxy]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
-
-
N-hydroxy-4-[(4-[3-[(4-methoxybenzoyl)amino]propoxy]phenyl)sulfonyl]tetrahydro-2H-pyran-4-carboxamide
-
-
N-hydroxy-4-[(4-[4-[(4-methoxyphenyl)amino]-4-oxobutoxy]phenyl)sulfonyl]tetrahydro-2H-pyran-4-carboxamide
-
-
N-hydroxy-4-[(4-[4-[2-(trifluoromethyl)phenyl]piperidin-1-yl]phenyl)sulfonyl]tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-[(4-[4-[2-methoxy-5-(propan-2-yl)phenyl]piperidin-1-yl]phenyl)sulfonyl]tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-[(4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]phenyl)sulfonyl]tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-[(4-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]phenyl)sulfonyl]tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-[[4-(3-[[4-(trifluoromethoxy)benzoyl]amino]propoxy)phenyl]sulfonyl]tetrahydro-2H-pyran-4-carboxamide
-
-
N-hydroxy-4-[[4-(4-oxo-4-[[4-(trifluoromethoxy)phenyl]amino]butoxy)phenyl]sulfonyl]tetrahydro-2H-pyran-4-carboxamide
-
-
N-hydroxy-4-[[4-(4-phenylpiperazin-1-yl)phenyl]sulfonyl]tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-[[4-(4-phenylpiperidin-1-yl)phenyl]sulfonyl]tetrahydro-2H-pyran-4-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
N-hydroxy-4-[[4-(4-[methyl[4-(trifluoromethoxy)phenyl]amino]-4-oxobutoxy)phenyl]sulfonyl]tetrahydro-2H-pyran-4-carboxamide
-
-
N-hydroxy-4-[[4-(phenylsulfanyl)phenyl]sulfonyl]-1-(prop-2-yn-1-yl)piperidine-4-carboxamide
-
i.e. SC-276
N-hydroxy-N2-(2-methylpropyl)-N2-(naphthalen-2-ylsulfonyl)-D-valinamide
-
-
N-hydroxy-N2-(3-methylbutyl)-N2-(2,3,3a,7a-tetrahydro-1-benzofuran-5-ylsulfonyl)-D-valinamide
-
-
N-hydroxy-N2-(3-methylbutyl)-N2-(naphthalen-2-ylsulfonyl)-5-phenyl-D-norvalinamide
-
-
N-hydroxy-N2-(3-methylbutyl)-N2-(naphthalen-2-ylsulfonyl)-D-leucinamide
-
-
N-hydroxy-N2-(3-methylbutyl)-N2-(naphthalen-2-ylsulfonyl)-D-threoninamide
-
-
N-hydroxy-N2-(3-methylbutyl)-N2-(naphthalen-2-ylsulfonyl)-D-valinamide
-
-
N-hydroxy-N2-(3-methylbutyl)-N2-(quinolin-2-ylsulfonyl)-D-valinamide
-
-
N-hydroxy-N2-(3-methylbutyl)-N2-(quinolin-3-ylsulfonyl)-D-valinamide
-
-
N-hydroxy-N2-(3-methylbutyl)-N2-(quinolin-6-ylsulfonyl)-D-valinamide
-
-
N-hydroxy-N2-(3-methylbutyl)-N2-[(6-propoxynaphthalen-2-yl)sulfonyl]-D-valinamide
-
-
N-hydroxy-N2-(3-methylbutyl)-N2-[[6-(2-methylpropoxy)naphthalen-2-yl]sulfonyl]-D-valinamide
-
-
N-hydroxy-N2-(naphthalen-2-ylsulfonyl)-N2-(2-phenylethyl)-D-valinamide
-
-
N-hydroxy-N2-(naphthalen-2-ylsulfonyl)-N2-(3-phenylpropyl)-D-valinamide
-
-
N-hydroxy-N2-(naphthalen-2-ylsulfonyl)-N2-(pyridin-2-ylmethyl)-D-valinamide
-
-
N-hydroxy-N2-(naphthalen-2-ylsulfonyl)-N2-(pyridin-3-ylmethyl)-D-valinamide
-
-
N-hydroxy-N2-(naphthalen-2-ylsulfonyl)-N2-(pyridin-4-ylmethyl)-D-valinamide
-
-
N-hydroxy-N2-methyl-3-[(4-phenoxyphenyl)sulfonyl]-L-alaninamide
-
-
N-hydroxy-N2-[(4-methoxyphenyl)sulfonyl]-N2-(pyridin-4-ylmethyl)valinamide
-
-
N-hydroxy-N2-[(6-hydroxynaphthalen-2-yl)sulfonyl]-N2-(3-methylbutyl)-D-valinamide
-
-
N-hydroxy-N2-[(6-methoxynaphthalen-2-yl)sulfonyl]-N2-(3-methylbutyl)-D-valinamide
-
-
N-hydroxy-N2-[(7-hydroxynaphthalen-2-yl)sulfonyl]-N2-(3-methylbutyl)-D-valinamide
-
-
N-hydroxy-N2-[(7-methoxynaphthalen-2-yl)sulfonyl]-N2-(3-methylbutyl)-D-valinamide
-
-
N-hydroxy-N2-[2-(morpholin-4-yl)ethyl]-N2-(naphthalen-2-ylsulfonyl)-D-valinamide
-
-
N-hydroxy-N2-[[6-(3-methylbutoxy)naphthalen-2-yl]sulfonyl]-N2-(3-methylbutyl)-D-valinamide
-
-
N-methyl-4-(4-methylphenoxy)-N-(pyridin-4-ylmethyl)benzamide
-
-
N-methyl-4-(4-methylphenoxy)benzamide
-
-
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-(3-[[(furan-2-ylcarbonyl)amino]methyl]phenyl)furan-2-carboxamide
-
-
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-(4-ethoxyphenyl)furan-2-carboxamide
-
-
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-(4-methoxyphenyl)furan-2-carboxamide
-
-
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-(4-methylphenyl)furan-2-carboxamide
-
-
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-(4-phenoxyphenyl)furan-2-carboxamide
-
-
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[3-([[(2-methylfuran-3-yl)carbonyl]amino]methyl)phenyl]furan-2-carboxamide
-
-
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-(1H-pyrazol-3-ylmethoxy)phenyl]furan-2-carboxamide
-
-
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-(methylcarbamoyl)phenyl]furan-2-carboxamide
-
-
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-(methylsulfamoyl)phenyl]furan-2-carboxamide
-
-
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-[(1,5-dimethyl-1H-pyrazol-3-yl)methoxy]phenyl]furan-2-carboxamide
-
-
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-[(1-methyl-1H-pyrazol-3-yl)methoxy]phenyl]furan-2-carboxamide
-
-
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-[(5-methyl-1H-pyrazol-3-yl)methoxy]phenyl]furan-2-carboxamide
-
-
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-[(6-methylpyridin-2-yl)methoxy]phenyl]furan-2-carboxamide
-
-
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-[(methylsulfonyl)amino]phenyl]furan-2-carboxamide
-
-
N-[(4'-[[(3,4-dimethyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
-
-
N-[(4'-[[(3-methyl-4-phenoxy-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
-
-
N-[(4'-[[(3-methyl-4-phenyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
-
-
N-[(4'-[[(4-amino-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
-
-
N-[(4'-[[(4-cyano-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
-
-
N-[(4'-[[(4-ethenyl-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
-
-
N-[(4'-[[(4-ethoxy-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
-
-
N-[(4'-[[(4-ethyl-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
-
-
N-[(4'-[[(4-hydroxy-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
-
-
N-[(4'-[[(4-methoxy-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
-
-
N-[(4-[5-[([3-methyl-4-[(methylsulfonyl)amino]-1-benzofuran-2-yl]carbonyl)amino]pyridin-2-yl]phenyl)sulfonyl]-L-threonine
-
replacing a backbone benzene with a pyridine and valine with threonine results in greatly reduced plasma protein binding of the compound
N-[(4-[5-[([3-methyl-4-[(methylsulfonyl)amino]-1-benzofuran-2-yl]carbonyl)amino]pyridin-2-yl]phenyl)sulfonyl]-L-valine
-
-
N-[2-(4,5-dihydro-1,3-oxazol-2-yl)-1H-indol-5-yl]acetamide
-
-
N-[2-(4-[benzyl[2-(hydroxycarbamoyl)-4,6-dimethylphenyl]sulfamoyl]phenoxy)ethyl]-1-benzofuran-2-carboxamide
-
WAY-170523
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-1,5-dimethyl-1H-pyrazole-3-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-1-methyl-1H-imidazole-2-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-1-methyl-1H-pyrazole-3-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-1-methyl-1H-pyrazole-4-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-2-(trifluoromethyl)pyrimidine-4-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-2-methyl-1,3-thiazole-4-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-3-methylfuran-2-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-3-methylpyridine-2-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-5-ethylpyridine-3-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-5-methylfuran-2-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-6-(trifluoromethyl)pyridine-2-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-6-methylpyridine-2-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-7-methylimidazo[1,2-a]pyridine-2-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-8-methylimidazo[1,2-a]pyridine-2-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]imidazo[1,2-a]pyridine-2-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]pyridine-2-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]pyridine-3-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]pyridine-4-carboxamide
-
-
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]pyrimidine-4-carboxamide
-
-
N-[3-(5-[[1-cyclopropyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-2-(trifluoromethyl)pyrimidine-4-carboxamide
-
-
N-[3-(5-[[1-cyclopropyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-6-(trifluoromethyl)pyridine-2-carboxamide
-
-
N-[3-(5-[[2-(methylamino)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl]carbamoyl]furan-2-yl)benzyl]-2-(trifluoromethyl)pyrimidine-4-carboxamide
-
-
N-[3-(5-[[2-(methylamino)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl]carbamoyl]furan-2-yl)benzyl]-6-(trifluoromethyl)pyridine-2-carboxamide
-
-
N-[3-(5-[[3-hydroxy-3-methyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl]furan-2-yl)benzyl]-2-(trifluoromethyl)pyrimidine-4-carboxamide
-
-
N-[3-(5-[[3-hydroxy-3-methyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl]furan-2-yl)benzyl]-6-(trifluoromethyl)pyridine-2-carboxamide
-
-
N-[3-(5-[[3-methyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl]furan-2-yl)benzyl]-2-(trifluoromethyl)pyrimidine-4-carboxamide
-
-
N-[3-(5-[[3-methyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl]furan-2-yl)benzyl]-6-(trifluoromethyl)pyridine-2-carboxamide
-
-
N-[3-(dimethylamino)propyl]-4-(4-methylphenoxy)benzamide
-
-
N-[4-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)phenyl]-1-benzofuran-2-carboxamide
-
-
N-[4-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)phenyl]-1-methyl-1H-pyrazole-3-carboxamide
-
-
N-[4-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)phenyl]-4,5-dimethylfuran-2-carboxamide
-
-
N-[4-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)phenyl]-5-methyl-1H-pyrazole-3-carboxamide
-
-
N-[4-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)phenyl]-5-methylfuran-2-carboxamide
-
-
N-[4-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)phenyl]-6-methylpyridine-2-carboxamide
-
-
N-[4-(morpholin-4-yl)butyl]-1-benzofuran-2-carboxamide
-
i.e. CL-82198
N-[[(3-phenyl-1,2-oxazol-5-yl)methyl]carbamothioyl]benzamide
-
competitive, is synergic with acetohydroxamic acid
N-[[4'-([[3-methyl-4-(methylamino)-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
-
-
N-[[4'-([[3-methyl-4-(morpholin-4-yl)-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
-
-
N-[[4'-([[3-methyl-4-(prop-1-yn-1-yl)-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
-
-
N-[[4'-([[4-(3-hydroxypropyl)-3-methyl-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
-
-
N-[[4'-([[4-(3-methoxypropyl)-3-methyl-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
-
-
N-[[4'-([[4-(acetylamino)-3-methyl-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
-
-
N-[[4'-([[4-(dimethylamino)-3-methyl-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
-
-
N-[[4'-([[4-(furan-2-yl)-3-methyl-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
-
-
N-[[4-(4-fluorophenoxy)phenyl]sulfonyl]-N-[1-(hydroxycarbamoyl)cyclopentyl]-b-alanine
-
-
N-[[4-(5-[[(4-cyano-3-methyl-1-benzofuran-2-yl)carbonyl]amino]pyridin-2-yl)phenyl]sulfonyl]-L-valine
-
-
N2-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-N-hydroxy-N2-(3-methylbutyl)-D-valinamide
-
-
N2-(3a,7a-dihydro-1-benzothiophen-5-ylsulfonyl)-N-hydroxy-N2-(3-methylbutyl)-D-valinamide
-
-
N2-benzyl-N-hydroxy-N2-(naphthalen-2-ylsulfonyl)-D-valinamide
-
-
N2-ethyl-1H-indole-2,5-dicarboxamide
-
-
N2-[(2S)-2-[[(4-benzylbenzyl)(hydroxy)phosphoryl]methyl]-4-phenylbutanoyl]-N,3-dimethyl-L-valinamide
-
-
N2-[(2S)-2-[[(4-benzylbenzyl)(hydroxy)phosphoryl]methyl]-6-phenoxyhexanoyl]-N,3-dimethyl-L-valinamide
-
-
N2-[(3,4-dimethoxyphenyl)sulfonyl]-N-hydroxy-N2-(3-methylbutyl)-D-valinamide
-
-
N2-[(4'-bromobiphenyl-4-yl)sulfonyl]-N-hydroxy-D-valinamide
-
-
N2-[(6-ethoxynaphthalen-2-yl)sulfonyl]-N-hydroxy-N2-(3-methylbutyl)-D-valinamide
-
-
N2-[(6-ethylnaphthalen-2-yl)sulfonyl]-N-hydroxy-N2-(3-methylbutyl)-D-valinamide
-
-
N2-[(7-ethoxynaphthalen-2-yl)sulfonyl]-N-hydroxy-N2-(3-methylbutyl)-D-valinamide
-
-
N2-[2-(dimethylamino)ethyl]-N-hydroxy-N2-(naphthalen-2-ylsulfonyl)-D-valinamide
-
-
N2-[[6-(benzyloxy)naphthalen-2-yl]sulfonyl]-N-hydroxy-N2-(3-methylbutyl)-D-valinamide
-
-
O-tert-butyl-N-hydroxy-N2-(3-methylbutyl)-N2-(naphthalen-2-ylsulfonyl)-D-serinamide
-
-
P53
-
down-regulation of enzyme expression, possibly contributes to the dysregulation of the enzyme observed in cancer
Ro32-3555
-
a broad-spectrum MMP inhibitor
RS 102,481
-
a small molecule preferential inhibitor of MMP13, the compound is able to potently inhibit the release of type II collagen degradation peptides from human osteoarthritis articular cartilage explants
tissue matrix metalloproteinase inhibitor fragments of TIMP-1
-
-
-
tissue matrix metalloproteinase inhibitor fragments of TIMP-2
-
-
-
tissue matrix metalloproteinase inhibitor hybrid N.TIMP-1/C.TIMP-2
-
complex formation is not affected by the C-terminal domain of the enzyme, inhibition mechanism, wild-type enzyme and enzyme fragment 249-451
-
tissue matrix metalloproteinase inhibitor TIMP-1
-
tissue matrix metalloproteinase inhibitor TIMP-2
-
tissue matrix metalloproteinase inhibitor TIMP-3
-
tissue matrix metalloproteinase inhibitor-1
-
in a ratio of enzyme to inhibitor of 1:1
-
tissue matrix metalloproteinase inhibitor-2
-
in a ratio of enzyme to inhibitor of 1:1
-
tissue matrix metalloproteinase inhibitor-3
-
fast inhibition, in a ratio of enzyme to inhibitor of 1:1
-
transforming growth factor-beta1
-
i.e. TGFbeta1, accelerates the decay of the enzymes mRNA and decreased enzyme expression in osteoblasts
-
hydroxamic acid inhibitor CGS 27023
-
hydroxamic acid inhibitor CGS 27023
complex formation with the catalytic fragment of the enzyme, inhibitor binding mechanism
N,N'-bis(pyridin-3-ylmethyl)pyrimidine-4,6-dicarboxamide
-
N,N'-bis(pyridin-3-ylmethyl)pyrimidine-4,6-dicarboxamide
50% inhibition at 6600 nM
1-(4-phenoxyphenyl)-1,7,9-triazaspiro[4.5]decane-2,6,8,10-tetrone
-
-
1-(4-phenoxyphenyl)-1,7,9-triazaspiro[4.5]decane-2,6,8,10-tetrone
-
comparison of selectivity with other matrix metalloproteinases
4-[[1-methyl-2,4-dioxo-6-(3-phenylprop-1-yn-1-yl)-1,4-dihydroquinazolin-3(2H)-yl]methyl]benzoic acid
-
-
4-[[1-methyl-2,4-dioxo-6-(3-phenylprop-1-yn-1-yl)-1,4-dihydroquinazolin-3(2H)-yl]methyl]benzoic acid
-
noncompetitive, extremely selective for inhibition of MMP13 over all other MMPs
5-(4-chlorophenyl)-N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]furan-2-carboxamide
-
-
5-(4-chlorophenyl)-N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]furan-2-carboxamide
-
discovery and optimization of potency and selectivity of the non-Zn-chelating MMP-13 inhibitor with the aid of protein co-crystal structural information, binding mode, overview. 1 binds in the active site region despite not interacting with the catalytic zinc
tissue matrix metalloproteinase inhibitor TIMP-1
-
1:1 stoichiometric fashion
-
tissue matrix metalloproteinase inhibitor TIMP-1
-
complex formation is promoted by the C-terminal domain of the enzyme, inhibition mechanism, wild-type enzyme and enzyme fragment 249-451
-
tissue matrix metalloproteinase inhibitor TIMP-2
-
1:1 stoichiometric fashion
-
tissue matrix metalloproteinase inhibitor TIMP-2
-
complex formation is not affected by the C-terminal domain of the enzyme, inhibition mechanism, wild-type enzyme and enzyme fragment 249-451
-
tissue matrix metalloproteinase inhibitor TIMP-3
-
1:1 stoichiometric fashion
-
tissue matrix metalloproteinase inhibitor TIMP-3
-
complex formation is promoted by the C-terminal domain of the enzyme, inhibition mechanism, wild-type enzyme and enzyme fragment 249-451
-
additional information
design, synthesis and biological evaluation of selective matrix metalloproteinase-13 N-O-isopropyl sulfonamido-based hydroxamate inhibitors as potential therapeutic agents for osteoarthritis, docking study and molecular modelling, overview
-
additional information
discovery of (pyridin-4-yl)-2H-tetrazole as a scaffold to identify highly selective MMP-13 inhibitors for the treatment of osteoarthritis
-
additional information
-
development and optimization of potent 3,4-disubstituted benzofuran P1' MMP-13 inhibitors, overview
-
additional information
-
development of MMP-13 inhibitors mechanistically distinct from previously reported broad-spectrum MMP inhibitors with improved selectivity and pharmacokinetics. Chondroprotective effect of MMP-13-selective inhibitors
-
additional information
-
development of MMP-13 selective isonipecotamide alpha-sulfone hydroxamate inhibitors, overview
-
additional information
-
MMP-13 activity is not directly inhibited by the imidazo[5,1-c][1,4]thiazine derivative ITZ-1
-
additional information
-
no inhibition of MMP-13 by MMP-3 inhibitor N-isobutyl-N-[4-methoxyphenylsulphonyl] glycyl hydroxamic acid or by doxycycline
-
additional information
-
selective inhibition of MMP-13 may be achieved by targeting the hemopexin domain of the protease, which is critical for substrate specificity, systematic cheminformatics-based drug design with virtual screening, overview
-
additional information
-
selectivity and metabolic stability of non-zinc-chelating MMP-13 inhibitors, overview
-
additional information
-
structure-function relationships of different inhibitor types, overview. No inhibition by 27, i.e. CGS27023A
-
additional information
-
synthesis of a series of phenyl piperidine alpha-sulfone hydroxamate derivatives, utilizing a combination of solution-phase and resin-bound library technologies, to afford compounds that are potent and highly selective for MMP-13, selectivity analysis compared to other MMPs, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abscess
Colorectal adenocarcinoma with mucinous component: relation of MMP-13, EGFR, and E-cadherin expressions to clinicopathological features and prognosis.
Acute Lung Injury
Deficiency of matrix metalloproteinase-13 increases inflammation after acute lung injury.
Acute Lung Injury
Induction of the Matrix Metalloproteinase 13 Gene in Bronchial Epithelial Cells by Interferon and Identification of its Novel Functional Polymorphism.
Adenocarcinoma
Active matrix metalloproteases are expressed early on and are high during the Barrett's esophagus malignancy sequence.
Adenocarcinoma
Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of Metalloproteinase (MMP)-13.
Adenocarcinoma
Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas.
Adenocarcinoma
Colorectal adenocarcinoma with mucinous component: relation of MMP-13, EGFR, and E-cadherin expressions to clinicopathological features and prognosis.
Adenocarcinoma
Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer.
Adenocarcinoma
Hypoxia induces oncogene yes-associated protein 1 nuclear translocation to promote pancreatic ductal adenocarcinoma invasion via epithelial-mesenchymal transition.
Adenocarcinoma
MMP-13 In-Vivo Molecular Imaging Reveals Early Expression in Lung Adenocarcinoma.
Adenocarcinoma
MMP13 is a potential prognostic marker for colorectal cancer.
Adenocarcinoma
[Expression and clinical significance of collagenase-3 (MMP-13) in gastric cancer]
Adenocarcinoma of Lung
?-Catenin Cooperates with CREB Binding Protein to Promote the Growth of Tumor Cells.
Adenocarcinoma of Lung
MMP-13 In-Vivo Molecular Imaging Reveals Early Expression in Lung Adenocarcinoma.
Adenocarcinoma of Lung
Therapeutic effect of Resveratrol in the treatment of osteoarthritis via the MALAT1/miR-9/NF-?B signaling pathway.
Adenocarcinoma, Mucinous
Colorectal adenocarcinoma with mucinous component: relation of MMP-13, EGFR, and E-cadherin expressions to clinicopathological features and prognosis.
Adenocarcinoma, Mucinous
Differential expression of matrix metalloproteinase-13 in mucinous and nonmucinous colorectal carcinomas.
Adenoma
Matrix metalloproteinase-13 expression in the progression of colorectal adenoma to carcinoma : Matrix metalloproteinase-13 expression in the colorectal adenoma and carcinoma.
Adenoma
Matrix metalloproteinase-13 refines pathological staging of precancerous colorectal lesions.
Adenoma
MMP-13 In-Vivo Molecular Imaging Reveals Early Expression in Lung Adenocarcinoma.
Adenoma
The Expression and Significance of CXCR5 and MMP-13 in Colorectal Cancer.
Adenomatous Polyps
Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential?
Adenomatous Polyps
Matrix metalloproteinase-13 expression in the progression of colorectal adenoma to carcinoma : Matrix metalloproteinase-13 expression in the colorectal adenoma and carcinoma.
Adrenal Cortex Neoplasms
Gelatinase A and membrane-type 1 matrix metalloproteinase mRNA: expressed in adrenocortical cancers but not in adenomas.
Albuminuria
Absence of Gelatinase (MMP-9) or Collagenase (MMP-13) Attenuates Adriamycin-Induced Albuminuria and Glomerulosclerosis.
Alveolar Bone Loss
Matrix metalloproteinase-13 is highly expressed in destructive periodontal disease activity.
Alzheimer Disease
Blood-brain barrier damage in vascular dementia.
Alzheimer Disease
Matrix metalloproteinase 13, a new target for therapy in Alzheimer's disease.
Alzheimer Disease
MMP13 inhibition rescues cognitive decline in Alzheimer transgenic mice via BACE1 regulation.
Aneurysm
Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury.
Aneurysm
MicroRNA and gene expression changes in unruptured human cerebral aneurysms.
Aneurysm
Nitric oxide induces the progression of abdominal aortic aneurysms through the matrix metalloproteinase inducer EMMPRIN.
Angina, Unstable
High plasma levels of matrix metalloproteinase-8 in patients with unstable angina.
Angiofibroma
Metalloproteinases in juvenile angiofibroma--a collagen rich tumor.
Ankylosis
Abnormal Mechanical Loading Induces Cartilage Degeneration by Accelerating Meniscus Hypertrophy and Mineralization After ACL Injuries In Vivo.
Ankylosis
The role of pyrophosphate/phosphate homeostasis in terminal differentiation and apoptosis of growth plate chondrocytes.
Aortic Aneurysm, Abdominal
Decreased collagen and increased matrix metalloproteinase-13 in experimental abdominal aortic aneurysms in males compared with females.
Aortic Aneurysm, Abdominal
Elevated expression of matrix metalloproteinase-13 in abdominal aortic aneurysms.
Aortic Aneurysm, Abdominal
Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture.
Aortic Aneurysm, Abdominal
Immune cells and molecular mediators in the pathogenesis of the abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome.
Arteriosclerosis
Reduced intragraft mRNA expression of matrix metalloproteinases Mmp3, Mmp12, Mmp13 and Adam8, and diminished transplant arteriosclerosis in Ccr5-deficient mice.
Arthralgia
A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
Arthritis
1,25-Dihydroxyvitamin D3 activates MMP13 gene expression in chondrocytes through p38 MARK pathway.
Arthritis
A correlation between knee cartilage degradation observed by arthroscopy and synovial proteinases activities.
Arthritis
A low ratio of n-6/n-3 polyunsaturated fatty acids suppresses matrix metalloproteinase 13 expression and reduces adjuvant-induced arthritis in rats.
Arthritis
A study of Sirt1 regulation and the effect of resveratrol on synoviocyte invasion and associated joint destruction in rheumatoid arthritis.
Arthritis
Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13).
Arthritis
Adenovirus mediated intra-articular expression of collagenase-3 (MMP-13) induces inflammatory arthritis in mice.
Arthritis
Basic fibroblast growth factor stimulates matrix metalloproteinase-13 via the molecular cross-talk between the mitogen-activated protein kinases and protein kinase Cdelta pathways in human adult articular chondrocytes.
Arthritis
Blockade of IL-17 alleviated inflammation in rat arthritis and MMP-13 expression.
Arthritis
CCAAT/enhancer binding protein beta mediates expression of matrix metalloproteinase 13 in human articular chondrocytes in inflammatory arthritis.
Arthritis
Chondrocyte hypertrophy can be induced by a cryptic sequence of type II collagen and is accompanied by the induction of MMP-13 and collagenase activity: implications for development and arthritis.
Arthritis
Collagenase-3 (MMP-13) deficiency protects C57BL/6 mice from antibody-induced arthritis.
Arthritis
Cytokine-induced cysteine- serine-rich nuclear protein-1 (CSRNP1) selectively contributes to MMP1 expression in human chondrocytes.
Arthritis
Development of a Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-7/-13 Inhibitor.
Arthritis
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.
Arthritis
Discovery of Potent, Selective, and Orally Active Carboxylic Acid Based Inhibitors of Matrix Metalloproteinase-13 (dagger).
Arthritis
Distal interleukin-1? (IL-1?) response element of human matrix metalloproteinase-13 (MMP-13) binds activator protein 1 (AP-1) transcription factors and regulates gene expression.
Arthritis
DPSCs Attenuate Experimental Progressive TMJ Arthritis by Inhibiting the STAT1 Pathway.
Arthritis
Effects of Intra-Articular Resveratrol Injections on Cartilage Destruction and Synovial Inflammation in Experimental Temporomandibular Joint Osteoarthritis.
Arthritis
Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis.
Arthritis
Flexibility and variability of TIMP binding: X-ray structure of the complex between collagenase-3/MMP-13 and TIMP-2.
Arthritis
Gadd45beta deficiency in rheumatoid arthritis: Enhanced synovitis through JNK signaling.
Arthritis
Hesperidin inhibits synovial cell inflammation and macrophage polarization through suppression of the PI3K/AKT pathway in complete Freund's adjuvant-induced arthritis in mice.
Arthritis
Identification and differential expression of human collagenase-3 mRNA species derived from internal deletion, alternative splicing, and different polyadenylation and transcription initiation sites.
Arthritis
In Vivo Dual Fluorescence Imaging to Detect Joint Destruction.
Arthritis
In vivo imaging of matrix metalloproteinase 12 and matrix metalloproteinase 13 activities in the mouse model of collagen-induced arthritis.
Arthritis
Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes.
Arthritis
Inhibition of interleukin 1-induced matrix metalloproteinase 13 expression in human chondrocytes by interferon gamma.
Arthritis
Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes.
Arthritis
Inhibition of joint inflammation and destruction induced by anti-type II collagen antibody/lipopolysaccharide (LPS)-induced arthritis in mice due to deletion of macrophage migration inhibitory factor (MIF).
Arthritis
Inhibition of Matrix Metalloproteinase-3 and -13 Synthesis Induced by IL-1{beta} in Chondrocytes from Mice Lacking Microsomal Prostaglandin E Synthase-1.
Arthritis
Inhibitory effects of insulin-like growth factor-1 and osteogenic protein-1 on fibronectin fragment- and interleukin-1beta-stimulated matrix metalloproteinase-13 expression in human chondrocytes.
Arthritis
Joint diseases and matrix metalloproteinases: a role for MMP-13.
Arthritis
Kruppel-like factor 2 (KLF2) regulates monocyte differentiation and functions in mBSA and IL-1?-induced arthritis.
Arthritis
Levels of Matrix Metalloproteinases in Arthroplasty Patients and Their Correlation With Inflammatory and Thrombotic Activation Processes.
Arthritis
LncRNA H19 regulates macrophage polarization and promotes Freund's complete adjuvant-induced arthritis by upregulating KDM6A.
Arthritis
Mast cell-restricted, tetramer-forming tryptases induce aggrecanolysis in articular cartilage by activating matrix metalloproteinase-3 and -13 zymogens.
Arthritis
Matrix metalloproteinase-13: A special focus on its regulation by signaling cascades and microRNAs in bone.
Arthritis
MMP-13 is constitutively produced in human chondrocytes and co-endocytosed with ADAMTS-5 and TIMP-3 by the endocytic receptor LRP1.
Arthritis
Modulation of matrix metalloprotease 13 (collagenase 3) gene expression in equine chondrocytes by interleukin 1 and corticosteroids.
Arthritis
MyD88, IRAK1 and TRAF6 knockdown in human chondrocytes inhibits interleukin-1-induced matrix metalloproteinase-13 gene expression and promoter activity by impairing MAP kinase activation.
Arthritis
Norisoboldine alleviates joint destruction in rats with adjuvant-induced arthritis by reducing RANKL, IL-6, PGE2, and MMP-13 expression.
Arthritis
Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants.
Arthritis
PEP-1-FK506BP12 inhibits matrix metalloproteinase expression in human articular chondrocytes and in a mouse carrageenan-induced arthritis model.
Arthritis
Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
Arthritis
Serum and knee synovial fluid matrix metalloproteinase-13 and tumor necrosis factor-alpha levels in patients with late-stage osteoarthritis.
Arthritis
Serum and knee synovial fluid matrixmetalloproteinase-13 and tumor necrosis factor-alpha levels in patients with late stage osteoarthritis.
Arthritis
Soluble Siglec-9 suppresses arthritis in a collagen-induced arthritis mouse model and inhibits M1 activation of RAW264.7 macrophages.
Arthritis
Stromal cell-derived factor-1 induces matrix metalloprotease-13 expression in human chondrocytes.
Arthritis
Suppression of hyaluronan synthesis alleviates inflammatory response in murine arthritis and in human rheumatoid synovial fibroblasts.
Arthritis
TAP2, a peptide antagonist of Toll-like receptor 4, attenuates pain and cartilage degradation in a monoiodoacetate-induced arthritis rat model.
Arthritis
The promoting effect of MMP13 on mediating the development of HFLS-RA by the target of miR-19a through IL-17 signaling pathway.
Arthritis
Thrombin promotes matrix metalloproteinase-13 expression through the PKC? c-Src/EGFR/PI3K/Akt/AP-1 signaling pathway in human chondrocytes.
Arthritis
Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors.
Arthritis
UP1306: A Composition Containing Standardized Extracts of Acacia catechu and Morus alba for Arthritis Management.
Arthritis
YB-1 binds to the MMP-13 promoter sequence and represses MMP-13 transactivation via the AP-1 site.
Arthritis, Experimental
In vivo imaging of matrix metalloproteinase 12 and matrix metalloproteinase 13 activities in the mouse model of collagen-induced arthritis.
Arthritis, Experimental
Madecassoside impedes invasion of rheumatoid fibroblast-like synoviocyte from adjuvant arthritis rats via inhibition of NF-?B-mediated matrix metalloproteinase-13 expression.
Arthritis, Experimental
UP1306: A Composition Containing Standardized Extracts of Acacia catechu and Morus alba for Arthritis Management.
Arthritis, Experimental
[Effect of electroacupuncture on articular morphological changes and serum inflammatory factors and synovial MMPs in collagen-induced arthritis rats].
Arthritis, Infectious
Streptococcus pyogenes degrades extracellular matrix in chondrocytes via MMP-13.
Arthritis, Psoriatic
Differences in Osteoimmunological Biomarkers Predictive of Psoriatic Arthritis among a Large Italian Cohort of Psoriatic Patients.
Arthritis, Rheumatoid
15-deoxy-?(12,14) -prostaglandin-J2 and Ciglitazone Inhibit TNF-?-induced matrix metalloproteinase 13 production via the antagonism of NF-?B activation in human synovial fibroblasts.
Arthritis, Rheumatoid
Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators.
Arthritis, Rheumatoid
Anti-inflammatory and anti-arthritic effects of the ethanolic extract of Aralia continentalis Kitag. in IL-1?-stimulated human fibroblast-like synoviocytes and rodent models of polyarthritis and nociception.
Arthritis, Rheumatoid
CCAAT/enhancer binding protein beta mediates expression of matrix metalloproteinase 13 in human articular chondrocytes in inflammatory arthritis.
Arthritis, Rheumatoid
Characterisation of the cell type-specificity of collagenase 3 mRNA expression in comparison with membrane type 1 matrix metalloproteinase and gelatinase A in the synovial membrane in rheumatoid arthritis.
Arthritis, Rheumatoid
Characterization of collagenase 3 (matrix metalloproteinase 13) messenger RNA expression in the synovial membrane and synovial fibroblasts of patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Cheminformatics-based drug design approach for identification of inhibitors targeting the characteristic residues of MMP-13 hemopexin domain.
Arthritis, Rheumatoid
Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis.
Arthritis, Rheumatoid
Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: differential expression with collagenase-1 (matrix metalloproteinase-1).
Arthritis, Rheumatoid
Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ: in vitro mimicking effect by transforming growth factor beta.
Arthritis, Rheumatoid
Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate.
Arthritis, Rheumatoid
Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis.
Arthritis, Rheumatoid
Contribution of an adenine to guanine single nucleotide polymorphism of the matrix metalloproteinase-13 (MMP-13) -77 promoter region to the production of anticyclic citrullinated peptide antibodies in patients with HLA-DRB1*shared epitope-negative rheumatoid arthritis.
Arthritis, Rheumatoid
Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification.
Arthritis, Rheumatoid
Discoidin domain receptor 2 is associated with the increased expression of matrix metalloproteinase-13 in synovial fibroblasts of rheumatoid arthritis.
Arthritis, Rheumatoid
Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis.
Arthritis, Rheumatoid
Effects of celecoxib on human chondrocytes--enhanced production of chemokines.
Arthritis, Rheumatoid
Expression of interleukin-1 beta, tumor necrosis factor alpha, interleukins-6, -10 and -4, and metalloproteases by freshly isolated mononuclear cells from early never-treated and non-acute treated rheumatoid arthritis patients.
Arthritis, Rheumatoid
In Vivo Dual Fluorescence Imaging to Detect Joint Destruction.
Arthritis, Rheumatoid
Indole Inhibitors of MMP-13 for Arthritic Disorders.
Arthritis, Rheumatoid
Induction of collagenase-3 (MMP-13) in rheumatoid arthritis synovial fibroblasts.
Arthritis, Rheumatoid
Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium.
Arthritis, Rheumatoid
Messenger-RNA expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases, and transcription factors in rheumatic synovial cells under mechanical stimuli.
Arthritis, Rheumatoid
MKK3/6-p38 MAPK negatively regulates murine MMP-13 gene expression induced by IL-1beta and TNF-alpha in immortalized periodontal ligament fibroblasts.
Arthritis, Rheumatoid
Pyrrolidine dithiocarbamate, a NF-kappaB inhibitor, upregulates MMP-1 and MMP-13 in IL-1beta-stimulated rheumatoid arthritis fibroblast-like synoviocytes.
Arthritis, Rheumatoid
RANTES/CCL5 Induces Collagen Degradation by Activating MMP-1 and MMP-13 Expression in Human Rheumatoid Arthritis Synovial Fibroblasts.
Arthritis, Rheumatoid
Reduction of cytokine-induced expression and activity of MMP-1 and MMP-13 by mechanical strain in MH7A rheumatoid synovial cells.
Arthritis, Rheumatoid
Retinoic Acid-Platinum (II) Complex [RT-Pt(II)] Protects Against Rheumatoid Arthritis in Mice via MEK/Nuclear Factor kappa B (NF-?B) Pathway Downregulation.
Arthritis, Rheumatoid
Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis.
Arthritis, Rheumatoid
Stimulation of collagenase 3 expression in synovial fibroblasts of patients with rheumatoid arthritis by contact with a three-dimensional collagen matrix or with normal cartilage when coimplanted in NOD/SCID mice.
Arthritis, Rheumatoid
T cells regulate the expression of matrix metalloproteinase in human osteoblasts via a dual mitogen-activated protein kinase mechanism.
Arthritis, Rheumatoid
Taurine chloramine differentially inhibits matrix metalloproteinase 1 and 13 synthesis in interleukin-1beta stimulated fibroblast-like synoviocytes.
Arthritis, Rheumatoid
The expression of collagenase 3 (MMP-13) mRNA in the synovial tissue is associated with histopathologic type II synovitis in rheumatoid arthritis.
Arthritis, Rheumatoid
The influence of alpha1-acid glycoprotein on collagenase-3 activity in early rheumatoid arthritis.
Arthritis, Rheumatoid
Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors.
Arthritis, Rheumatoid
Variation in the matrix metalloproteinase-3, -7, -12 and -13 genes is associated with functional status in rheumatoid arthritis.
Arthritis, Rheumatoid
Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13).
Arthritis, Rheumatoid
[Dynamics of matrix metalloproteinase (MMP)-13 in the patients with rheumatoid arthritis]
Asthma
Targeting matrix metalloproteinase-13 in bronchial epithelial repair.
Ataxia Telangiectasia
Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells.
Atherosclerosis
Activation of inflammatory mediators and potential role of ah-receptor ligands in foam cell formation.
Atherosclerosis
Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury.
Atherosclerosis
Endothelial nitric oxide deficiency reduces MMP-13-mediated cleavage of ICAM-1 in vascular endothelium: a role in atherosclerosis.
Atherosclerosis
FOXO3a (Forkhead Transcription Factor O Subfamily Member 3a) Links Vascular Smooth Muscle Cell Apoptosis, Matrix Breakdown, Atherosclerosis, and Vascular Remodeling Through a Novel Pathway Involving MMP13 (Matrix Metalloproteinase 13).
Atherosclerosis
MMP-13 is constitutively produced in human chondrocytes and co-endocytosed with ADAMTS-5 and TIMP-3 by the endocytic receptor LRP1.
Atherosclerosis
MMP13 promoter polymorphism is associated with atherosclerosis in the abdominal aorta of young black males.
Atherosclerosis
Non-Invasive Detection of Extracellular Matrix Metalloproteinase Inducer EMMPRIN, a New Therapeutic Target against Atherosclerosis, Inhibited by Endothelial Nitric Oxide.
Atherosclerosis
Role of matrix metalloproteinase-8 in atherosclerosis.
Atherosclerosis
Selective Imaging of Matrix Metalloproteinase-13 to Detect Extracellular Matrix Remodeling in Atherosclerotic Lesions.
Atherosclerosis
Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis.
Bacterial Infections
Identification and characterization of matrix metalloproteinase-13 sequence structure and expression during embryogenesis and infection in channel catfish (Ictalurus punctatus).
Barrett Esophagus
Active matrix metalloproteases are expressed early on and are high during the Barrett's esophagus malignancy sequence.
Basal Cell Nevus Syndrome
MMP-13 expression in keratocyst odontogenic tumour associated with NBCCS and sporadic keratocysts.
Blister
Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid.
Bone Cysts
Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis.
Bone Diseases
Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease.
Bone Neoplasms
Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells.
Bone Neoplasms
Transcriptional activation of collagenase-3 by transforming growth factor-beta1 is via MAPK and Smad pathways in human breast cancer cells.
Bone Resorption
A matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis.
Bone Resorption
Alendronate reduced peri-tunnel bone loss and enhanced tendon graft to bone tunnel healing in anterior cruciate ligament reconstruction.
Bone Resorption
AU-rich elements in the collagenase 3 mRNA mediate stabilization of the transcript by cortisol in osteoblasts.
Bone Resorption
Catabolic activity of osteoblast lineage cells contributes to osteoclastic bone resorption in vitro.
Bone Resorption
Differential regulation of MMP-13 (collagenase-3) and MMP-3 (stromelysin-1) in mouse calvariae.
Bone Resorption
Effects of 17 beta-estradiol on the expression of interstitial collagenases-8 and -13 (MMP-8 and MMP-13) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in ovariectomized rat osteoblastic cells.
Bone Resorption
Evidence for the role of matrix metalloproteinase-13 in bone resorption by giant cell tumor of bone.
Bone Resorption
Expression of MMP-2, 9 and 13 in newly formed bone after sinus augmentation using inorganic bovine bone in human.
Bone Resorption
Expression of MMP-8 and MMP-13 in the development of periradicular lesions.
Bone Resorption
High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage.
Bone Resorption
Identification and characterization of Runx2 phosphorylation sites involved in matrix metalloproteinase-13 promoter activation.
Bone Resorption
Immunolocalization of matrix metalloproteinase-13 on bone surface under osteoclasts in rat tibia.
Bone Resorption
Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice.
Bone Resorption
In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation.
Bone Resorption
Interface membrane fibroblasts around aseptically loosened endoprostheses express MMP-13.
Bone Resorption
LPS-induced premature osteocyte senescence: Implications in inflammatory alveolar bone loss and periodontal disease pathogenesis.
Bone Resorption
Matrix metalloproteinase-13 is highly expressed in destructive periodontal disease activity.
Bone Resorption
Mechanisms of glucocorticoid action in bone.
Bone Resorption
MiR-126-5p regulates osteoclast differentiation and bone resorption in giant cell tumor through inhibition of MMP-13.
Bone Resorption
MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases.
Bone Resorption
Neural crest-mediated bone resorption is a determinant of species-specific jaw length.
Bone Resorption
Overexpression of Runx2 directed by the matrix metalloproteinase-13 promoter containing the AP-1 and Runx/RD/Cbfa sites alters bone remodeling in vivo.
Bone Resorption
Parathyroid hormone increases the expression level of matrix metalloproteinase-13 in vivo.
Bone Resorption
Platelet-derived growth factor induces collagenase 3 transcription in osteoblasts through the activator protein 1 complex.
Bone Resorption
Psychological stress and aging: role of glucocorticoids (GCs).
Bone Resorption
Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis.
Bone Resorption
Silencing matrix metalloproteinase-13 (Mmp-13) reduces inflammatory bone resorption associated with LPS-induced periodontal disease in vivo.
Bone Resorption
The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K.
Bone Resorption
The use of different analgesics in orthodontic tooth movements.
Bone Resorption
Transcriptional induction of matrix metalloproteinase-13 (collagenase-3) by 1alpha,25-dihydroxyvitamin D3 in mouse osteoblastic MC3T3-E1 cells.
Bone Resorption
Transforming growth factor-beta 1 regulation of collagenase-3 expression in osteoblastic cells by cross-talk between the Smad and MAPK signaling pathways and their components, Smad2 and Runx2.
Bone Resorption
Triclosan Blocks Mmp 13 Expression in Hormone-Stimulated Osteoblasts.
Bone Resorption
[Electroacupuncture Intervention Improves Cartilage Degeneration and Subchondral Bone Osteoporosis of Knee-joint Possibly by Adjusting OPG/RANK/RANKL Signaling in Ovariectomized Rats].
Bowen's Disease
Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas.
Brain Infarction
A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke.
Brain Injuries
A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke.
Brain Injuries
Blood biomarkers to guide stroke thrombolysis.
Brain Injuries
Blood-brain barrier damage in vascular dementia.
Brain Injuries
Stroke biomarkers: Can they help us to guide stroke thrombolysis?
Brain Injuries
Stroke biomarkers: can they help us to guide stroke thrombolysis?
Brain Ischemia
Focal cerebral ischemia induces changes in both MMP-13 and aggrecan around individual neurons.
Brain Ischemia
Matrix metalloproteinase-13 is activated and is found in the nucleus of neural cells after cerebral ischemia.
Brain Ischemia
Matrix metalloproteinase-13 participates in neuroprotection and neurorepair after cerebral ischemia in mice.
Brain Neoplasms
Using urinary bFGF and TIMP3 levels to predict the presence of juvenile pilocytic astrocytoma and establish a distinct biomarker signature.
Breast Neoplasms
A computational study of non-coding RNAs on the regulation of activating transcription factor 3 in human breast cancer cells.
Breast Neoplasms
A matrix metalloproteinase gene expressed in human T lymphocytes is identical with collagenase 3 from breast carcinomas.
Breast Neoplasms
Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13).
Breast Neoplasms
An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer.
Breast Neoplasms
Biochemical characterization of human collagenase-3.
Breast Neoplasms
Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node.
Breast Neoplasms
Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of Metalloproteinase (MMP)-13.
Breast Neoplasms
Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis.
Breast Neoplasms
Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage.
Breast Neoplasms
Cobalt chloride-induced hypoxia modulates the invasive potential and matrix metalloproteinases of primary and metastatic breast cancer cells.
Breast Neoplasms
Collagenase 3 (matrix metalloproteinase 13) gene expression by HaCaT keratinocytes is enhanced by tumor necrosis factor alpha and transforming growth factor beta.
Breast Neoplasms
Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor.
Breast Neoplasms
Collagenase-3 (MMP-13) is expressed by hypertrophic chondrocytes, periosteal cells, and osteoblasts during human fetal bone development.
Breast Neoplasms
Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.
Breast Neoplasms
Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx.
Breast Neoplasms
Constitutive expression and regulation of collagenase-3 in human breast cancer cells.
Breast Neoplasms
Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes.
Breast Neoplasms
Differential effects of transforming growth factor-beta on the expression of collagenase-1 and collagenase-3 in human fibroblasts.
Breast Neoplasms
Differential expression of matrix metalloproteinase-13 in association with invasion of breast cancer.
Breast Neoplasms
Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness.
Breast Neoplasms
ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis.
Breast Neoplasms
Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors.
Breast Neoplasms
Expression of collagenase-3 in the rat ovary during the ovulatory process.
Breast Neoplasms
Functional characterization of selective exosite-binding inhibitors of matrix metalloproteinase-13 (MMP-13) - experimental validation in human breast and colon cancer.
Breast Neoplasms
Golgi Membrane Protein 1 (GOLM1) Promotes Growth and Metastasis of Breast Cancer Cells via Regulating Matrix Metalloproteinase-13 (MMP13).
Breast Neoplasms
Gremlin-1 Promotes Metastasis of Breast Cancer Cells by Activating STAT3-MMP13 Signaling Pathway.
Breast Neoplasms
Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity.
Breast Neoplasms
In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation.
Breast Neoplasms
Induction of MMP-13 expression in bone-metastasizing cancer cells by type I collagen through integrin ?1?1 and ?2?1-p38 MAPK signaling.
Breast Neoplasms
Is collagenase-3 (MMP-13) expression in chondrosarcoma of the jaws a true marker for tumor aggressiveness?
Breast Neoplasms
Long non-coding RNA LINC00511/miR-150/MMP13 axis promotes breast cancer proliferation, migration and invasion.
Breast Neoplasms
Many new down- and up-regulatory signaling pathways, from known cancer progression suppressors to matrix metalloproteinases, differ widely in cells of various cancers.
Breast Neoplasms
Markers of breast cancer stromal fibroblasts in the primary tumour site associated with lymph node metastasis: a systematic review including our case series.
Breast Neoplasms
Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
Breast Neoplasms
Matrix Metalloproteinase 13 Inhibitors for Modulation of Osteoclastogenesis: Enhancement of Solubility and Stability.
Breast Neoplasms
Matrix metalloproteinase 13 is induced in fibroblasts in polyomavirus middle T antigen-driven mammary carcinoma without influencing tumor progression.
Breast Neoplasms
Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression.
Breast Neoplasms
Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: the role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis.
Breast Neoplasms
MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13.
Breast Neoplasms
miR-130b-3p inhibits cell invasion and migration by targeting the Notch ligand Delta-like 1 in breast carcinoma.
Breast Neoplasms
MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases.
Breast Neoplasms
MMP13 is potentially a new tumor marker for breast cancer diagnosis.
Breast Neoplasms
Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas.
Breast Neoplasms
New pathway links from cancer-progression determinants to gene expression of matrix metalloproteinases in breast cancer cells.
Breast Neoplasms
New signaling pathways from cancer progression modulators to mRNA expression of matrix metalloproteinases in breast cancer cells.
Breast Neoplasms
P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway.
Breast Neoplasms
Parathyroid hormone-related peptide regulates matrix metalloproteinase-13 gene expression in bone metastatic breast cancer cells.
Breast Neoplasms
Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis.
Breast Neoplasms
Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression.
Breast Neoplasms
Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion.
Breast Neoplasms
Quantitative real-time RT-PCR of ITGA7, SVEP1, TNS1, LPHN3, SEMA3G, KLB and MMP13 mRNA expression in breast cancer.
Breast Neoplasms
Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions.
Breast Neoplasms
Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.
Breast Neoplasms
RKIP Inhibits Local Breast Cancer Invasion by Antagonizing the Transcriptional Activation of MMP13.
Breast Neoplasms
RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion.
Breast Neoplasms
S100A4 Elevation Empowers Expression of Metastasis Effector Molecules in Human Breast Cancer.
Breast Neoplasms
S100A4 promotes invasion and angiogenesis in breast cancer MDA-MB-231 cells by upregulating matrix metalloproteinase-13.
Breast Neoplasms
Slit2 inhibits breast cancer metastasis by activating M1-like phagocytic and anti-fibrotic macrophages.
Breast Neoplasms
Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells.
Breast Neoplasms
Stimulation of ATF3 interaction with Smad4 via TGF-?1 for matrix metalloproteinase 13 gene activation in human breast cancer cells.
Breast Neoplasms
Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
Breast Neoplasms
Stromal matrix metalloprotease-13 knockout alters Collagen I structure at the tumor-host interface and increases lung metastasis of C57BL/6 syngeneic E0771 mammary tumor cells.
Breast Neoplasms
Structural analysis and promoter characterization of the human collagenase-3 gene (MMP13).
Breast Neoplasms
The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexin-like domain.
Breast Neoplasms
The human collagenase-3 (CLG3) gene is located on chromosome 11q22.3 clustered to other members of the matrix metalloproteinase gene family.
Breast Neoplasms
Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro.
Breast Neoplasms
Toll-Like Receptor 9 Agonists Promote Cellular Invasion by Increasing Matrix Metalloproteinase Activity.
Breast Neoplasms
Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity.
Breast Neoplasms
Transcriptional activation of collagenase-3 by transforming growth factor-beta1 is via MAPK and Smad pathways in human breast cancer cells.
Breast Neoplasms
Transforming growth factor-?1 regulation of ATF-3, c-Jun and JunB proteins for activation of matrix metalloproteinase-13 gene in human breast cancer cells.
Breast Neoplasms
Transforming growth factor-beta1 regulation of ATF-3 and identification of ATF-3 target genes in breast cancer cells.
Breast Neoplasms
Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.
Breast Neoplasms
Tumor-Derived Matrix Metalloproteinase-13 (MMP-13) Expression in Benign and Malignant Breast Lesions.
Breast Neoplasms
Upregulated osterix promotes invasion and bone metastasis and predicts for a poor prognosis in breast cancer.
Breast Neoplasms
Upregulation of matrix metalloproteinases (MMPs) in breast cancer xenografts: a major induction of stromal MMP-13.
Breast Neoplasms
[Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer]
Bursitis
Genetic variants involved in extracellular matrix homeostasis play a role in the susceptibility to frozen shoulder: a case-control study.
Carcinogenesis
Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential?
Carcinogenesis
ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis.
Carcinogenesis
Extracellular signal-regulated kinase transmits palytoxin-stimulated signals leading to altered gene expression in mouse keratinocytes.
Carcinogenesis
Host-derived MMP-13 exhibits a protective role in lung metastasis of melanoma cells by local endostatin production.
Carcinogenesis
Human collagenase-3 is expressed in malignant squamous epithelium of the skin.
Carcinogenesis
Increase of MMP-13 expression in multi-stage oral carcinogenesis and epigallocatechin-3-gallate suppress MMP-13 expression.
Carcinogenesis
Matrix metalloproteinase-13 expression in the progression of colorectal adenoma to carcinoma : Matrix metalloproteinase-13 expression in the colorectal adenoma and carcinoma.
Carcinogenesis
Mitogen activated protein kinases selectively regulate palytoxin-stimulated gene expression in mouse keratinocytes.
Carcinogenesis
Olive Leaf Extract and Its Main Component Oleuropein Prevent Chronic Ultraviolet B Radiation-Induced Skin Damage and Carcinogenesis in Hairless Mice.
Carcinogenesis
Overexpression of MMP13 is associated with clinical outcomes and poor prognosis in oral squamous cell carcinoma.
Carcinogenesis
PLD1 promotes tumor invasion by regulation of MMP-13 expression via NF-?B signaling in bladder cancer.
Carcinogenesis
The Sp1-mediaded allelic regulation of MMP13 expression by an ESCC susceptibility SNP rs2252070.
Carcinogenesis
Tumor promoter-induced MMP-13 gene expression in a model of initiated epidermis.
Carcinoma
Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2.
Carcinoma
Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells.
Carcinoma
AJUBA promotes the migration and invasion of esophageal squamous cell carcinoma cells through upregulation of MMP10 and MMP13 expression.
Carcinoma
Alpha v beta 6 integrin down-regulates the MMP-13 expression in oral squamous cell carcinoma cells.
Carcinoma
Association of polymorphisms in IL-8, MMP-1 and MMP-13 with the risk and prognosis of oral and oropharyngeal squamous cell carcinoma.
Carcinoma
Circulating IgG response to stromelysin-3, collagenase-3, galectin-3 and mesothelin in patients with pharynx/larynx squamous cell carcinoma.
Carcinoma
Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients.
Carcinoma
Clinical significance of serum matrix metalloproteinase-13 levels in patients with esophageal squamous cell carcinoma (ESCC).
Carcinoma
Collagenase 3 is a target of Cbfa1, a transcription factor of the runt gene family involved in bone formation.
Carcinoma
Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas.
Carcinoma
Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.
Carcinoma
Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx.
Carcinoma
Colorectal signet ring cell carcinoma: Influence of EGFR, E-cadherin and MMP-13 expression on clinicopathological features and prognosis.
Carcinoma
Common polymorphism in the MMP-13 gene may contribute to the risk of human cancers: a meta-analysis.
Carcinoma
Correlation Between the Expression of Matrix Metalloproteinase-9, Matrix Metalloproteinase-13, Tissue Inhibitor of Metalloproteinases-1, p16 and Differentiation of Head and Neck Squamous Cell Carcinoma: A Prospective Observational Study.
Carcinoma
Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification.
Carcinoma
Crosstalk between MMP-13, CD44, and TWIST1 and its role in regulation of EMT in patients with esophageal squamous cell carcinoma.
Carcinoma
CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway.
Carcinoma
Differential expression of matrix metalloproteinase-13 in mucinous and nonmucinous colorectal carcinomas.
Carcinoma
Effects of selective MMP-13 inhibition in Squamous Cell Carcinoma depend on estrogen.
Carcinoma
Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness.
Carcinoma
ETS-1 regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell SKOV-3.
Carcinoma
Evaluation of Collagen in Leukoplakia, Oral Submucous Fibrosis and Oral Squamous Cell Carcinomas Using Polarizing Microscopy and Immunohistochemistry
Carcinoma
Expression of collagenase-1 (MMP-1), collagenase-3 (MMP-13) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in laryngeal squamous cell carcinomas.
Carcinoma
Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer.
Carcinoma
Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck.
Carcinoma
Expression of collagenase-3 (matrix metalloproteinase-13) in transitional-cell carcinoma of the urinary bladder.
Carcinoma
Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase.
Carcinoma
Expression of collagenase-3 (MMP-13) by tumor cells in squamous cell carcinomas of the head and neck.
Carcinoma
Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells.
Carcinoma
Expression of CXCR4, MMP-13 and ?-catenin in different histological subtypes of facial basal cell carcinoma.
Carcinoma
Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines.
Carcinoma
Expression of MMP-13 is associated with invasion and metastasis of papillary thyroid carcinoma.
Carcinoma
Expression of MMP-3, MMP-13, TIMP-2 and TIMP-3 in the VX2 carcinoma of the New Zealand white rabbit.
Carcinoma
FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13.
Carcinoma
Human collagenase-3 is expressed in malignant squamous epithelium of the skin.
Carcinoma
Identification of GOLM1 as a positively regulator of tumor metastasis by regulating MMP13 in gastric carcinoma.
Carcinoma
Increase of MMP-13 expression in multi-stage oral carcinogenesis and epigallocatechin-3-gallate suppress MMP-13 expression.
Carcinoma
Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness.
Carcinoma
Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-gamma is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1.
Carcinoma
Interleukin-1 Receptor Antagonist Has a Novel Function in the Regulation of Matrix Metalloproteinase-13 Expression.
Carcinoma
Interleukin-11 induces the expression of matrix metalloproteinase 13 in gastric cancer SCH cells partly via the PI3K-AKT and JAK-STAT3 pathways.
Carcinoma
Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells.
Carcinoma
Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer.
Carcinoma
Matrix metalloproteinase 13 is induced in fibroblasts in polyomavirus middle T antigen-driven mammary carcinoma without influencing tumor progression.
Carcinoma
Matrix Metalloproteinase-13 - A Potential Biomarker for Detection and Prognostic Assessment of Patients with Esophageal Squamous Cell Carcinoma.
Carcinoma
Matrix metalloproteinase-13 expression in the progression of colorectal adenoma to carcinoma : Matrix metalloproteinase-13 expression in the colorectal adenoma and carcinoma.
Carcinoma
MicroRNA-27b-3p inhibits the proliferation and invasion of cutaneous squamous cell carcinoma by targeting EGFR and MMP-13.
Carcinoma
MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-beta1.
Carcinoma
MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma.
Carcinoma
MMP13 can be a useful differentiating marker between squamous cell carcinoma and benign hyperkeratotic lesions in recessive dystrophic epidermolysis bullosa.
Carcinoma
MUC1 induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13.
Carcinoma
Nanocapsulated quercetin downregulates rat hepatic MMP-13 and controls diethylnitrosamine-induced carcinoma.
Carcinoma
Nucleolin binds specifically to an AP-1 DNA sequence and represses AP1-dependent transactivation of the matrix metalloproteinase-13 gene.
Carcinoma
Overexpression of MMP13 is associated with clinical outcomes and poor prognosis in oral squamous cell carcinoma.
Carcinoma
Pathophysiological changes induced by Pseudomonas aeruginosa infection are involved in MMP-12 and MMP-13 upregulation in human carcinoma epithelial cells and a pneumonia mouse model.
Carcinoma
Prognostic value of matrix metalloproteinases in oral squamous cell carcinoma.
Carcinoma
Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma.
Carcinoma
Role of matrix metalloproteinase 13 gene expression in the evaluation of radiation response in oral squamous cell carcinoma.
Carcinoma
Salivary MMP-1, MMP-2, MMP-3 and MMP-13 Levels in Patients with Oral Lichen Planus and Squamous Cell Carcinoma
Carcinoma
Secretion of N- and O-linked Glycoproteins from 4T1 Murine Mammary Carcinoma Cells.
Carcinoma
Serum and saliva collagenase-3 (MMP-13) in patients with oral lichen planus and oral squamous cell carcinoma.
Carcinoma
Serum matrix metalloproteinase-13 as a diagnostic biomarker for cutaneous squamous cell carcinoma.
Carcinoma
Suppressive effect of calcipotriol on the induction of matrix metalloproteinase (MMP)-9 and MMP-13 in a human squamous cell carcinoma cell line.
Carcinoma
Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo.
Carcinoma
The functional polymorphisms on promoter region of matrix metalloproteinase-12, -13 genes may alter the risk of epithelial ovarian carcinoma in chinese.
Carcinoma
The immunoexpression of MMP-1 and MMP-13 in eyelid basal cell carcinoma.
Carcinoma
The usefulness of new serum tumor markers in head and neck squamous cell carcinoma.
Carcinoma
Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas.
Carcinoma
Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.
Carcinoma
Type III Secretion System of Pseudomonas aeruginosa Affects Matrix Metalloproteinase 12 (MMP-12) and MMP-13 Expression via Nuclear Factor ?B Signaling in Human Carcinoma Epithelial Cells and a Pneumonia Mouse Model.
Carcinoma
Vascular expression of matrix metalloproteinase-13 (collagenase-3) in basal cell carcinoma.
Carcinoma
Withdrawal: ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3.
Carcinoma
[Association of functional polymorphisms on MMP-12 and MMP-13 gene promoter region with epithelial ovarian carcinoma.]
Carcinoma
[Collagenase 3 mRNA expression in squamous epithelial carcinomas of the oropharynx]
Carcinoma
[Collagenase-3 (MMP-13) expression in epithelial cancers of the eyelids]
Carcinoma
[Diagnostic value of E-cadherin, MMP-9, activated MMP-13 and anti-p53 antibodies in squamous cell carcinomas of head and neck]
Carcinoma
[Expression and clinical significance of collagenase-3 (MMP-13) in gastric cancer]
Carcinoma
[Matrix metalloproteinases and their tissue inhibitors in malignancies of the female genital tract]
Carcinoma
[Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer]
Carcinoma
[The association of MMP-13 polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adeno-carcinoma]
Carcinoma, Acinar Cell
Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer.
Carcinoma, Basal Cell
Expression of CXCR4, MMP-13 and ?-catenin in different histological subtypes of facial basal cell carcinoma.
Carcinoma, Basal Cell
Human collagenase-3 is expressed in malignant squamous epithelium of the skin.
Carcinoma, Basal Cell
Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells.
Carcinoma, Basal Cell
The immunoexpression of MMP-1 and MMP-13 in eyelid basal cell carcinoma.
Carcinoma, Basal Cell
Vascular expression of matrix metalloproteinase-13 (collagenase-3) in basal cell carcinoma.
Carcinoma, Basal Cell
[Collagenase-3 (MMP-13) expression in epithelial cancers of the eyelids]
Carcinoma, Ductal
Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.
Carcinoma, Ductal
Tumor-Derived Matrix Metalloproteinase-13 (MMP-13) Expression in Benign and Malignant Breast Lesions.
Carcinoma, Hepatocellular
Functional polymorphisms in the promoters of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12 and MMP-13 are not associated with hepatocellular carcinoma risk.
Carcinoma, Hepatocellular
Golgi protein 73 activation of MMP-13 promotes hepatocellular carcinoma cell invasion.
Carcinoma, Hepatocellular
No association of MMP-7, MMP-8, and MMP-21 polymorphisms with the risk of hepatocellular carcinoma in a Chinese population.
Carcinoma, Intraductal, Noninfiltrating
Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.
Carcinoma, Intraductal, Noninfiltrating
Expression of metalloproteases and their inhibitors by tumor and stromal cells in ductal carcinoma in situ of the breast and their relationship with microinvasive events.
Carcinoma, Intraductal, Noninfiltrating
Gene expression profiling during rat mammary carcinogenesis induced by 7,12-dimethylbenz[a]anthracene.
Carcinoma, Lobular
Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.
Carcinoma, Non-Small-Cell Lung
Association of MMP9-1562C/T and MMP13-77A/G Polymorphisms with Non-Small Cell Lung Cancer in Southern Chinese Population.
Carcinoma, Non-Small-Cell Lung
Matrix metalloproteinase 13: a potential intermediate between low expression of microRNA-125b and increasing metastatic potential of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
The functional polymorphisms on promoter region of matrix metalloproteinase-12, -13 genes may alter the risk of epithelial ovarian carcinoma in chinese.
Carcinoma, Ovarian Epithelial
[Association of functional polymorphisms on MMP-12 and MMP-13 gene promoter region with epithelial ovarian carcinoma.]
Carcinoma, Renal Cell
MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-beta1.
Carcinoma, Renal Cell
Suppressed Expression but Not Activity of Collagenases MMP-1 and MMP-13 in Human Renal Carcinoma.
Carcinoma, Renal Cell
Suppression of tunicamycin-induced CD44v6 ectodomain shedding and apoptosis is correlated with temporal expression patterns of active ADAM10, MMP-9 and MMP-13 proteins in Caki-2 renal carcinoma cells.
Carcinoma, Signet Ring Cell
Colorectal signet ring cell carcinoma: Influence of EGFR, E-cadherin and MMP-13 expression on clinicopathological features and prognosis.
Carcinoma, Squamous Cell
Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells.
Carcinoma, Squamous Cell
Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells.
Carcinoma, Squamous Cell
Alpha v beta 6 integrin down-regulates the MMP-13 expression in oral squamous cell carcinoma cells.
Carcinoma, Squamous Cell
Association of polymorphisms in IL-8, MMP-1 and MMP-13 with the risk and prognosis of oral and oropharyngeal squamous cell carcinoma.
Carcinoma, Squamous Cell
Circulating IgG response to stromelysin-3, collagenase-3, galectin-3 and mesothelin in patients with pharynx/larynx squamous cell carcinoma.
Carcinoma, Squamous Cell
Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas.
Carcinoma, Squamous Cell
Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx.
Carcinoma, Squamous Cell
Complement factor I upregulates expression of matrix metalloproteinase-13 and -2 and promotes invasion of cutaneous squamous carcinoma cells.
Carcinoma, Squamous Cell
Correlation Between the Expression of Matrix Metalloproteinase-9, Matrix Metalloproteinase-13, Tissue Inhibitor of Metalloproteinases-1, p16 and Differentiation of Head and Neck Squamous Cell Carcinoma: A Prospective Observational Study.
Carcinoma, Squamous Cell
Effects of selective MMP-13 inhibition in Squamous Cell Carcinoma depend on estrogen.
Carcinoma, Squamous Cell
Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness.
Carcinoma, Squamous Cell
Expression of collagenase-1 (MMP-1), collagenase-3 (MMP-13) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in laryngeal squamous cell carcinomas.
Carcinoma, Squamous Cell
Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck.
Carcinoma, Squamous Cell
Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase.
Carcinoma, Squamous Cell
Expression of collagenase-3 (MMP-13) by tumor cells in squamous cell carcinomas of the head and neck.
Carcinoma, Squamous Cell
Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells.
Carcinoma, Squamous Cell
Human collagenase-3 is expressed in malignant squamous epithelium of the skin.
Carcinoma, Squamous Cell
Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-gamma is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1.
Carcinoma, Squamous Cell
MicroRNA-27b-3p inhibits the proliferation and invasion of cutaneous squamous cell carcinoma by targeting EGFR and MMP-13.
Carcinoma, Squamous Cell
MMP13 can be a useful differentiating marker between squamous cell carcinoma and benign hyperkeratotic lesions in recessive dystrophic epidermolysis bullosa.
Carcinoma, Squamous Cell
Salivary MMP-1, MMP-2, MMP-3 and MMP-13 Levels in Patients with Oral Lichen Planus and Squamous Cell Carcinoma
Carcinoma, Squamous Cell
Serum matrix metalloproteinase-13 as a diagnostic biomarker for cutaneous squamous cell carcinoma.
Carcinoma, Squamous Cell
Suppressive effect of calcipotriol on the induction of matrix metalloproteinase (MMP)-9 and MMP-13 in a human squamous cell carcinoma cell line.
Carcinoma, Squamous Cell
Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo.
Carcinoma, Squamous Cell
The usefulness of new serum tumor markers in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas.
Carcinoma, Squamous Cell
[Collagenase 3 mRNA expression in squamous epithelial carcinomas of the oropharynx]
Carcinoma, Squamous Cell
[Collagenase-3 (MMP-13) expression in epithelial cancers of the eyelids]
Carcinoma, Squamous Cell
[Diagnostic value of E-cadherin, MMP-9, activated MMP-13 and anti-p53 antibodies in squamous cell carcinomas of head and neck]
Carcinoma, Squamous Cell
[Matrix metalloproteinases and their tissue inhibitors in malignancies of the female genital tract]
Cardiovascular Diseases
Serum tissue-degrading proteinases and incident cardiovascular disease events.
Cholestasis
Secondary biliary cirrhosis in the rat is prevented by decreasing NF-?B nuclear translocation and TGF-? expression using allopurinol, an inhibitor of xanthine oxidase.
Cholesteatoma
Evaluation of significant gene expression changes in congenital and acquired cholesteatoma.
Cholesteatoma
The localization of matrix metalloproteinases-8 and -13 in cholesteatoma, deep-meatal and post-auricular skin: a comparative analysis.
Cholesteatoma
[The expression and significance of DDR2 and MMP-13in human middle ear cholesteatoma].
Cholesteatoma, Middle Ear
[The expression and significance of DDR2 and MMP-13in human middle ear cholesteatoma].
Chondroma
Expression of MMPs is dependent on the activity of mitogen-activated protein kinase in chondrosarcoma.
Chondroma
Overexpression of A disintegrin and metalloproteinase 28 is correlated with high histologic grade in conventional chondrosarcoma.
Chondrosarcoma
alpha-MSH inhibits TNF-alpha-induced matrix metalloproteinase-13 expression by modulating p38 kinase and nuclear factor kappaB signaling in human chondrosarcoma HTB-94 cells.
Chondrosarcoma
Bone morphogenetic protein-2 enhances the motility of chondrosarcoma cells via activation of matrix metalloproteinase-13.
Chondrosarcoma
Carnosol and Related Substances Modulate Chemokine and Cytokine Production in Macrophages and Chondrocytes.
Chondrosarcoma
CCAAT-Enhancer-binding protein beta activation of MMP-1 gene expression in SW1353 cells: independent roles of extracellular signal-regulated and p90/Ribosomal S6 kinases.
Chondrosarcoma
CCN3 increases cell motility and MMP-13 expression in human chondrosarcoma through integrin dependent pathway.
Chondrosarcoma
Characterization and regulation of ADAMTS-16.
Chondrosarcoma
Chondroprotective effects and multi-target mechanisms of Icariin in IL-1 beta-induced human SW 1353 chondrosarcoma cells and a rat osteoarthritis model.
Chondrosarcoma
Collagen and aggrecan degradation is blocked in interleukin-1-treated cartilage explants by an inhibitor of IkappaB kinase through suppression of metalloproteinase expression.
Chondrosarcoma
Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor.
Chondrosarcoma
Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis.
Chondrosarcoma
CTGF enhances migration and MMP-13 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells.
Chondrosarcoma
Cyr61 increases migration and MMP-13 expression via alphavbeta3 integrin, FAK, ERK and AP-1-dependent pathway in human chondrosarcoma cells.
Chondrosarcoma
Cysteine proteinases in chondrosarcomas.
Chondrosarcoma
Differential regulation of cytokine-induced MMP-1 and MMP-13 expression by p38 kinase inhibitors in human chondrosarcoma cells: potential role of Runx2 in mediating p38 effects.
Chondrosarcoma
Downregulation of Matrix Metalloproteinase-13 by the Root Extract of Cyathula officinalis Kuan and its Constituents in IL-1?-treated Chondrocytes.
Chondrosarcoma
Doxycycline and its quaternary ammonium derivative for adjuvant therapies of chondrosarcoma.
Chondrosarcoma
Endothelin-1 promotes MMP-13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/mTOR pathways.
Chondrosarcoma
Expression of collagenase-3 (matrix metalloproteinase-13) in transitional-cell carcinoma of the urinary bladder.
Chondrosarcoma
Expression of collagenase-3 (MMP-13) in c-fos-induced osteosarcomas and chondrosarcomas is restricted to a subset of cells of the osteo-/chondrogenic lineage.
Chondrosarcoma
Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas.
Chondrosarcoma
Expression of MMP-9 decreases metastatic potential of Chondrosarcoma: an immunohistochemical study.
Chondrosarcoma
Expression of MMPs is dependent on the activity of mitogen-activated protein kinase in chondrosarcoma.
Chondrosarcoma
Ginsenoside Rb1 inhibits matrix metalloproteinase 13 through down-regulating Notch signaling pathway in osteoarthritis.
Chondrosarcoma
IL-6 Increases MMP-13 Expression and Motility in Human Chondrosarcoma Cells.
Chondrosarcoma
Increased receptor activator of nuclear factor ?? ligand/osteoprotegerin ratio exacerbates cartilage destruction in osteoarthritis in vitro.
Chondrosarcoma
Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes.
Chondrosarcoma
Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3.
Chondrosarcoma
Is collagenase-3 (MMP-13) expression in chondrosarcoma of the jaws a true marker for tumor aggressiveness?
Chondrosarcoma
Matrix metalloproteinase-13 expression in IL-1?-treated chondrocytes by activation of the p38 MAPK/c-Fos/AP-1 and JAK/STAT pathways.
Chondrosarcoma
Mithramycin downregulates proinflammatory cytokine-induced matrix metalloproteinase gene expression in articular chondrocytes.
Chondrosarcoma
Novel p38 mitogen-activated protein kinase inhibitor R-130823 protects cartilage by down-regulating matrix metalloproteinase-1,-13 and prostaglandin E2 production in human chondrocytes.
Chondrosarcoma
Overexpression of A disintegrin and metalloproteinase 28 is correlated with high histologic grade in conventional chondrosarcoma.
Chondrosarcoma
Quercitrin alleviates cartilage extracellular matrix degradation and delays ACLT rat osteoarthritis development: An in vivo and in vitro study.
Chondrosarcoma
Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression.
Chondrosarcoma
Rho iso-alpha acids from hops inhibit the GSK-3/NF-kappaB pathway and reduce inflammatory markers associated with bone and cartilage degradation.
Chondrosarcoma
Roxatidine Attenuates Degradation of Extracellular Matrix.
Chondrosarcoma
SOX9 Knockout Induces Polyploidy and Changes Sensitivity to Tumor Treatment Strategies in a Chondrosarcoma Cell Line.
Chondrosarcoma
Suppressed invasive and migratory behaviors of SW1353 chondrosarcoma cells through the regulation of Src, Rac1 GTPase, and MMP13.
Chondrosarcoma
The triterpenoid CDDO inhibits expression of matrix metalloproteinase-1, matrix metalloproteinase-13 and Bcl-3 in primary human chondrocytes.
Chondrosarcoma
Thrombin enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway.
Chorioamnionitis
Prolidase, matrix metalloproteinases 1 and 13 activity, oxidative-antioxidative status as a marker of preterm premature rupture of membranes and chorioamnionitis in maternal vaginal washing fluids.
Choriocarcinoma
Matrix metalloproteinases and their inhibitors in gestational trophoblastic diseases and normal placenta.
Choroidal Neovascularization
Bone marrow-derived mesenchymal cells and MMP13 contribute to experimental choroidal neovascularization.
Chronic Periodontitis
Characterization of progressive periodontal lesions in chronic periodontitis patients: levels of chemokines, cytokines, matrix metalloproteinase-13, periodontal pathogens and inflammatory cells.
Chronic Periodontitis
Collagenase-2 (MMP-8) and collagenase-3 (MMP-13) in adult periodontitis: molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue.
Chronic Periodontitis
Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation.
Chronic Periodontitis
Evaluation of collagenase-3 matrix metalloproteinase-13 gene-associated polymorphisms 11A/12A and -77A/G and its associated alleles with and without periodontitis.
Chronic Periodontitis
Immunohistochemical expression of matrix metalloproteinase 13 in chronic periodontitis.
Chronic Periodontitis
Matrix metalloproteinase-13 is highly expressed in destructive periodontal disease activity.
Chronic Periodontitis
MMP-13 and TIMP-1 determinations in progressive chronic periodontitis.
Chronic Periodontitis
MMP-13 promoter polymorphisms in patients with chronic periodontitis: effects on GCF MMP-13 levels and outcome of periodontal therapy.
Chronic Periodontitis
MMP13, TIMP2 and TGFB3 Gene Polymorphisms in Brazilian Chronic Periodontitis and Periimplantitis Subjects.
Chronic Periodontitis
Proteolytic roles of matrix metalloproteinase (MMP)-13 during progression of chronic periodontitis: initial evidence for MMP-13/MMP-9 activation cascade.
Colitis
Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice.
Colitis
Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis.
Colitis
Macrophage migration inhibitory factor contributes to the development of acute dextran sulphate sodium-induced colitis in Toll-like receptor 4 knockout mice.
Colitis
TNF? cleavage beyond TACE/ADAM17: matrix metalloproteinase 13 is a potential therapeutic target in sepsis and colitis.
Colitis, Ischemic
Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations.
Colitis, Ulcerative
Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis.
Colitis, Ulcerative
Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations.
Colitis, Ulcerative
Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential?
Colonic Neoplasms
A role for CITED2, a CBP/p300 interacting protein, in colon cancer cell invasion.
Colonic Neoplasms
Clinical value of microRNA-135a and MMP-13 in colon cancer.
Colonic Neoplasms
Functional characterization of selective exosite-binding inhibitors of matrix metalloproteinase-13 (MMP-13) - experimental validation in human breast and colon cancer.
Colonic Neoplasms
ING2 is upregulated in colon cancer and increases invasion by enhanced MMP13 expression.
Colonic Neoplasms
Polymorphisms in MMP-1, MMP-2, MMP-7, MMP-13 and MT2A do not contribute to breast, lung and colon cancer risk in polish population.
Colonic Neoplasms
ROCK-II mediates colon cancer invasion via regulation of MMP-2 and MMP-13 at the site of invadopodia as revealed by multiphoton imaging.
Colonic Neoplasms
Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1, -3, and -13 gene expression by multiplex PCR in colorectal carcinomas.
Colorectal Neoplasms
Association of MMP7-181A/G and MMP13-77A/G polymorphisms with colorectal cancer in a Mexican population.
Colorectal Neoplasms
Clinicopathological significance and prognostic value of MMP-13 expression in colorectal cancer.
Colorectal Neoplasms
Differential expression of Janus kinase 3 (JAK3), matrix metalloproteinase 13 (MMP13), heat shock protein 60 (HSP60), and mouse double minute 2 (MDM2) in human colorectal cancer progression using human cancer cDNA microarrays.
Colorectal Neoplasms
Differential expression of matrix metalloproteinase-13 in mucinous and nonmucinous colorectal carcinomas.
Colorectal Neoplasms
Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential?
Colorectal Neoplasms
ING Proteins as Potential Anticancer Drug Targets.
Colorectal Neoplasms
ING2, a tumor associated gene, enhances PAI?1 and HSPA1A expression with HDAC1 and mSin3A through the PHD domain and C?terminal.
Colorectal Neoplasms
Low collagenase-1 (MMP-1) and MT1-MMP expression levels are favourable survival markers in advanced colorectal carcinoma.
Colorectal Neoplasms
Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer.
Colorectal Neoplasms
Matrix metalloproteinase-13 is regulated by toll-like receptor-9 in colorectal cancer cells and mediates cellular migration.
Colorectal Neoplasms
Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
Colorectal Neoplasms
Microcystin-LR promotes migration and invasion of colorectal cancer through matrix metalloproteinase-13 up-regulation.
Colorectal Neoplasms
MMP13 is a potential prognostic marker for colorectal cancer.
Colorectal Neoplasms
Overexpression of MMP-13 gene in colorectal cancer with liver metastasis.
Colorectal Neoplasms
Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1, -3, and -13 gene expression by multiplex PCR in colorectal carcinomas.
Colorectal Neoplasms
The Expression and Significance of CXCR5 and MMP-13 in Colorectal Cancer.
Communicable Diseases
Differential expression of matrix metalloproteinases in bacterial meningitis.
Connective Tissue Diseases
Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis.
Corneal Diseases
Thymic stromal lymphopoietin is expressed in human corneal stromal cells and secreted upon protease-activated receptor 1 activation.
Corneal Neovascularization
Keratocytes create stromal spaces to promote corneal neovascularization via MMP13 expression.
Corneal Neovascularization
Public data mining plus domestic experimental study defined involvement of the old-yet-uncharacterized gene matrix-remodeling associated 7 (MXRA7) in physiopathology of the eye.
Coronary Artery Disease
High plasma levels of matrix metalloproteinase-8 in patients with unstable angina.
Coronary Artery Disease
Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome.
Coronary Artery Disease
Matrix metalloproteinase 13 genotype in rs640198 polymorphism is associated with severe coronary artery disease.
Coronary Artery Disease
The Relation between eNOS -786 C/T, 4 a/b, MMP-13 rs640198 G/T, Eotaxin 426 C/T, -384 A/G, and 67 G/A Polymorphisms and Long-Term Outcome in Patients with Coronary Artery Disease.
Craniofacial Abnormalities
Matrix Metalloproteinase-13 Is Required for Zebra fish (Danio rerio) Development and Is a Target for Glucocorticoids.
Crohn Disease
Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations.
Crohn Disease
Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential?
Cysts
High matrix metalloproteinase activity is a hallmark of periapical granulomas.
Cysts
MMP-13 expression in keratocyst odontogenic tumour associated with NBCCS and sporadic keratocysts.
Cysts
MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma.
Dementia, Vascular
Blood-brain barrier damage in vascular dementia.
Dental Caries
Association of ENAM, TUFT1, MMP13, IL1B, IL10 and IL1RN gene polymorphism and dental caries susceptibility in Chinese children.
Dental Caries
Association of genetic variants in enamel-formation genes with dental caries: A meta- and gene-cluster analysis.
Dental Caries
Matrix metalloproteinases gene variants and dental caries in Czech children.
Dental Caries
MMP13 Contributes to Dental Caries Associated with Developmental Defects of Enamel.
Dental Caries
MMP13 polymorphism decreases risk for dental caries.
Dermatitis
Combination of retinoids and narrow-band ultraviolet B inhibits matrix metalloproteinase 13 expression in HaCaT keratinocytes and a mouse model of psoriasis.
Dermatitis
Inflammation in stasis dermatitis upregulates MMP-1, MMP-2 and MMP-13 expression.
Diabetes Mellitus
Crevicular fluid matrix metalloproteinase-8, -13, and TIMP-1 levels in type 2 diabetics.
Diabetes Mellitus
Effect of Subantimicrobial Dose Doxycycline Treatment on Gingival Crevicular Fluid Levels of MMP-9 and MMP-13 in Periodontitis Stage 2, Grade B in Subjects with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Matrix metalloproteinase 13 in the ligamentum flavum from lumbar spinal canal stenosis patients with and without diabetes mellitus.
Diabetes Mellitus, Type 1
The skin remodeling in type 1 diabetes and insulin resistance animal models.
Diabetes Mellitus, Type 2
Crevicular fluid matrix metalloproteinase-8, -13, and TIMP-1 levels in type 2 diabetics.
Diabetes Mellitus, Type 2
Effect of Subantimicrobial Dose Doxycycline Treatment on Gingival Crevicular Fluid Levels of MMP-9 and MMP-13 in Periodontitis Stage 2, Grade B in Subjects with Type 2 Diabetes Mellitus.
Diabetic Neuropathies
Oxidative stress-dependent MMP-13 activity underlies glucose neurotoxicity.
Diverticulitis
Collagenase-3 (MMP-13) expression by inflamed mucosa in inflammatory bowel disease.
Diverticulitis
Comparative analysis of the expression of metalloproteases and their inhibitors in resected crohn's disease and complicated diverticular disease.
Dwarfism
FoxA family members are crucial regulators of the hypertrophic chondrocyte differentiation program.
Dwarfism
Osteoarthritis-like changes in the heterozygous sedc mouse associated with the HtrA1-Ddr2-Mmp-13 degradative pathway: a new model of osteoarthritis.
Dwarfism
The ras-GTPase activity of neurofibromin restrains ERK-dependent FGFR signaling during endochondral bone formation.
Dysplastic Nevus Syndrome
Matrix metalloproteinases MMP-1, MMP-2, and MMP-13 are overexpressed in primary nodular melanoma.
Endometriosis
Genetic polymorphisms of matrix metalloproteinase 12 and 13 genes are implicated in endometriosis progression.
Endometriosis
Matrix metalloproteinase-13 and membrane type-1 matrix metalloproteinase in peritoneal fluid of women with endometriosis.
Endometriosis
[Association of matrix metalloproteinases' polymorphisms of MMP3 and MMP9 with development of genital endometriosis].
Epidermolysis Bullosa Dystrophica
MMP13 can be a useful differentiating marker between squamous cell carcinoma and benign hyperkeratotic lesions in recessive dystrophic epidermolysis bullosa.
Erythema
Noninvasive Assessment of UV-induced Skin Damage: Comparison of Optical Measurements to Histology and MMP Expression.
Esophageal Neoplasms
The Sp1-mediaded allelic regulation of MMP13 expression by an ESCC susceptibility SNP rs2252070.
Esophageal Squamous Cell Carcinoma
AJUBA promotes the migration and invasion of esophageal squamous cell carcinoma cells through upregulation of MMP10 and MMP13 expression.
Esophageal Squamous Cell Carcinoma
Clinical significance of serum matrix metalloproteinase-13 levels in patients with esophageal squamous cell carcinoma (ESCC).
Esophageal Squamous Cell Carcinoma
Crosstalk between MMP-13, CD44, and TWIST1 and its role in regulation of EMT in patients with esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13.
Esophageal Squamous Cell Carcinoma
Increase of MMP-13 expression in multi-stage oral carcinogenesis and epigallocatechin-3-gallate suppress MMP-13 expression.
Esophageal Squamous Cell Carcinoma
Matrix Metalloproteinase-13 - A Potential Biomarker for Detection and Prognostic Assessment of Patients with Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
MUC1 induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13.
Esophageal Squamous Cell Carcinoma
Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
[The association of MMP-13 polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adeno-carcinoma]
Fasciitis
Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis.
Fibroadenoma
Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas.
Fibromatosis, Aggressive
Invasion and MMP expression profile in desmoid tumours.
Fibromatosis, Gingival
The Effect of MMP-13, MMP-12, and AMBN on Gingival Enlargement and Root Deformation In a New Type of Gingival Fibromatosis.
Fibrosarcoma
Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells.
Fibrosarcoma
Identification of matrix metalloproteinase inhibitors by chemical arrays.
Fluorosis, Dental
Polymorphisms in genes involved in enamel development are associated with dental fluorosis.
Gallbladder Neoplasms
Nedd4L modulates the transcription of metalloproteinase-1 and -13 genes to increase the invasive activity of gallbladder cancer.
gelatinase b deficiency
Histochemical aspects of the vascular invasion at the erosion zone of the epiphyseal cartilage in MMP-9-deficient mice.
Giant Cell Tumor of Bone
AP-1 as a Regulator of MMP-13 in the Stromal Cell of Giant Cell Tumor of Bone.
Giant Cell Tumor of Bone
Evidence for the role of matrix metalloproteinase-13 in bone resorption by giant cell tumor of bone.
Giant Cell Tumors
AP-1 as a Regulator of MMP-13 in the Stromal Cell of Giant Cell Tumor of Bone.
Giant Cell Tumors
Evidence for the role of matrix metalloproteinase-13 in bone resorption by giant cell tumor of bone.
Giant Cell Tumors
MiR-126-5p regulates osteoclast differentiation and bone resorption in giant cell tumor through inhibition of MMP-13.
Giant Cell Tumors
Upregulation of MMP-13 via Runx2 in the stromal cell of Giant Cell Tumor.
Gingival Overgrowth
The Effect of MMP-13, MMP-12, and AMBN on Gingival Enlargement and Root Deformation In a New Type of Gingival Fibromatosis.
Gingival Pocket
Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation.
Gingival Recession
Triclosan Blocks Mmp 13 Expression in Hormone-Stimulated Osteoblasts.
Gingivitis
Gingival crevicular fluid matrix metalloproteinase-13 levels and molecular forms in various types of periodontal diseases.
Glioblastoma
Cancer stem-like cells of glioblastoma characteristically express MMP-13 and display highly invasive activity.
Glioblastoma
Ginsenoside Rh2 inhibits metastasis of glioblastoma multiforme through Akt-regulated MMP13.
Glioblastoma
Osthole suppresses the migratory ability of human glioblastoma multiforme cells via inhibition of focal adhesion kinase-mediated matrix metalloproteinase-13 expression.
Glioma
Abnormal increase of miR-4262 promotes cell proliferation and migration by targeting large tumor suppressor 1 in gliomas.
Glioma
Exogenous endothelin-1 induces cell migration and matrix metalloproteinase expression in U251 human glioblastoma multiforme.
Glioma
Glial cell line-derived neurotrophic factor induces cell migration and matrix metalloproteinase-13 expression in glioma cells.
Glioma
Increased expression of matrix metalloproteinase-13 in glioma is associated with poor overall survival of patients.
Glioma
Leptin induces migration and invasion of glioma cells through MMP-13 production.
Glioma
RUNX2 Promotes Malignant Progression in Glioma.
Glioma
Transactivation by Runt related factor-2 of matrix metalloproteinase-13 in astrocytes.
Granuloma
Effective Amelioration of Liver Fibrosis Through Lentiviral Vector Carrying Toxoplasma gondii gra15II in Murine Model.
Granuloma
High matrix metalloproteinase activity is a hallmark of periapical granulomas.
Hamartoma
Expression of matrix metalloproteinases and their endogenous tissue inhibitors in skin lesions from patients with tuberous sclerosis.
Head and Neck Neoplasms
Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer.
Head and Neck Neoplasms
Irradiation-induced dynamic changes of gene signatures reveal gain of metastatic ability in nasopharyngeal carcinoma.
Heart Diseases
The cloning and functional analysis of canine matrix metalloproteinase-13 gene promoter.
Heart Neoplasms
[The association of MMP-13 polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adeno-carcinoma]
Hidradenitis Suppurativa
Adalimumab Induces a Wound Healing Profile in Patients with Hidradenitis Suppurativa by Regulating Macrophage Differentiation and Matrix Metalloproteinase Expression.
Hypercalcemia
Parathyroid hormone increases the expression level of matrix metalloproteinase-13 in vivo.
Hypercholesterolemia
Rosuvastatin therapy does not affect serum MMP-13 or TIMP-1 levels in hypercholesterolemic patients.
Hyperglycemia
Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways.
Hyperglycemia
PPAR? is involved in the hyperglycemia-induced inflammatory responses and collagen degradation in human chondrocytes and diabetic mouse cartilages.
Hyperhomocysteinemia
Homocysteine causes dysfunction of chondrocytes and oxidative stress through repression of SIRT1/AMPK pathway: A possible link between hyperhomocysteinemia and osteoarthritis.
Hyperostosis
Possible role of matrix metalloproteinases (MMPs) in hyperostosis of intracranial meningiomas.
Hypertension
Estrogen effects on MMP-13 and MMP-14 regulation of left ventricular mass in Dahl salt-induced hypertension.
Idiopathic Pulmonary Fibrosis
Pivotal role of matrix metalloproteinase 13 in extracellular matrix turnover in idiopathic pulmonary fibrosis.
Infections
Collagenase-3 (MMP-13) in fetal membranes and amniotic fluid during pregnancy.
Infections
Effect of adenovirus-mediated overexpression of decorin on metalloproteinases, tissue inhibitors of metalloproteinases and cytokines secretion by human gingival fibroblasts.
Infections
Expression analysis of matrix metalloproteinase-13 in human gastric cancer in the presence of Helicobacter Pylori infection.
Infections
Higher molecular weight polyethylene glycol increases cell proliferation while improving barrier function in an in vitro colon cancer model.
Infections
Identification and characterization of matrix metalloproteinase-13 sequence structure and expression during embryogenesis and infection in channel catfish (Ictalurus punctatus).
Infections
Interleukin-1 Receptor Antagonist Has a Novel Function in the Regulation of Matrix Metalloproteinase-13 Expression.
Infections
Matrix Metalloproteinase-13 as a Target for Suppressing Corneal Ulceration Caused by Pseudomonas aeruginosa Infection.
Infections
Matrix Metalloproteinase-13 in Atherosclerotic Plaque Is Increased by Influenza A Virus Infection.
Infections
Mayaro Virus Infects Human Chondrocytes and Induces the Expression of Arthritis-Related Genes Associated with Joint Degradation.
Infections
NF-?B/TWIST1 Mediates Migration and Phagocytosis of Macrophages in the Mice Model of Implant-Associated Staphylococcus aureus Osteomyelitis.
Infections
Pathophysiological changes induced by Pseudomonas aeruginosa infection are involved in MMP-12 and MMP-13 upregulation in human carcinoma epithelial cells and a pneumonia mouse model.
Infections
Proinflammatory gene expression in mouse ST2 cell line in response to infection by Porphyromonas gingivalis.
Infections
Public data mining plus domestic experimental study defined involvement of the old-yet-uncharacterized gene matrix-remodeling associated 7 (MXRA7) in physiopathology of the eye.
Infections
TGFbeta directs gene expression of activated microglia to an anti-inflammatory phenotype strongly focusing on chemokine genes and cell migratory genes.
Infections
Transforming growth factor-beta induces collagenase-3 expression by human gingival fibroblasts via p38 mitogen-activated protein kinase.
Infections
Type III Secretion System of Pseudomonas aeruginosa Affects Matrix Metalloproteinase 12 (MMP-12) and MMP-13 Expression via Nuclear Factor ?B Signaling in Human Carcinoma Epithelial Cells and a Pneumonia Mouse Model.
Inflammatory Bowel Diseases
Collagenase-3 (MMP-13) expression by inflamed mucosa in inflammatory bowel disease.
Inflammatory Bowel Diseases
Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential?
Influenza, Human
Matrix Metalloproteinase-13 in Atherosclerotic Plaque Is Increased by Influenza A Virus Infection.
Insulin Resistance
The skin remodeling in type 1 diabetes and insulin resistance animal models.
Intervertebral Disc Degeneration
17?-Estradiol inhibits intervertebral disc degeneration by down-regulating MMP-3 and MMP-13 and up-regulating type II collagen in a rat model.
Intervertebral Disc Degeneration
Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats.
Intervertebral Disc Degeneration
Autophagy-activated nucleus pulposus cells deliver exosomal miR-27a to prevent extracellular matrix degradation by targeting MMP-13.
Intervertebral Disc Degeneration
Bone morphogenic protein-2 signaling in human disc degeneration and correlation to the Pfirrmann MRI grading system.
Intervertebral Disc Degeneration
BRD4 inhibition regulates MAPK, NF-?B signals, and autophagy to suppress MMP-13 expression in diabetic intervertebral disc degeneration.
Intervertebral Disc Degeneration
Downregulation of miR-27b is Involved in Loss of Type II Collagen by Directly Targeting Matrix Metalloproteinase 13 (MMP13) in Human Intervertebral Disc Degeneration.
Intervertebral Disc Degeneration
Dysregulated miR-127-5p contributes to type II collagen degradation by targeting matrix metalloproteinase-13 in human intervertebral disc degeneration.
Intervertebral Disc Degeneration
Elevated expression of hypoxia-inducible factor-2alpha regulated catabolic factors during intervertebral disc degeneration.
Intervertebral Disc Degeneration
Interleukin-1? exacerbates the catabolic effects of human nucleus pulposus cells through activation of the Nuclear Factor kappa B signaling pathway under hypoxic conditions.
Intervertebral Disc Degeneration
Lumbar Disc Degeneration is Facilitated by MiR-100-Mediated FGFR3 Suppression.
Intervertebral Disc Degeneration
Rhizoma drynariae total flavonoids inhibit the inflammatory response and matrix degeneration via MAPK pathway in a rat degenerative cervical intervertebral disc model.
Intervertebral Disc Degeneration
Salubrinal Suppresses IL-17-Induced Upregulation of MMP-13 and Extracellular Matrix Degradation Through the NF-kB Pathway in Human Nucleus Pulposus Cells.
Intervertebral Disc Degeneration
Specific inhibitory protein Dkk-1 blocking Wnt/?-catenin signaling pathway improve protectives effect on the extracellular matrix.
Intervertebral Disc Degeneration
[Effects of electroacupuncture stimulation of "Jiaji" (EX-B 2) on expression of matrix metalloproteinase-13 and tissue inhibitor of metalloproteinase-1 in intervertebral disc tissue in rabbits with lumbar intervertebral disc degeneration].
Intervertebral Disc Degeneration
[Mechanism of Yiqi Huayu Bushen Recipe in treating cervical syndrome with kidney deficiency in rats]
Intervertebral Disc Displacement
The increased expression of matrix metalloproteinases associated with elastin degradation and fibrosis of the ligamentum flavum in patients with lumbar spinal stenosis.
Intervertebral Disc Displacement
Transcript levels of major MMPs and ADAMTS-4 in relation to the clinicopathological profile of patients with lumbar disc herniation.
Iron Overload
The detrimental effect of iron on OA chondrocytes: Importance of pro-inflammatory cytokines induced iron influx and oxidative stress.
Ischemic Attack, Transient
Matrix metalloproteinase-13 participates in neuroprotection and neurorepair after cerebral ischemia in mice.
Ischemic Stroke
Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
Jaw Cysts
Collagenase-3 expression in periapical lesions: an immunohistochemical study.
Joint Diseases
Basic Fibroblast Growth Factor Activates the MAPK and NF{kappa}B Pathways That Converge on Elk-1 to Control Production of Matrix Metalloproteinase-13 by Human Adult Articular Chondrocytes.
Joint Diseases
Characterisation of the cell type-specificity of collagenase 3 mRNA expression in comparison with membrane type 1 matrix metalloproteinase and gelatinase A in the synovial membrane in rheumatoid arthritis.
Joint Diseases
Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis.
Joint Diseases
Joint diseases and matrix metalloproteinases: a role for MMP-13.
Joint Diseases
Protein kinase C isoforms zeta and iota mediate collagenase expression and cartilage destruction via STAT3- and ERK-dependent c-fos induction.
Joint Diseases
Structural analysis and promoter characterization of the human collagenase-3 gene (MMP13).
Joint Diseases
TAK1 downregulation reduces IL-1beta induced expression of MMP13, MMP1 and TNF-alpha.
Joint Diseases
Upregulated ank expression in osteoarthritis can promote both chondrocyte MMP-13 expression and calcification via chondrocyte extracellular PPi excess.
Joint Instability
Contribution of runt-related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability.
Joint Instability
Matrix metalloproteinase-13 expression in rabbit knee joint connective tissues: influence of maturation and response to injury.
Kallmann Syndrome
Cigarette smoke modulates PC3 prostate cancer cell migration by altering adhesion molecules and the extracellular matrix.
Kashin-Beck Disease
Morphology and Phenotype Expression of Types I, II, III, and X Collagen and MMP-13 of Chondrocytes Cultured from Articular Cartilage of Kashin-Beck Disease.
Keloid
Extracorporeal shockwave therapy for treatment of keloid scars.
Keloid
Suppressed TGF-beta1 expression is correlated with up-regulation of matrix metalloproteinase-13 in keloid regression after flashlamp pulsed-dye laser treatment.
Keloid
Tissue Engineering for In Vitro Analysis of Matrix Metalloproteinases in the Pathogenesis of Keloid Lesions.
Keloid
Tretinoin reverses upregulation of matrix metalloproteinase-13 in human keloid-derived fibroblasts.
Keratitis
Corneal Cross-Linking Has No Effect on Matrix Metalloproteinase 9 and 13 Levels During Fungal Keratitis on the Early Stage.
Keratoacanthoma
Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13, are present in epithelial cells of keratoacanthomas.
Keratoconus
Collagenolytic proteinases in keratoconus.
Keratoconus
Keratoconus: an inflammatory disorder?
Keratosis, Seborrheic
Human collagenase-3 is expressed in malignant squamous epithelium of the skin.
Leg Ulcer
Biomarker directed chronic wound therapy - A new treatment paradigm.
Leg Ulcer
Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds.
Leukemia
Freshly isolated osteoarthritic chondrocytes are catabolically more active than normal chondrocytes, but less responsive to catabolic stimulation with interleukin-1beta.
Leukemia
High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis.
Leukemia
Leukemia inhibitory factor and oncostatin M stimulate collagenase-3 expression in osteoblasts.
Leukoplakia, Oral
Evaluation of Collagen in Leukoplakia, Oral Submucous Fibrosis and Oral Squamous Cell Carcinomas Using Polarizing Microscopy and Immunohistochemistry
Lichen Planus, Oral
Salivary MMP-1, MMP-2, MMP-3 and MMP-13 Levels in Patients with Oral Lichen Planus and Squamous Cell Carcinoma
Lichen Planus, Oral
Serum and saliva collagenase-3 (MMP-13) in patients with oral lichen planus and oral squamous cell carcinoma.
Liver Cirrhosis
Activity of MMP1 and MMP13 and amino acid metabolism in patients with alcoholic liver cirrhosis.
Liver Cirrhosis
Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis.
Liver Cirrhosis
Antifibrotic effect of MMP13-encoding plasmid DNA delivered using polyethylenimine shielded with hyaluronic acid.
Liver Cirrhosis
Antifibrotic Effects of a Recombinant Adeno-Associated Virus Carrying Small Interfering RNA Targeting TIMP-1 in Rat Liver Fibrosis.
Liver Cirrhosis
Carvedilol Attenuates the Progression of Hepatic Fibrosis Induced by Bile Duct Ligation.
Liver Cirrhosis
Disruption of tissue-type plasminogen activator gene in mice aggravated liver fibrosis.
Liver Cirrhosis
Effect of all-trans retinoic acid on liver fibrosis induced by common bile duct ligation in rats.
Liver Cirrhosis
Effective Prevention of Liver Fibrosis by Liver-targeted Hydrodynamic Gene Delivery of Matrix Metalloproteinase-13 in a Rat Liver Fibrosis Model.
Liver Cirrhosis
Effects of Fibrotic Tissue on Liver-targeted Hydrodynamic Gene Delivery.
Liver Cirrhosis
Effects of sub-chronic exposure to atmospheric PM2.5 on fibrosis, inflammation, endoplasmic reticulum stress and apoptosis in the livers of rats.
Liver Cirrhosis
Enhanced interstitial collagenase (matrix metalloproteinase-13) production of Kupffer cell by gadolinium chloride prevents pig serum-induced rat liver fibrosis.
Liver Cirrhosis
Expression pattern of matrix metalloproteinases-13 in a rat model of alcoholic liver fibrosis.
Liver Cirrhosis
Extracellular matrix metabolism-related gene expression in bile duct-ligated rats.
Liver Cirrhosis
Gene expression of interstitial collagenase in both progressive and recovery phase of rat liver fibrosis induced by carbon tetrachloride.
Liver Cirrhosis
Gynura Rhizoma containing pyrrolizidine alkaloids induces the hepatic sinusoidal obstruction syndrome in mice via upregulating fibrosis-related factors.
Liver Cirrhosis
Interleukin-1? upregulates matrix metalloproteinase-13 gene expression via c-Jun N-terminal kinase and p38 MAPK pathways in rat hepatic stellate cells.
Liver Cirrhosis
Involvement of fibroblast-specific protein 1 (S100A4) and matrix metalloproteinase-13 (MMP-13) in CCl4-induced reversible liver fibrosis.
Liver Cirrhosis
Liver repair and regeneration after ischemia-reperfusion injury is associated with prolonged fibrosis.
Liver Cirrhosis
Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis.
Liver Cirrhosis
Matrix Metalloproteinase-13 Promotes Recovery from Experimental Liver Cirrhosis in Rats.
Liver Cirrhosis
MMP-13 deletion decreases profibrogenic molecules and attenuates N-nitrosodimethylamine-induced liver injury and fibrosis in mice.
Liver Cirrhosis
Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats.
Liver Cirrhosis
Protective effects of curcumin, ?-lipoic acid, and N-acetylcysteine against carbon tetrachloride-induced liver fibrosis in rats.
Liver Cirrhosis
Reversibility of hepatic fibrosis: from the first report of collagenase in the liver to the possibility of gene therapy for recovery.
Liver Cirrhosis
S-Nitroso-N-acetylcysteine induces de-differentiation of activated hepatic stellate cells and promotes antifibrotic effects in vitro.
Liver Cirrhosis
Salvia miltiorrhiza reduces experimentally-induced hepatic fibrosis in rats.
Liver Cirrhosis
Tgfb3 and Mmp13 regulated the initiation of liver fibrosis progression as dynamic network biomarkers.
Liver Cirrhosis
Thalidomide Accelerates the Degradation of Extracellular Matrix in Rat Hepatic Cirrhosis via Down-Regulation of Transforming Growth Factor-?1.
Liver Cirrhosis
Transplantation of bone marrow mesenchymal stromal cells attenuates liver fibrosis in mice by regulating macrophage subtypes.
Liver Cirrhosis
[Dynamic evolution of MMP-13, TIMP-1, type I and III collagen and their interaction in experimental liver fibrosis]
Liver Cirrhosis
[Gene expression of interstitial collagenase MMP-13 in progressive phase of rat liver fibrosis induced by ethanol]
Liver Cirrhosis
[Preventive and therapeutic effects of Qiwei Yugan Granule on hepatic fibrosis in rats].
Liver Cirrhosis, Alcoholic
Activity of MMP1 and MMP13 and amino acid metabolism in patients with alcoholic liver cirrhosis.
Liver Cirrhosis, Experimental
Matrix Metalloproteinase-13 Promotes Recovery from Experimental Liver Cirrhosis in Rats.
Liver Diseases
Bcl-2 overexpression in hepatic stellate cell line CFSC-2G, induces a pro-fibrotic state.
Lung Diseases
Induction of the Matrix Metalloproteinase 13 Gene in Bronchial Epithelial Cells by Interferon and Identification of its Novel Functional Polymorphism.
Lung Injury
Collagenase-3 induction in rat lung fibroblasts requires the combined effects of tumor necrosis factor-alpha and 12-lipoxygenase metabolites: a model of macrophage-induced, fibroblast-driven extracellular matrix remodeling during inflammatory lung injury.
Lung Injury
Deficiency of matrix metalloproteinase-13 increases inflammation after acute lung injury.
Lung Injury
Delayed resolution of bleomycin-induced pulmonary fibrosis in absence of MMP13 (collagenase 3).
Lung Neoplasms
Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer.
Lung Neoplasms
Association of matrix metalloproteinase family gene polymorphisms with lung cancer risk: logistic regression and generalized odds of published data.
Lung Neoplasms
Association of MMP9-1562C/T and MMP13-77A/G Polymorphisms with Non-Small Cell Lung Cancer in Southern Chinese Population.
Lung Neoplasms
Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells.
Lung Neoplasms
Effect of lentivirus-mediated integrin ?V?3-shRNA on tumor growth of mice with lung cancer xenografts.
Lung Neoplasms
Matrix metalloproteinase 13: a potential intermediate between low expression of microRNA-125b and increasing metastatic potential of non-small cell lung cancer.
Lung Neoplasms
Matrix metalloproteinase family gene polymorphisms and lung cancer susceptibility: an updated meta-analysis.
Lung Neoplasms
Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
Lung Neoplasms
MMP-13 In-Vivo Molecular Imaging Reveals Early Expression in Lung Adenocarcinoma.
Lung Neoplasms
MMP-2 and MMP-13 affect vasculogenic mimicry formation in large cell lung cancer.
Lung Neoplasms
Polymorphism +17 C/G in matrix metalloprotease MMP8 decreases lung cancer risk.
Lung Neoplasms
Somatic Copy-Number Alterations Contribute to Brain Metastasis.
Lung Neoplasms
Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1.
Lung Neoplasms
The relationship of metalloproteinase gene polymorphisms and lung cancer.
Lung Neoplasms
Thrombospondin 2 promotes tumor metastasis by inducing matrix metalloproteinase-13 production in lung cancer cells.
Lung Neoplasms
[Expression and significance of matrix metalloproteinases and their tissue inhibitors in the infiltration and metastasis of lung cancer.]
Lupus Erythematosus, Systemic
Elevated serum levels of MMP-2, MMP-3, and MMP-13 in Chinese patients with systemic lupus erythematosus.
Lyme Disease
Induction of host matrix metalloproteinases by Borrelia burgdorferi differs in human and murine lyme arthritis.
Lymphatic Metastasis
Clinical significance of serum matrix metalloproteinase-13 levels in patients with esophageal squamous cell carcinoma (ESCC).
Lymphatic Metastasis
Clinicopathological significance and prognostic value of MMP-13 expression in colorectal cancer.
Lymphatic Metastasis
Differential expression of matrix metalloproteinase-13 in mucinous and nonmucinous colorectal carcinomas.
Lymphatic Metastasis
Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer.
Lymphatic Metastasis
Hypoxia-Induced Matrix Metalloproteinase-13 Expression in Exosomes from Nasopharyngeal Carcinoma Enhances Metastases.
Lymphatic Metastasis
Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness.
Lymphatic Metastasis
Leptin signaling enhances cell invasion and promotes the metastasis of human pancreatic cancer via increasing MMP-13 production.
Lymphatic Metastasis
Matrix metalloproteinase 13: a potential intermediate between low expression of microRNA-125b and increasing metastatic potential of non-small cell lung cancer.
Lymphatic Metastasis
MMP13 is a potential prognostic marker for colorectal cancer.
Lymphatic Metastasis
MUC1 induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13.
Lymphatic Metastasis
Overexpression of MMP13 is associated with clinical outcomes and poor prognosis in oral squamous cell carcinoma.
Lymphatic Metastasis
Role of matrix metalloproteinase 13 gene expression in the evaluation of radiation response in oral squamous cell carcinoma.
Lymphatic Metastasis
S100A4 promotes invasion and angiogenesis in breast cancer MDA-MB-231 cells by upregulating matrix metalloproteinase-13.
Lymphatic Metastasis
SIRT1 inhibits gastric cancer proliferation and metastasis via STAT3/MMP-13 signaling.
Lymphatic Metastasis
The usefulness of new serum tumor markers in head and neck squamous cell carcinoma.
Lymphatic Metastasis
[Diagnostic value of E-cadherin, MMP-9, activated MMP-13 and anti-p53 antibodies in squamous cell carcinomas of head and neck]
Lymphoma
Blocking HOTAIR protects human chondrocytes against IL-1?-induced cell apoptosis, ECM degradation, inflammatory response and oxidative stress via regulating miR-222-3p/ADAM10 axis.
Lymphoma
Exhausting circ_0136474 and Restoring miR-766-3p Attenuate Chondrocyte Oxidative Injury in IL-1?-Induced Osteoarthritis Progression Through Regulating DNMT3A.
Lymphoma, B-Cell
Blocking HOTAIR protects human chondrocytes against IL-1?-induced cell apoptosis, ECM degradation, inflammatory response and oxidative stress via regulating miR-222-3p/ADAM10 axis.
Lymphoma, B-Cell
Exhausting circ_0136474 and Restoring miR-766-3p Attenuate Chondrocyte Oxidative Injury in IL-1?-Induced Osteoarthritis Progression Through Regulating DNMT3A.
Lymphoma, B-Cell
Overexpression of long non-coding RNA XIST promotes IL-1?-induced degeneration of nucleus pulposus cells through targeting miR-499a-5p.
Lymphoma, B-Cell
Sirt1 regulates apoptosis and extracellular matrix degradation in resveratrol-treated osteoarthritis chondrocytes via the Wnt/?-catenin signaling pathways.
Macular Degeneration
Bone marrow-derived mesenchymal cells and MMP13 contribute to experimental choroidal neovascularization.
Malocclusion
Malocclusion model of temporomandibular joint osteoarthritis in mice with and without receptor for advanced glycation end products.
Marfan Syndrome
Gelatinolytic activity in gingival crevicular fluid and saliva of growing patients with Marfan syndrome: a case-control study.
matrix metalloproteinase-13 deficiency
Altered endochondral bone development in matrix metalloproteinase 13-deficient mice.
matrix metalloproteinase-13 deficiency
Delayed resolution of bleomycin-induced pulmonary fibrosis in absence of MMP13 (collagenase 3).
matrix metalloproteinase-13 deficiency
Loss of matrix metalloproteinase-13 attenuates murine radiation-induced pulmonary fibrosis.
matrix metalloproteinase-13 deficiency
Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development.
matrix metalloproteinase-13 deficiency
Matrix metalloproteinase-13 participates in neuroprotection and neurorepair after cerebral ischemia in mice.
matrix metalloproteinase-13 deficiency
Osteocyte dysfunction promotes osteoarthritis through MMP13-dependent suppression of subchondral bone homeostasis.
Melanoma
Anti-Metastasis Effects of Ginsenoside Rg3 in B16F10 Cells.
Melanoma
AT1 receptors activation enhances the expression of MMP-2, MMP-13 and VEGF but not MMP-9 in B16F10 melanoma cells.
Melanoma
Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma.
Melanoma
Cumulative influence of matrix metalloproteinase-1 and -2 in the migration of melanoma cells within three-dimensional type I collagen lattices.
Melanoma
Development of a solid-phase assay for analysis of matrix metalloproteinase activity.
Melanoma
Diverse matrix metalloproteinase functions regulate cancer amoeboid migration.
Melanoma
Dual effects of collagenase-3 on melanoma: metastasis promotion and disruption of vasculogenic mimicry.
Melanoma
Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas.
Melanoma
Expression of collagenase-3 (matrix metalloproteinase-13) in transitional-cell carcinoma of the urinary bladder.
Melanoma
High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma.
Melanoma
High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Melanoma
Host-derived MMP-13 exhibits a protective role in lung metastasis of melanoma cells by local endostatin production.
Melanoma
Matrix metalloproteinases in human melanoma.
Melanoma
Matrix metalloproteinases MMP-1, MMP-2, and MMP-13 are overexpressed in primary nodular melanoma.
Melanoma
MMP-21 is upregulated at early stages of melanoma progression but disappears with more aggressive phenotype.
Melanoma
MMP13 mediates cell cycle progression in melanocytes and melanoma cells: in vitro studies of migration and proliferation.
Melanoma
Stromal collagenase in melanoma: a vascular connection.
Melanoma
Stromal expression of MMP-13 is required for melanoma invasion and metastasis.
Melanoma
Studies of the humoral factors produced by layered chondrocyte sheets.
Melanoma
Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1.
Melanoma
[Inhibition of matrix metalloproteinases 9 and 13 affects the degree of lymphocytic infiltration and the expression levels of microRNA miR-21 and miR-let-7b in melanoma cells in vivo].
Meningioma
Possible role of matrix metalloproteinases (MMPs) in hyperostosis of intracranial meningiomas.
Meningitis, Bacterial
Differential expression of matrix metalloproteinases in bacterial meningitis.
Mouth Neoplasms
A metalloproteinase-13 polymorphism affecting its gene expression is associated with advanced stages of oral cancer.
Mouth Neoplasms
Corrigendum: Matrix metalloproteinase-13 is a target gene of high-mobility group box-containing protein 1 in modulating oral cancer cell invasion.
Mouth Neoplasms
MMP-13 is involved in oral cancer cell metastasis.
Mouth Neoplasms
Retraction: MMP-13 is involved in oral cancer cell metastasis.
Multiple Myeloma
Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival.
Multiple Myeloma
MMP13 Regulates Aggressiveness of Pediatric Multiple Myeloma Through VEGF-C.
Multiple Myeloma
Regulation of metastasis of pediatric multiple myeloma by MMP13.
Multiple Myeloma
[Expression of IL-17 and MMP-13 in Bone Marrow Biopsy of Pafsents with Multiple Myeloma and Its Clicnical Significomce].
Muscular Atrophy
Knocking-out matrix metalloproteinase-13 exacerbates rotator cuff muscle fatty infiltration.
Musculoskeletal Diseases
Regulated transcription of human matrix metalloproteinase 13 (MMP13) and interleukin-1 beta (IL1B) genes in chondrocytes depends on methylation of specific proximal promoter CpG sites.
Myocardial Infarction
Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction.
Myocardial Infarction
Relationship of long-term prognosis to MMP and TIMP polymorphisms in patients after ST elevation myocardial infarction.
Nasal Polyps
Involvement of the extracellular matrix proteins periostin and tenascin C in nasal polyp remodeling by regulating the expression of MMPs.
Nasopharyngeal Carcinoma
Hypoxia-Induced Matrix Metalloproteinase-13 Expression in Exosomes from Nasopharyngeal Carcinoma Enhances Metastases.
Nasopharyngeal Carcinoma
Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins.
Neoplasm Metastasis
(2-Aminobenzothiazole)-Methyl-1,1-Bisphosphonic Acids: Targeting Matrix Metalloproteinase 13 Inhibition to the Bone.
Neoplasm Metastasis
Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells.
Neoplasm Metastasis
An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer.
Neoplasm Metastasis
Anti-Metastasis Effects of Ginsenoside Rg3 in B16F10 Cells.
Neoplasm Metastasis
Association of MMP7-181A/G and MMP13-77A/G polymorphisms with colorectal cancer in a Mexican population.
Neoplasm Metastasis
Astragalus Polysaccharide (PG2) Suppresses Macrophage Migration Inhibitory Factor and Aggressiveness of Lung Adenocarcinoma Cells.
Neoplasm Metastasis
Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells.
Neoplasm Metastasis
Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of Metalloproteinase (MMP)-13.
Neoplasm Metastasis
Cancer-Osteoblast Interaction Reduces Sost Expression in Osteoblasts and Up-Regulates lncRNA MALAT1 in Prostate Cancer.
Neoplasm Metastasis
Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Neoplasm Metastasis
Clinical significance of serum matrix metalloproteinase-13 levels in patients with esophageal squamous cell carcinoma (ESCC).
Neoplasm Metastasis
Clinicopathological significance and prognostic value of MMP-13 expression in colorectal cancer.
Neoplasm Metastasis
Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma.
Neoplasm Metastasis
Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas.
Neoplasm Metastasis
Constitutive expression and regulation of collagenase-3 in human breast cancer cells.
Neoplasm Metastasis
Correlation Between the Expression of Matrix Metalloproteinase-9, Matrix Metalloproteinase-13, Tissue Inhibitor of Metalloproteinases-1, p16 and Differentiation of Head and Neck Squamous Cell Carcinoma: A Prospective Observational Study.
Neoplasm Metastasis
Correlation of COX-2 and MMP-13 expressions with gastric cancer and their effects on prognosis.
Neoplasm Metastasis
Crosstalk between MMP-13, CD44, and TWIST1 and its role in regulation of EMT in patients with esophageal squamous cell carcinoma.
Neoplasm Metastasis
Different matrix micro-environments in colon cancer and diverticular disease.
Neoplasm Metastasis
Differential expression of matrix metalloproteinase-13 in association with invasion of breast cancer.
Neoplasm Metastasis
Differential expression of matrix metalloproteinase-13 in mucinous and nonmucinous colorectal carcinomas.
Neoplasm Metastasis
Differential expression of matrix metalloproteinases and miRNAs in the metastasis of oral squamous cell carcinoma.
Neoplasm Metastasis
Dual effects of collagenase-3 on melanoma: metastasis promotion and disruption of vasculogenic mimicry.
Neoplasm Metastasis
ETS-1 regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell SKOV-3.
Neoplasm Metastasis
Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer.
Neoplasm Metastasis
Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck.
Neoplasm Metastasis
Expression of MMP-13 is associated with invasion and metastasis of papillary thyroid carcinoma.
Neoplasm Metastasis
Gelatinase A and membrane-type 1 matrix metalloproteinase mRNA: expressed in adrenocortical cancers but not in adenomas.
Neoplasm Metastasis
Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma.
Neoplasm Metastasis
Ginsenoside Rh2 inhibits metastasis of glioblastoma multiforme through Akt-regulated MMP13.
Neoplasm Metastasis
Golgi Membrane Protein 1 (GOLM1) Promotes Growth and Metastasis of Breast Cancer Cells via Regulating Matrix Metalloproteinase-13 (MMP13).
Neoplasm Metastasis
Golgi protein 73 activation of MMP-13 promotes hepatocellular carcinoma cell invasion.
Neoplasm Metastasis
High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma.
Neoplasm Metastasis
Host and tumor derived MMP13 regulate extravasation and establishment of colorectal metastases in the liver.
Neoplasm Metastasis
Host-derived MMP-13 exhibits a protective role in lung metastasis of melanoma cells by local endostatin production.
Neoplasm Metastasis
Hypoxia-Induced Matrix Metalloproteinase-13 Expression in Exosomes from Nasopharyngeal Carcinoma Enhances Metastases.
Neoplasm Metastasis
Hypoxia-Inducible Factor-1? (HIF-1?) Promotes Hypoxia-Induced Invasion and Metastasis in Ovarian Cancer by Targeting Matrix Metallopeptidase 13 (MMP13).
Neoplasm Metastasis
Identification of GOLM1 as a positively regulator of tumor metastasis by regulating MMP13 in gastric carcinoma.
Neoplasm Metastasis
Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness.
Neoplasm Metastasis
Induction of MMP-13 expression in bone-metastasizing cancer cells by type I collagen through integrin ?1?1 and ?2?1-p38 MAPK signaling.
Neoplasm Metastasis
Infiltrating neutrophils increase bladder cancer cell invasion via modulation of androgen receptor (AR)/MMP13 signals.
Neoplasm Metastasis
ING2 is upregulated in colon cancer and increases invasion by enhanced MMP13 expression.
Neoplasm Metastasis
Inhibition of epidermal growth factor receptor signaling prohibits metastasis of gastric cancer via downregulation of MMP7 and MMP13.
Neoplasm Metastasis
Irradiation-induced dynamic changes of gene signatures reveal gain of metastatic ability in nasopharyngeal carcinoma.
Neoplasm Metastasis
Leptin signaling enhances cell invasion and promotes the metastasis of human pancreatic cancer via increasing MMP-13 production.
Neoplasm Metastasis
LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway.
Neoplasm Metastasis
Low collagenase-1 (MMP-1) and MT1-MMP expression levels are favourable survival markers in advanced colorectal carcinoma.
Neoplasm Metastasis
Markers of breast cancer stromal fibroblasts in the primary tumour site associated with lymph node metastasis: a systematic review including our case series.
Neoplasm Metastasis
Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
Neoplasm Metastasis
Matrix Metalloproteinase 13 Inhibitors for Modulation of Osteoclastogenesis: Enhancement of Solubility and Stability.
Neoplasm Metastasis
Matrix metalloproteinase 13 is induced in fibroblasts in polyomavirus middle T antigen-driven mammary carcinoma without influencing tumor progression.
Neoplasm Metastasis
Matrix metalloproteinase 13-containing exosomes promote nasopharyngeal carcinoma metastasis.
Neoplasm Metastasis
Matrix metalloproteinase 13: a potential intermediate between low expression of microRNA-125b and increasing metastatic potential of non-small cell lung cancer.
Neoplasm Metastasis
Matrix metalloproteinase-13 is regulated by toll-like receptor-9 in colorectal cancer cells and mediates cellular migration.
Neoplasm Metastasis
Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.
Neoplasm Metastasis
Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression.
Neoplasm Metastasis
Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: the role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis.
Neoplasm Metastasis
Microcystin-LR promotes melanoma cell invasion and enhances matrix metalloproteinase-2/-9 expression mediated by NF-?B activation.
Neoplasm Metastasis
MicroRNA-143 Regulates Human Osteosarcoma Metastasis by Regulating Matrix Metalloprotease-13 Expression.
Neoplasm Metastasis
MiR99a modulates MMP7 and MMP13 to regulate invasiveness of Kaposi's sarcoma.
Neoplasm Metastasis
MKK3/6-p38 MAPK negatively regulates murine MMP-13 gene expression induced by IL-1beta and TNF-alpha in immortalized periodontal ligament fibroblasts.
Neoplasm Metastasis
MMP-13 is involved in oral cancer cell metastasis.
Neoplasm Metastasis
MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-beta1.
Neoplasm Metastasis
MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases.
Neoplasm Metastasis
MMP-21 is upregulated at early stages of melanoma progression but disappears with more aggressive phenotype.
Neoplasm Metastasis
MMP13 is a potential prognostic marker for colorectal cancer.
Neoplasm Metastasis
MMP13 Regulates Aggressiveness of Pediatric Multiple Myeloma Through VEGF-C.
Neoplasm Metastasis
MUC1 induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13.
Neoplasm Metastasis
Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells.
Neoplasm Metastasis
Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis.
Neoplasm Metastasis
Overexpression of MMP-13 gene in colorectal cancer with liver metastasis.
Neoplasm Metastasis
Overexpression of MMP13 is associated with clinical outcomes and poor prognosis in oral squamous cell carcinoma.
Neoplasm Metastasis
PAI-1, a target gene of miR-143, regulates invasion and metastasis by upregulating MMP-13 expression of human osteosarcoma.
Neoplasm Metastasis
Pituitary tumor-transforming gene 1 regulates invasion of prostate cancer cells through MMP13.
Neoplasm Metastasis
Polyketides from the marine-derived fungus Aspergillus falconensis: In silico and in vitro cytotoxicity studies.
Neoplasm Metastasis
Quantitative real-time RT-PCR of ITGA7, SVEP1, TNS1, LPHN3, SEMA3G, KLB and MMP13 mRNA expression in breast cancer.
Neoplasm Metastasis
Regulation of metastasis of pediatric multiple myeloma by MMP13.
Neoplasm Metastasis
Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Neoplasm Metastasis
Retraction: MMP-13 is involved in oral cancer cell metastasis.
Neoplasm Metastasis
RKIP Inhibits Local Breast Cancer Invasion by Antagonizing the Transcriptional Activation of MMP13.
Neoplasm Metastasis
Role of matrix metalloproteinase 13 gene expression in the evaluation of radiation response in oral squamous cell carcinoma.
Neoplasm Metastasis
Role of matrix metalloproteinases and their inhibitors in tumor invasion and metastasis.
Neoplasm Metastasis
Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis.
Neoplasm Metastasis
Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
Neoplasm Metastasis
S100A4 promotes invasion and angiogenesis in breast cancer MDA-MB-231 cells by upregulating matrix metalloproteinase-13.
Neoplasm Metastasis
SENP2 regulates MMP13 expression in a bladder cancer cell line through SUMOylation of TBL1/TBLR1.
Neoplasm Metastasis
SIRT1 inhibits gastric cancer proliferation and metastasis via STAT3/MMP-13 signaling.
Neoplasm Metastasis
Small leucine zipper protein promotes the metastasis of castration-resistant prostate cancer through transcriptional regulation of matrix metalloproteinase-13.
Neoplasm Metastasis
Somatic Copy-Number Alterations Contribute to Brain Metastasis.
Neoplasm Metastasis
Stromal collagenase in melanoma: a vascular connection.
Neoplasm Metastasis
Stromal expression of MMP-13 is required for melanoma invasion and metastasis.
Neoplasm Metastasis
Stromal matrix metalloprotease-13 knockout alters Collagen I structure at the tumor-host interface and increases lung metastasis of C57BL/6 syngeneic E0771 mammary tumor cells.
Neoplasm Metastasis
SUMO-Specific Protease 2 Suppresses Cell Migration and Invasion through Inhibiting the Expression of MMP13 in Bladder Cancer Cells.
Neoplasm Metastasis
Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1.
Neoplasm Metastasis
Suppressive effect of calcipotriol on the induction of matrix metalloproteinase (MMP)-9 and MMP-13 in a human squamous cell carcinoma cell line.
Neoplasm Metastasis
The CBM Complex Underwrites NF-?B Activation to Promote HER2-Associated Tumor Malignancy.
Neoplasm Metastasis
The Expression and Significance of CXCR5 and MMP-13 in Colorectal Cancer.
Neoplasm Metastasis
The Prolactin Inducible Protein Modulates Antitumor Immune Responses and Metastasis in a Mouse Model of Triple Negative Breast Cancer.
Neoplasm Metastasis
The Role of Matrix Metalloproteinases in the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma.
Neoplasm Metastasis
The Transcription Factor SPDEF Suppresses Prostate Tumor Metastasis.
Neoplasm Metastasis
The usefulness of new serum tumor markers in head and neck squamous cell carcinoma.
Neoplasm Metastasis
Thrombospondin 2 promotes tumor metastasis by inducing matrix metalloproteinase-13 production in lung cancer cells.
Neoplasm Metastasis
Transforming growth factor-?1 regulation of ATF-3, c-Jun and JunB proteins for activation of matrix metalloproteinase-13 gene in human breast cancer cells.
Neoplasm Metastasis
Transforming growth factor-beta1 regulation of ATF-3 and identification of ATF-3 target genes in breast cancer cells.
Neoplasm Metastasis
Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals.
Neoplasm Metastasis
Tumor-Derived Matrix Metalloproteinase-13 (MMP-13) Expression in Benign and Malignant Breast Lesions.
Neoplasm Metastasis
Tunicamycin promotes metastasis through upregulating endoplasmic reticulum stress induced GRP78 expression in thyroid carcinoma.
Neoplasm Metastasis
Upregulated osterix promotes invasion and bone metastasis and predicts for a poor prognosis in breast cancer.
Neoplasm Metastasis
[Collagenase 3 mRNA expression in squamous epithelial carcinomas of the oropharynx]
Neoplasm Metastasis
[Diagnostic value of E-cadherin, MMP-9, activated MMP-13 and anti-p53 antibodies in squamous cell carcinomas of head and neck]
Neoplasm Metastasis
[Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer]
Neoplasms
7,8-Dihydroxyflavone activates Nrf2/HO-1 signaling pathways and protects against osteoarthritis.
Neoplasms
A comparative pilot study of oral diacerein and locally treated diacerein-loaded nanoparticles in a model of osteoarthritis.
Neoplasms
A dietary polysaccharide from Eucheuma cottonii downregulates proinflammatory cytokines and ameliorates osteoarthritis-associated cartilage degradation in obese rats.
Neoplasms
A feedback inhibition between miRNA-127 and TGF?/c-Jun cascade in HCC cell migration via MMP13.
Neoplasms
A novel cyclo-oxygenase-2 inhibitor modulates catabolic and antiinflammatory mediators in osteoarthritis.
Neoplasms
A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential.
Neoplasms
Abnormal increase of miR-4262 promotes cell proliferation and migration by targeting large tumor suppressor 1 in gliomas.
Neoplasms
Activation of fibroblast collagenase-1 expression by tumor cells of squamous cell carcinomas is mediated by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase-2.
Neoplasms
Activation of inflammatory mediators and potential role of ah-receptor ligands in foam cell formation.
Neoplasms
Active matrix metalloproteases are expressed early on and are high during the Barrett's esophagus malignancy sequence.
Neoplasms
ADAMTS-1 metalloproteinase promotes tumor development through the induction of a stromal reaction in vivo.
Neoplasms
Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells.
Neoplasms
Advanced oxidation protein products induce inflammatory responses and invasive behaviour in fibroblast-like synoviocytes via the RAGE-NF-?B pathway.
Neoplasms
Alogliptin inhibits IL-1?-induced inflammatory response in fibroblast-like synoviocytes.
Neoplasms
Alpha v beta 6 integrin down-regulates the MMP-13 expression in oral squamous cell carcinoma cells.
Neoplasms
Altered Gene and Protein Expressions in Torn Rotator Cuff Tendon Tissues in Diabetic Patients.
Neoplasms
An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer.
Neoplasms
An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in antitumor therapies.
Neoplasms
Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis.
Neoplasms
Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer.
Neoplasms
Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis.
Neoplasms
Anti-inflammatory and anti-nociceptive effect of Betula platyphylla var. japonica in human interleukin-1?-stimulated fibroblast-like synoviocytes and in experimental animal models.
Neoplasms
Anti-Inflammatory Effects of Conditioned Medium of Periodontal Ligament-Derived Stem Cells on Chondrocytes, Synoviocytes, and Meniscus Cells.
Neoplasms
Anti-Metastasis Effects of Ginsenoside Rg3 in B16F10 Cells.
Neoplasms
AP-1 as a Regulator of MMP-13 in the Stromal Cell of Giant Cell Tumor of Bone.
Neoplasms
Aqueous garlic extract alleviates liver fibrosis and renal dysfunction in bile-duct-ligated rats.
Neoplasms
Artificial Intelligence Approach to Find Lead Compounds for Treating Tumors.
Neoplasms
Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer.
Neoplasms
Association of MMP7-181A/G and MMP13-77A/G polymorphisms with colorectal cancer in a Mexican population.
Neoplasms
Associations between knee structural measures, circulating inflammatory factors and MMP13 in patients with knee osteoarthritis.
Neoplasms
Astragalus Polysaccharide (PG2) Suppresses Macrophage Migration Inhibitory Factor and Aggressiveness of Lung Adenocarcinoma Cells.
Neoplasms
Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells.
Neoplasms
Avocado soybean unsaponifiables ameliorates cartilage and subchondral bone degeneration in mono-iodoacetate-induced knee osteoarthritis in rats.
Neoplasms
Bergapten alleviates osteoarthritis by regulating the ANP32A/ATM signaling pathway.
Neoplasms
Blueberries Improve Pain, Gait Performance, and Inflammation in Individuals with Symptomatic Knee Osteoarthritis.
Neoplasms
Bone marrow-derived myofibroblasts are the providers of pro-invasive matrix metalloproteinase 13 in primary tumor.
Neoplasms
Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.
Neoplasms
Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of Metalloproteinase (MMP)-13.
Neoplasms
Cancer stem-like cells of glioblastoma characteristically express MMP-13 and display highly invasive activity.
Neoplasms
Cancer-Osteoblast Interaction Reduces Sost Expression in Osteoblasts and Up-Regulates lncRNA MALAT1 in Prostate Cancer.
Neoplasms
Carnosine Prevents Type 2 Diabetes-Induced Osteoarthritis Through the ROS/NF-?B Pathway.
Neoplasms
CCR4 promotes metastasis via ERK/NF-?B/MMP13 pathway and acts downstream of TNF-? in colorectal cancer.
Neoplasms
CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis.
Neoplasms
Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis.
Neoplasms
Central and peripheral region tibial plateau chondrocytes respond differently to in vitro dynamic compression.
Neoplasms
Changes of synovial fluid biomarker levels after opening wedge high tibial osteotomy in patients with knee osteoarthritis.
Neoplasms
Characterization of collagenase 3 (matrix metalloproteinase 13) messenger RNA expression in the synovial membrane and synovial fibroblasts of patients with rheumatoid arthritis.
Neoplasms
Characterization of progressive periodontal lesions in chronic periodontitis patients: levels of chemokines, cytokines, matrix metalloproteinase-13, periodontal pathogens and inflammatory cells.
Neoplasms
Chloramphenicol causes mitochondrial stress, decreases ATP biosynthesis, induces matrix metalloproteinase-13 expression and solid-tumor cell invasion.
Neoplasms
Chondroprotective Effects and Mechanisms of Dextromethorphan: Repurposing Antitussive Medication for Osteoarthritis Treatment.
Neoplasms
Chondroprotective effects of platelet lysate towards monoiodoacetate-induced arthritis by suppression of TNF-?-induced activation of NF-?B pathway in chondrocytes.
Neoplasms
Circulating IgG response to stromelysin-3, collagenase-3, galectin-3 and mesothelin in patients with pharynx/larynx squamous cell carcinoma.
Neoplasms
Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: differential expression with collagenase-1 (matrix metalloproteinase-1).
Neoplasms
Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer.
Neoplasms
Collagenase 3 (matrix metalloproteinase 13) gene expression by HaCaT keratinocytes is enhanced by tumor necrosis factor alpha and transforming growth factor beta.
Neoplasms
Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation.
Neoplasms
Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor.
Neoplasms
Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma.
Neoplasms
Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas.
Neoplasms
Collagenase-3 expression by tumor cells and gelatinase B expression by stromal fibroblast-like cells are associated with biochemical recurrence after radical prostatectomy in patients with prostate cancer.
Neoplasms
Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.
Neoplasms
Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx.
Neoplasms
Collagenase-3 induction in rat lung fibroblasts requires the combined effects of tumor necrosis factor-alpha and 12-lipoxygenase metabolites: a model of macrophage-induced, fibroblast-driven extracellular matrix remodeling during inflammatory lung injury.
Neoplasms
Collagenases (MMP-1, -8 and -13) and trypsinogen-2 in fluid from benign and malignant ovarian cysts.
Neoplasms
Common polymorphism in the MMP-13 gene may contribute to the risk of human cancers: a meta-analysis.
Neoplasms
Comparative gene expression profiling of normal and degenerative discs: analysis of a rabbit annular laceration model.
Neoplasms
Considering Rotatability of Hydroxyl Groups for the Active Site Residues of MMP-13 in Retrospective Virtual Screening Campaigns.
Neoplasms
Constitutive expression and regulation of collagenase-3 in human breast cancer cells.
Neoplasms
Correlation Between the Expression of Matrix Metalloproteinase-9, Matrix Metalloproteinase-13, Tissue Inhibitor of Metalloproteinases-1, p16 and Differentiation of Head and Neck Squamous Cell Carcinoma: A Prospective Observational Study.
Neoplasms
Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC.
Neoplasms
Correlation of COX-2 and MMP-13 expressions with gastric cancer and their effects on prognosis.
Neoplasms
Correlation of Synovial Fluid Biomarkers With Cartilage Pathology and Associated Outcomes in Knee Arthroscopy.
Neoplasms
Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
Neoplasms
Crocin exerts anti-inflammatory and anti-catabolic effects on rat intervertebral discs by suppressing the activation of JNK.
Neoplasms
Crosstalk between MMP-13, CD44, and TWIST1 and its role in regulation of EMT in patients with esophageal squamous cell carcinoma.
Neoplasms
Curcumin and tetrahydrocurcumin both prevent osteoarthritis symptoms and decrease the expressions of pro-inflammatory cytokines in estrogen-deficient rats.
Neoplasms
CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway.
Neoplasms
Cyclophilin C-associated protein is a mediator for fibronectin fragment-induced matrix metalloproteinase-13 expression.
Neoplasms
Cytokine and catabolic enzyme expression in synovium, synovial fluid and articular cartilage of naturally osteoarthritic equine carpi.
Neoplasms
Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes.
Neoplasms
Cytokine profile in the gingival crevicular fluid of rheumatoid arthritis patients with chronic periodontitis.
Neoplasms
Cytokines, matrix metalloproteases, angiogenic and growth factors in tears of normal subjects and vernal keratoconjunctivitis patients.
Neoplasms
Development and Validation of a Serum Biomarker Panel for the Detection of Esophageal Squamous Cell Carcinoma through RNA Transcriptome Sequencing.
Neoplasms
Development of a Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-7/-13 Inhibitor.
Neoplasms
Development of a Rat Model of Mechanically Induced Tunable Pain and Associated Temporomandibular Joint Responses.
Neoplasms
Different matrix micro-environments in colon cancer and diverticular disease.
Neoplasms
Differential expression of Janus kinase 3 (JAK3), matrix metalloproteinase 13 (MMP13), heat shock protein 60 (HSP60), and mouse double minute 2 (MDM2) in human colorectal cancer progression using human cancer cDNA microarrays.
Neoplasms
Differential expression of matrix metalloproteinase-13 in association with invasion of breast cancer.
Neoplasms
Differential expression of matrix metalloproteinases and miRNAs in the metastasis of oral squamous cell carcinoma.
Neoplasms
Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer.
Neoplasms
Differential regulation of MMP-13 by chemical modified tetracyclines in osteoblasts.
Neoplasms
Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.
Neoplasms
Discovery of Potent, Selective, and Orally Active Carboxylic Acid Based Inhibitors of Matrix Metalloproteinase-13 (dagger).
Neoplasms
Down-regulation of expression of osteoblast and osteocyte markers in periodontal tissues associated with the spontaneous alveolar bone loss of interleukin-10 knockout mice.
Neoplasms
Dual effects of collagenase-3 on melanoma: metastasis promotion and disruption of vasculogenic mimicry.
Neoplasms
Dynamic biophysical strain modulates proinflammatory gene induction in meniscal fibrochondrocytes.
Neoplasms
Effect of lentivirus-mediated integrin ?V?3-shRNA on tumor growth of mice with lung cancer xenografts.
Neoplasms
Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance.
Neoplasms
Effects of bromopride on expression of metalloproteinases and interleukins in left colonic anastomoses: an experimental study.
Neoplasms
Effects of matrix metalloproteinase 13 on vascular smooth muscle cells migration via Akt-ERK dependent pathway.
Neoplasms
Effects of selective MMP-13 inhibition in Squamous Cell Carcinoma depend on estrogen.
Neoplasms
Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness.
Neoplasms
Elevation of matrix metalloproteinases and interleukin-6 in the culprit coronary artery of myocardial infarction.
Neoplasms
Enamel matrix derivative induces the expression of tissue inhibitor of matrix metalloproteinase-3 in human gingival fibroblasts via extracellular signal-regulated kinase.
Neoplasms
Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential?
Neoplasms
Enhanced tendon restoration effects of anti-inflammatory, lactoferrin-immobilized, heparin-polymeric nanoparticles in an Achilles tendinitis rat model.
Neoplasms
Epithelial cells up-regulate matrix metalloproteinases in cells within the same mammary carcinoma that have undergone an epithelial-mesenchymal transition.
Neoplasms
Estrogenic and antiestrogenic regulation of MMP-2 and MMP-13 mRNA in RUCA-I endometrial tumor cells in vitro and in vivo.
Neoplasms
ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis.
Neoplasms
Evaluation of Collagen in Leukoplakia, Oral Submucous Fibrosis and Oral Squamous Cell Carcinomas Using Polarizing Microscopy and Immunohistochemistry
Neoplasms
Evaluation of the post-treatment anti-inflammatory capacity of osteoarthritic chondrocytes: An in vitro study using baicalein.
Neoplasms
Evidence for the role of matrix metalloproteinase-13 in bone resorption by giant cell tumor of bone.
Neoplasms
Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes.
Neoplasms
Experimental periodontitis in mice selected for maximal or minimal inflammatory reactions: increased inflammatory immune responsiveness drives increased alveolar bone loss without enhancing the control of periodontal infection.
Neoplasms
Expression analysis of matrix metalloproteinase-13 in human gastric cancer in the presence of Helicobacter Pylori infection.
Neoplasms
Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors.
Neoplasms
Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer.
Neoplasms
Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck.
Neoplasms
Expression of collagenase-3 (MMP-13) by tumor cells in squamous cell carcinomas of the head and neck.
Neoplasms
Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells.
Neoplasms
Expression of collagenase-3 (MMP-13) in c-fos-induced osteosarcomas and chondrosarcomas is restricted to a subset of cells of the osteo-/chondrogenic lineage.
Neoplasms
Expression of CXCR4, MMP-13 and ?-catenin in different histological subtypes of facial basal cell carcinoma.
Neoplasms
Expression of matrix metalloproteinase (MMP)-2, MMP-9, MMP-13, and MT1-MMP in skin tumors of human papillomavirus type 8 transgenic mice.
Neoplasms
Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds.
Neoplasms
Expression of Matrix Metalloproteinase-13 and Ki-67 in Nonmelanoma Skin Cancer in Xeroderma Pigmentosum and Non-xeroderma Pigmentosum.
Neoplasms
Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck.
Neoplasms
Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines.
Neoplasms
Expression of MMP-13 is associated with invasion and metastasis of papillary thyroid carcinoma.
Neoplasms
Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response.
Neoplasms
Expression of synovial fluid biomarkers in patients with knee osteoarthritis and meniscus injury.
Neoplasms
Expression pattern and circulating levels of endostatin in patients with pancreas cancer.
Neoplasms
Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma.
Neoplasms
Expression profiling of murine intestinal adenomas reveals early deregulation of multiple matrix metalloproteinase (Mmp) genes.
Neoplasms
Flexibility and variability of TIMP binding: X-ray structure of the complex between collagenase-3/MMP-13 and TIMP-2.
Neoplasms
Follistatin-like protein 1 promotes inflammatory reactions in nucleus pulposus cells by interacting with the MAPK and NF?B signaling pathways.
Neoplasms
FOXO3a promotes tumor cell invasion through the induction of matrix metalloproteinases.
Neoplasms
Fragment-Based Discovery of 5-Arylisatin-Based Inhibitors of Matrix Metalloproteinases 2 and 13.
Neoplasms
Free Energy Calculations on Snake Venom Metalloproteinase BaP1.
Neoplasms
Function of microRNA-143 in different signal pathways in cancer: New insights into cancer therapy.
Neoplasms
Functional characterization of selective exosite-binding inhibitors of matrix metalloproteinase-13 (MMP-13) - experimental validation in human breast and colon cancer.
Neoplasms
Gelatinase A and membrane-type 1 matrix metalloproteinase mRNA: expressed in adrenocortical cancers but not in adenomas.
Neoplasms
Ghrelin protects against nucleus pulposus degeneration through inhibition of NF-?B signaling pathway and activation of Akt signaling pathway.
Neoplasms
Ginkgolide B attenuates collagen-induced rheumatoid arthritis and regulates fibroblast-like synoviocytes-mediated apoptosis and inflammation.
Neoplasms
Golgi protein 73 activation of MMP-13 promotes hepatocellular carcinoma cell invasion.
Neoplasms
Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes.
Neoplasms
High collagenase-1 expression correlates with a favourable chemoimmunotherapy response in human metastatic melanoma.
Neoplasms
High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis.
Neoplasms
High molecular weight hyaluronic acid regulates MMP13 expression in chondrocytes via DUSP10/MKP5.
Neoplasms
High-Frequency Near-Infrared Diode Laser Irradiation Attenuates IL-1?-Induced Expression of Inflammatory Cytokines and Matrix Metalloproteinases in Human Primary Chondrocytes.
Neoplasms
High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization.
Neoplasms
Histone Deacetylase Inhibitor Vorinostat (SAHA) Suppresses IL-1?-Induced Matrix Metallopeptidase-13 Expression by Inhibiting IL-6 in Osteoarthritis Chondrocyte.
Neoplasms
Host and tumor derived MMP13 regulate extravasation and establishment of colorectal metastases in the liver.
Neoplasms
Host-derived MMP-13 exhibits a protective role in lung metastasis of melanoma cells by local endostatin production.
Neoplasms
Human collagenase-3 is expressed in malignant squamous epithelium of the skin.
Neoplasms
Human macrophage metalloelastase (MMP-12) expression is induced in chondrocytes during fetal development and malignant transformation.
Neoplasms
Hyaluronan in part mediates IL-1beta-induced inflammation in mouse chondrocytes by up-regulating CD44 receptors.
Neoplasms
Hyaluronan-oligosaccharide-induced transcription of metalloproteases.
Neoplasms
Identification of GOLM1 as a positively regulator of tumor metastasis by regulating MMP13 in gastric carcinoma.
Neoplasms
Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor.
Neoplasms
Immunohistochemical analysis of MMP-13 and EMMPRIN in epithelial odontogenic lesions.
Neoplasms
Impact of miR-SNP rs2910164 on miR-146a expression in osteoarthritic chondrocytes.
Neoplasms
In Vitro Anti-Inflammation and Chondrogenic Differentiation Effects of Inclusion Nanocomplexes of Hyaluronic Acid-Beta Cyclodextrin and Simvastatin.
Neoplasms
In vitro effects of meloxicam on metabolism in articular chondrocytes from dogs with naturally occurring osteoarthritis.
Neoplasms
Increase of MMP-13 expression in multi-stage oral carcinogenesis and epigallocatechin-3-gallate suppress MMP-13 expression.
Neoplasms
Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness.
Neoplasms
Increased expression of matrix metalloproteinase-13 in glioma is associated with poor overall survival of patients.
Neoplasms
Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions.
Neoplasms
Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes.
Neoplasms
Induction of MMP-13 expression by soluble human glucocorticoid-induced tumor necrosis factor receptor in fibroblast-like synovial cells.
Neoplasms
Induction of MMP-13 expression in bone-metastasizing cancer cells by type I collagen through integrin ?1?1 and ?2?1-p38 MAPK signaling.
Neoplasms
Inflammation suppression by dexamethasone via inhibition of CD147-mediated NF-?B pathway in collagen-induced arthritis rats.
Neoplasms
Influence of the Molecular Weight of Poly(Lactide-Co-Glycolide) on the In Vivo Cartilage Repair by a Construct of Poly(Lactide-Co-Glycolide)/Fibrin Gel/Mesenchymal Stem Cells/Transforming Growth Factor-?1.
Neoplasms
ING Proteins as Potential Anticancer Drug Targets.
Neoplasms
ING2 is upregulated in colon cancer and increases invasion by enhanced MMP13 expression.
Neoplasms
Inhibition effect of curcumin on TNF-? and MMP-13 expression induced by advanced glycation end products in chondrocytes.
Neoplasms
Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-gamma is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1.
Neoplasms
Inhibition of epidermal growth factor receptor signaling prohibits metastasis of gastric cancer via downregulation of MMP7 and MMP13.
Neoplasms
Inhibition of SOX9 Promotes Inflammatory and Immune Responses of Dental Pulp.
Neoplasms
Insulin receptor substrate 1 regulates the cellular differentiation and the matrix metallopeptidase expression of preosteoblastic cells.
Neoplasms
Interferon ?2b increases MMP-13 and IL-10 expression in Kupffer cells through MAPK signaling pathways.
Neoplasms
Interpretation of immunohistochemistry data of tumor should consider microenvironmental factors.
Neoplasms
Interstitial collagenases as markers of tumor progression.
Neoplasms
Invasion and MMP expression profile in desmoid tumours.
Neoplasms
Involvement of H-Ras and reactive oxygen species in proinflammatory cytokine-induced matrix metalloproteinase-13 expression in human articular chondrocytes.
Neoplasms
Is collagenase-3 (MMP-13) expression in chondrosarcoma of the jaws a true marker for tumor aggressiveness?
Neoplasms
Is exclusion of leukocytes from platelet-rich plasma (PRP) a better choice for early intervertebral disc regeneration?
Neoplasms
Joint hemorrhage accelerates cartilage degeneration in a rat immobilized knee model.
Neoplasms
Levels of Matrix Metalloproteinases in Arthroplasty Patients and Their Correlation With Inflammatory and Thrombotic Activation Processes.
Neoplasms
LINC01534 Promotes the Aberrant Metabolic Dysfunction and Inflammation in IL-1?-Simulated Osteoarthritic Chondrocytes by Targeting miR-140-5p.
Neoplasms
LncRNA TUG1 promotes osteoarthritis-induced degradation of chondrocyte extracellular matrix via miR-195/MMP-13 axis.
Neoplasms
Local cytokines induce differential expression of matrix metalloproteinases but not their tissue inhibitors in human endometrial fibroblasts.
Neoplasms
Low collagenase-1 (MMP-1) and MT1-MMP expression levels are favourable survival markers in advanced colorectal carcinoma.
Neoplasms
Many new down- and up-regulatory signaling pathways, from known cancer progression suppressors to matrix metalloproteinases, differ widely in cells of various cancers.
Neoplasms
Matrilysin-1 (MMP-7) and MMP-19 are expressed by Paget's cells in extramammary Paget's disease.
Neoplasms
Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
Neoplasms
Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer.
Neoplasms
Matrix metalloproteinase 13 is induced in fibroblasts in polyomavirus middle T antigen-driven mammary carcinoma without influencing tumor progression.
Neoplasms
Matrix metalloproteinase 13-containing exosomes promote nasopharyngeal carcinoma metastasis.
Neoplasms
Matrix metalloproteinase 13: a potential intermediate between low expression of microRNA-125b and increasing metastatic potential of non-small cell lung cancer.
Neoplasms
Matrix metalloproteinase-13 (MMP-13) directly and indirectly promotes tumor angiogenesis.
Neoplasms
Matrix Metalloproteinase-13 - A Potential Biomarker for Detection and Prognostic Assessment of Patients with Esophageal Squamous Cell Carcinoma.
Neoplasms
Matrix metalloproteinase-13 expression in the progression of colorectal adenoma to carcinoma : Matrix metalloproteinase-13 expression in the colorectal adenoma and carcinoma.
Neoplasms
Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
Neoplasms
Matrix metalloproteinase-13: A special focus on its regulation by signaling cascades and microRNAs in bone.
Neoplasms
Matrix metalloproteinase-13 is a target gene of high-mobility group box-containing protein 1 in modulating oral cancer cell invasion.
Neoplasms
Matrix Metalloproteinase-3 is Key Effector of TNF-?-Induced Collagen Degradation in Skin.
Neoplasms
Matrix metalloproteinases and E-cadherin immunoreactivity in different basal cell carcinoma histological types.
Neoplasms
Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression.
Neoplasms
Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis.
Neoplasms
Mechanical strain attenuates cytokine-induced ADAMTS9 expression via transient receptor potential vanilloid type 1.
Neoplasms
Mesenchymal stem cells induce a fibrolytic phenotype by regulating mmu-miR-6769b-5p expression in macrophages.
Neoplasms
Microcystin-LR promotes melanoma cell invasion and enhances matrix metalloproteinase-2/-9 expression mediated by NF-?B activation.
Neoplasms
Microcystin-LR promotes migration and invasion of colorectal cancer through matrix metalloproteinase-13 up-regulation.
Neoplasms
MicroRNA Mediate Visfatin and Resistin Induction of Oxidative Stress in Human Osteoarthritic Synovial Fibroblasts Via NF-?B Pathway.
Neoplasms
MicroRNA-125b Down-regulates Matrix Metallopeptidase 13 and Inhibits Cutaneous Squamous Cell Carcinoma Cell Proliferation, Migration, and Invasion.
Neoplasms
MiR-126-5p regulates osteoclast differentiation and bone resorption in giant cell tumor through inhibition of MMP-13.
Neoplasms
miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer.
Neoplasms
MK801 regulates the expression of key osteoarthritis factors in osteoarthritis synovial fibroblasts through complement C5.
Neoplasms
MKK3/6-p38 MAPK negatively regulates murine MMP-13 gene expression induced by IL-1beta and TNF-alpha in immortalized periodontal ligament fibroblasts.
Neoplasms
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors.
Neoplasms
MMP-13 In-Vivo Molecular Imaging Reveals Early Expression in Lung Adenocarcinoma.
Neoplasms
MMP-13 is constitutively produced in human chondrocytes and co-endocytosed with ADAMTS-5 and TIMP-3 by the endocytic receptor LRP1.
Neoplasms
MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases.
Neoplasms
MMP-2 and MMP-13 affect vasculogenic mimicry formation in large cell lung cancer.
Neoplasms
MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma.
Neoplasms
MMP13 inhibition rescues cognitive decline in Alzheimer transgenic mice via BACE1 regulation.
Neoplasms
MMP13 is a potential prognostic marker for colorectal cancer.
Neoplasms
MMP13 is potentially a new tumor marker for breast cancer diagnosis.
Neoplasms
MMP13 Regulates Aggressiveness of Pediatric Multiple Myeloma Through VEGF-C.
Neoplasms
MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression.
Neoplasms
Muscone Protects Vertebral End-plate Degeneration by Antiinflammatory Property.
Neoplasms
Myeloperoxidase is increased in human cerebral aneurysms and increases formation and rupture of cerebral aneurysms in mice.
Neoplasms
New pathway links from cancer-progression determinants to gene expression of matrix metalloproteinases in breast cancer cells.
Neoplasms
Non-bone metastatic cancers promote osteocyte-induced bone destruction.
Neoplasms
Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells.
Neoplasms
Olive Leaf Extract and Its Main Component Oleuropein Prevent Chronic Ultraviolet B Radiation-Induced Skin Damage and Carcinogenesis in Hairless Mice.
Neoplasms
Oral administration of EP4-selective agonist KAG-308 suppresses mouse knee osteoarthritis development through reduction of chondrocyte hypertrophy and TNF secretion.
Neoplasms
Ovariectomy Exacerbates Apical Periodontitis in Rats with an Increase in Expression of Proinflammatory Cytokines and Matrix Metalloproteinases.
Neoplasms
Overexpression of MMP-13 gene in colorectal cancer with liver metastasis.
Neoplasms
Overexpression of MMP13 is associated with clinical outcomes and poor prognosis in oral squamous cell carcinoma.
Neoplasms
p63 transcriptionally regulates the expression of matrix metallopeptidase 13.
Neoplasms
Peroxisome proliferator--activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes.
Neoplasms
PI3K, Erk signaling in BMP7-induced epithelial-mesenchymal transition (EMT) of PC-3 prostate cancer cells in 2- and 3-dimensional cultures.
Neoplasms
Piperine inhibit inflammation, alveolar bone loss and collagen fibers breakdown in a rat periodontitis model.
Neoplasms
Platycodi Radix attenuates dimethylnitrosamine-induced liver fibrosis in rats by inducing Nrf2-mediated antioxidant enzymes.
Neoplasms
PLD1 promotes tumor invasion by regulation of MMP-13 expression via NF-?B signaling in bladder cancer.
Neoplasms
Polyketides from the marine-derived fungus Aspergillus falconensis: In silico and in vitro cytotoxicity studies.
Neoplasms
Possible role of matrix metalloproteinases (MMPs) in hyperostosis of intracranial meningiomas.
Neoplasms
Preconditioning of Adipose-Derived Mesenchymal Stem-Like Cells with Eugenol Potentiates Their Migration and Proliferation In Vitro and Therapeutic Abilities in Rat Hepatic Fibrosis.
Neoplasms
Primary ductal adenocarcinoma of the lacrimal gland: case report.
Neoplasms
Prognostic significance of matrix metalloproteinase-2, -8, -9, and -13 in oral tongue cancer.
Neoplasms
Prognostic value of matrix metalloproteinases in oral squamous cell carcinoma.
Neoplasms
Proinflammatory cytokines and lipopolysaccharides up regulate MMP-3 and MMP-13 production in Asian elephant (Elephas maximus) chondrocytes: attenuation by anti-arthritic agents.
Neoplasms
Prostaglandin EP2 receptor signalling inhibits the expression of matrix metalloproteinase 13 in human osteoarthritic chondrocytes.
Neoplasms
Protective effects of cilengitide on inflammation in chondrocytes under excessive mechanical stress.
Neoplasms
Protein isoprenylation regulates secretion of matrix metalloproteinase 1 from rheumatoid synovial fibroblasts: effects of statins and farnesyl and geranylgeranyl transferase inhibitors.
Neoplasms
Proteoglycan degradation after injurious compression of bovine and human articular cartilage in vitro: interaction with exogenous cytokines.
Neoplasms
Proteolysis of the collagen fibril in osteoarthritis.
Neoplasms
Rational design of matrix metalloproteinase-13 activatable probes for enhanced specificity.
Neoplasms
Reciprocal modulation of matrix metalloproteinase-13 and type I collagen genes in rat hepatic stellate cells.
Neoplasms
Reduction in arthritis severity and modulation of immune function in tissue factor cytoplasmic domain mutant mice.
Neoplasms
Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions.
Neoplasms
Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer.
Neoplasms
Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in osteoblastic cells.
Neoplasms
Regulation of metastasis of pediatric multiple myeloma by MMP13.
Neoplasms
Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma.
Neoplasms
Regulation of the inflammatory cycle by a controllable release hydrogel for eliminating postoperative inflammation after discectomy.
Neoplasms
Relationship between morphological features and kinetic patterns of enhancement of the dynamic breast magnetic resonance imaging and tumor expression of metalloproteases and their inhibitors in invasive breast cancer.
Neoplasms
Relative efficacies of omega-3 polyunsaturated fatty acids in reducing expression of key proteins in a model system for studying osteoarthritis.
Neoplasms
Retraction Note to: Common polymorphism in the MMP-13 gene may contribute to the risk of human cancers: a meta-analysis.
Neoplasms
Rhizoma drynariae total flavonoids inhibit the inflammatory response and matrix degeneration via MAPK pathway in a rat degenerative cervical intervertebral disc model.
Neoplasms
Rho/ROCK and MEK/ERK activation by transforming growth factor-alpha induces articular cartilage degradation.
Neoplasms
Rice Porridge Containing Welsh Onion Root Water Extract Alleviates Osteoarthritis-Related Pain Behaviors, Glucose Levels, and Bone Metabolism in Osteoarthritis-Induced Ovariectomized Rats.
Neoplasms
RKIP Inhibits Local Breast Cancer Invasion by Antagonizing the Transcriptional Activation of MMP13.
Neoplasms
Roflumilast prevents lymphotoxin ? (TNF-?)-induced inflammation activation and degradation of type 2 collagen in chondrocytes.
Neoplasms
Role of matrix metalloproteinases and their inhibitors in tumor invasion and metastasis.
Neoplasms
Rosa multiflora Thunb Flower Extract Attenuates Ultraviolet-Induced Photoaging in Skin Cells and Hairless Mice.
Neoplasms
Runt-related gene 2 is involved in the inhibition of matrix metalloproteinase-13 expression by roxithromycin in human gingival epithelial cell cultures.
Neoplasms
Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
Neoplasms
RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion.
Neoplasms
S100A4 Elevation Empowers Expression of Metastasis Effector Molecules in Human Breast Cancer.
Neoplasms
Salvia miltiorrhiza-asarum ointment combined with Chinese medical massage alleviates symptoms of osteoarthritis in a rat model through the Notch1/ matrix metalloproteinase-13 signaling pathway.
Neoplasms
Scutellarin Attenuates the IL-1?-Induced Inflammation in Mouse Chondrocytes and Prevents Osteoarthritic Progression.
Neoplasms
Serum and knee synovial fluid matrix metalloproteinase-13 and tumor necrosis factor-alpha levels in patients with late-stage osteoarthritis.
Neoplasms
Serum and saliva collagenase-3 (MMP-13) in patients with oral lichen planus and oral squamous cell carcinoma.
Neoplasms
Serum matrix metalloproteinase-13 as a diagnostic biomarker for cutaneous squamous cell carcinoma.
Neoplasms
SIRT1 inhibits gastric cancer proliferation and metastasis via STAT3/MMP-13 signaling.
Neoplasms
SP600125, a JNK-Specific Inhibitor, Regulates in vitro Auricular Cartilage Regeneration by Promoting Cell Proliferation and Inhibiting Extracellular Matrix Metabolism.
Neoplasms
Stromal collagenase in melanoma: a vascular connection.
Neoplasms
Stromal expression of MMP-13 is required for melanoma invasion and metastasis.
Neoplasms
Stromal matrix metalloprotease-13 knockout alters Collagen I structure at the tumor-host interface and increases lung metastasis of C57BL/6 syngeneic E0771 mammary tumor cells.
Neoplasms
Structural analysis and promoter characterization of the human collagenase-3 gene (MMP13).
Neoplasms
SUMO-Specific Protease 2 Suppresses Cell Migration and Invasion through Inhibiting the Expression of MMP13 in Bladder Cancer Cells.
Neoplasms
Suppressive effect of calcipotriol on the induction of matrix metalloproteinase (MMP)-9 and MMP-13 in a human squamous cell carcinoma cell line.
Neoplasms
Systemic Th17-like cytokine pattern in gangrenous appendicitis but not in phlegmonous appendicitis.
Neoplasms
Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes.
Neoplasms
T cells regulate the expression of matrix metalloproteinase in human osteoblasts via a dual mitogen-activated protein kinase mechanism.
Neoplasms
T-614 attenuates knee osteoarthritis via regulating Wnt/?-catenin signaling pathway.
Neoplasms
Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo.
Neoplasms
Teneligliptin inhibits IL-1?-induced degradation of extracellular matrix in human chondrocytes.
Neoplasms
The CBM Complex Underwrites NF-?B Activation to Promote HER2-Associated Tumor Malignancy.
Neoplasms
The Clinical Significance and Molecular Features of the Spatial Tumor Shapes in Breast Cancers.
Neoplasms
The complexity of molecular processes in osteoarthritis of the knee joint.
Neoplasms
The differential effects of leukocyte-containing and pure platelet-rich plasma (PRP) on tendon stem/progenitor cells - implications of PRP application for the clinical treatment of tendon injuries.
Neoplasms
The Expression and Significance of CXCR5 and MMP-13 in Colorectal Cancer.
Neoplasms
The fibroblastic coconspirator in cancer progression.
Neoplasms
The IGF-I Receptor Can Alter the Matrix Metalloproteinase Repertoire of Tumor Cells through Transcriptional Regulation of PKC-{alpha}
Neoplasms
The immunoexpression of MMP-1 and MMP-13 in eyelid basal cell carcinoma.
Neoplasms
The Prolactin Inducible Protein Modulates Antitumor Immune Responses and Metastasis in a Mouse Model of Triple Negative Breast Cancer.
Neoplasms
The relationship of metalloproteinase gene polymorphisms and lung cancer.
Neoplasms
The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis.
Neoplasms
The Transcription Factor SPDEF Suppresses Prostate Tumor Metastasis.
Neoplasms
Theobromine mitigates IL-1?-induced oxidative stress, inflammatory response, and degradation of type II collagen in human chondrocytes.
Neoplasms
Thrombospondin 2 promotes tumor metastasis by inducing matrix metalloproteinase-13 production in lung cancer cells.
Neoplasms
TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro.
Neoplasms
TNF?-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2(+) neutrophils.
Neoplasms
Toll-like receptor-4 agonist inhibits motility and invasion of hepatoblastoma HepG2 cells in vitro.
Neoplasms
Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors.
Neoplasms
Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas.
Neoplasms
Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13, are present in epithelial cells of keratoacanthomas.
Neoplasms
Transforming growth factor-beta1 regulation of ATF-3 and identification of ATF-3 target genes in breast cancer cells.
Neoplasms
Transforming growth factor-beta2 suppresses collagen cleavage in cultured human osteoarthritic cartilage, reduces expression of genes associated with chondrocyte hypertrophy and degradation, and increases prostaglandin E(2) production.
Neoplasms
Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model.
Neoplasms
Tripterygium wilfordii Hook F extract suppresses proinflammatory cytokine-induced expression of matrix metalloproteinase genes in articular chondrocytes by inhibiting activating protein-1 and nuclear factor-kappaB activities.
Neoplasms
Trivalent metal ions based on inorganic compounds with in vitro inhibitory activity of matrix metalloproteinase 13.
Neoplasms
Tropomodulin 1 expression driven by NF-?B enhances breast cancer growth.
Neoplasms
Tumor promoter-induced MMP-13 gene expression in a model of initiated epidermis.
Neoplasms
Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.
Neoplasms
Tumor-Derived Matrix Metalloproteinase-13 (MMP-13) Expression in Benign and Malignant Breast Lesions.
Neoplasms
Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma.
Neoplasms
Upregulation of matrix metalloproteinases (MMPs) in breast cancer xenografts: a major induction of stromal MMP-13.
Neoplasms
Upregulation of MMP-13 via Runx2 in the stromal cell of Giant Cell Tumor.
Neoplasms
Ursolic acid protects chondrocytes, exhibits anti-inflammatory properties via regulation of the NF-?B/NLRP3 inflammasome pathway and ameliorates osteoarthritis.
Neoplasms
Urtica dioica extract suppresses miR-21 and metastasis-related genes in breast cancer.
Neoplasms
Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes.
Neoplasms
Vascular expression of matrix metalloproteinase-13 (collagenase-3) in basal cell carcinoma.
Neoplasms
Vitamin D Inhibits Activities of Metalloproteinase-9/-13 in Articular Cartilage In Vivo and In Vitro.
Neoplasms
YB-1 binds to the MMP-13 promoter sequence and represses MMP-13 transactivation via the AP-1 site.
Neoplasms
[Collagenase 3 mRNA expression in squamous epithelial carcinomas of the oropharynx]
Neoplasms
[Collagenase-3 (MMP-13) expression in epithelial cancers of the eyelids]
Neoplasms
[Diversity of invasiveness and matrix metalloproteinases expression profile of human gastric carcinoma xenografted in different tissue environments]
Neoplasms
[Effect of leptin on inducible NO and MMP-13 in rabbit articular chondrocytes in vitro]
Neoplasms
[Expression and clinical significance of collagenase-3 (MMP-13) in gastric cancer]
Neoplasms
[Inhibition of matrix metalloproteinases 9 and 13 affects the degree of lymphocytic infiltration and the expression levels of microRNA miR-21 and miR-let-7b in melanoma cells in vivo].
Neoplasms
[Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer]
Neoplasms
[The association of MMP-13 polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adeno-carcinoma]
Nerve Sheath Neoplasms
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors.
Neurofibroma
Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors.
Neurofibroma
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors.
Neurofibroma, Plexiform
Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors.
Neurofibromatoses
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors.
Neurofibromatosis 1
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors.
Neurofibrosarcoma
Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors.
Neurofibrosarcoma
High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization.
Neurofibrosarcoma
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors.
Nevus, Pigmented
Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma.
Non-alcoholic Fatty Liver Disease
Host and tumor derived MMP13 regulate extravasation and establishment of colorectal metastases in the liver.
Non-alcoholic Fatty Liver Disease
Short-Term Intake of a Fructose-, Fat- and Cholesterol-Rich Diet Causes Hepatic Steatosis in Mice: Effect of Antibiotic Treatment.
Obesity
Inhibition of MMP-13 prevents diet-induced obesity in mice and suppresses adipogenesis in 3T3-L1 preadipocytes.
Obesity
Obesity affects the chondrocyte responsiveness to leptin in patients with osteoarthritis.
Obesity
Tissue-specific differences in inflammatory infiltrate and matrix metalloproteinase expression in adipose tissue and liver of mice with diet-induced obesity.
Odontogenic Cysts
Collagenase-3 expression in periapical lesions: an immunohistochemical study.
Odontogenic Cysts
Expression and induction of collagenases (MMP-8 and -13) in plasma cells associated with bone-destructive lesions.
Odontogenic Cysts
Laminin-5 gamma 2 chain is colocalized with gelatinase-A (MMP-2) and collagenase-3 (MMP-13) in odontogenic keratocysts.
Odontogenic Cysts
MMP-13 expression in keratocyst odontogenic tumour associated with NBCCS and sporadic keratocysts.
Odontogenic Tumors
MMP-13 expression in keratocyst odontogenic tumour associated with NBCCS and sporadic keratocysts.
Oral Submucous Fibrosis
Evaluation of Collagen in Leukoplakia, Oral Submucous Fibrosis and Oral Squamous Cell Carcinomas Using Polarizing Microscopy and Immunohistochemistry
Osteoarthritis
15-deoxy-?(12,14) -prostaglandin-J2 and Ciglitazone Inhibit TNF-?-induced matrix metalloproteinase 13 production via the antagonism of NF-?B activation in human synovial fibroblasts.
Osteoarthritis
A low ratio of n-6/n-3 polyunsaturated fatty acids suppresses matrix metalloproteinase 13 expression and reduces adjuvant-induced arthritis in rats.
Osteoarthritis
A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
Osteoarthritis
A systematic computational analysis of human matrix metalloproteinase 13 (MMP-13) crystal structures and structure-based identification of prospective drug candidates as MMP-13 inhibitors repurposable for osteoarthritis.
Osteoarthritis
A Systematic Review of Basic Science and Animal Studies on the Use of Doxycycline to Reduce the Risk of Posttraumatic Osteoarthritis After Anterior Cruciate Ligament Rupture/Transection.
Osteoarthritis
Activating enhancer binding protein 2 epsilon (AP-2?)-deficient mice exhibit increased matrix metalloproteinase 13 expression and progressive osteoarthritis development.
Osteoarthritis
Activation of the discoidin domain receptor 2 induces expression of matrix metalloproteinase 13 associated with osteoarthritis in mice.
Osteoarthritis
Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators.
Osteoarthritis
Allogeneic adipose-derived mesenchymal stem cells promote the expression of chondrocyte redifferentiation markers and retard the progression of knee osteoarthritis in rabbits.
Osteoarthritis
Amelioration of post-traumatic osteoarthritis via nanoparticle depots delivering small interfering RNA to damaged cartilage.
Osteoarthritis
Analysis of the Relationship between RELA Gene Expression and MMP-13 Gene Expression in Synoviocyte Cells after Mesenchymal Stem Cell Wharton Jelly.
Osteoarthritis
Anti-Inflammatory Effect of Geniposide on Osteoarthritis by Suppressing the Activation of p38 MAPK Signaling Pathway.
Osteoarthritis
Assessment of cartilage degradation effects of matrix metalloproteinase-13 in equine cartilage cocultured with synoviocytes.
Osteoarthritis
Autocrine regulation of collagenase 3 (matrix metalloproteinase 13) during osteoarthritis.
Osteoarthritis
Basic Fibroblast Growth Factor Activates the MAPK and NF{kappa}B Pathways That Converge on Elk-1 to Control Production of Matrix Metalloproteinase-13 by Human Adult Articular Chondrocytes.
Osteoarthritis
Blocking of the P2X7 receptor inhibits the activation of the MMP-13 and NF-?B pathways in the cartilage tissue of rats with osteoarthritis.
Osteoarthritis
cAMP response element-binding (CREB) recruitment following a specific CpG demethylation leads to the elevated expression of the matrix metalloproteinase 13 in human articular chondrocytes and osteoarthritis.
Osteoarthritis
Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: confirmation by multivariate analysis that modulation of type II collagen and aggrecan degradation peptides parallels pathologic changes.
Osteoarthritis
Cartilage in facet joints of patients with ankylosing spondylitis (AS) shows signs of cartilage degeneration rather than chondrocyte hypertrophy: implications for joint remodeling in AS.
Osteoarthritis
Catabolism of Fibromodulin in Developmental Rudiment and Pathologic Articular Cartilage Demonstrates Novel Roles for MMP-13 and ADAMTS-4 in C-terminal Processing of SLRPs.
Osteoarthritis
CCAAT/enhancer binding protein beta mediates expression of matrix metalloproteinase 13 in human articular chondrocytes in inflammatory arthritis.
Osteoarthritis
Changes in Synovial Fluid Biomarkers after Experimental Equine Osteoarthritis.
Osteoarthritis
Characterization of an exosite binding inhibitor of matrix metalloproteinase 13.
Osteoarthritis
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
Osteoarthritis
Cheminformatics-based drug design approach for identification of inhibitors targeting the characteristic residues of MMP-13 hemopexin domain.
Osteoarthritis
Chondrocyte-intrinsic Smad3 represses Runx2-inducible MMP-13 expression to maintain articular cartilage and prevent osteoarthritis.
Osteoarthritis
CircTMBIM6 promotes osteoarthritis-induced chondrocyte extracellular matrix degradation via miR-27a/MMP13 axis.
Osteoarthritis
Circ_0136474 and MMP-13 suppressed cell proliferation by competitive binding to miR-127-5p in osteoarthritis.
Osteoarthritis
Cirsium japonicum var. maackii and apigenin block Hif-2?-induced osteoarthritic cartilage destruction.
Osteoarthritis
Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis.
Osteoarthritis
Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: differential expression with collagenase-1 (matrix metalloproteinase-1).
Osteoarthritis
Cloning, sequencing and characterization of the 5'-flanking region of the human collagenase-3 gene.
Osteoarthritis
Colchicine protects against cartilage degeneration by inhibiting MMP13 expression via PLC-?1 phosphorylation.
Osteoarthritis
Collagenase 1 and collagenase 3 expression in a guinea pig model of osteoarthritis.
Osteoarthritis
Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ: in vitro mimicking effect by transforming growth factor beta.
Osteoarthritis
Considering Rotatability of Hydroxyl Groups for the Active Site Residues of MMP-13 in Retrospective Virtual Screening Campaigns.
Osteoarthritis
Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification.
Osteoarthritis
Curcumin and tetrahydrocurcumin both prevent osteoarthritis symptoms and decrease the expressions of pro-inflammatory cytokines in estrogen-deficient rats.
Osteoarthritis
Cytokine-induced interleukin-1 receptor antagonist protein expression in genetically engineered equine mesenchymal stem cells for osteoarthritis treatment.
Osteoarthritis
Cytokine-induced MMP13 Expression in Human Chondrocytes Is Dependent on Activating Transcription Factor 3 (ATF3) Regulation.
Osteoarthritis
Delay in articular cartilage degeneration of the knee joint by the conditional removal of discoidin domain receptor 2 in a spontaneous mouse model of osteoarthritis.
Osteoarthritis
Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.
Osteoarthritis
Development of a neutralizing antibody specific for the active form of matrix metalloproteinase-13.
Osteoarthritis
Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of Osteoarthritis.
Osteoarthritis
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.
Osteoarthritis
Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.
Osteoarthritis
Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
Osteoarthritis
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.
Osteoarthritis
Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.
Osteoarthritis
Discovery of Potent, Selective, and Orally Active Carboxylic Acid Based Inhibitors of Matrix Metalloproteinase-13 (dagger).
Osteoarthritis
Does low level laser therapy has effects on inflammatory biomarkers IL-1?, IL-6, TNF-?, and MMP-13 in osteoarthritis of rat models-a systemic review and meta-analysis.
Osteoarthritis
Downregulation of microRNA-9 increases matrix metalloproteinase-13 expression levels and facilitates osteoarthritis onset.
Osteoarthritis
Effect of estrogen on the expression of matrix metalloproteinase (MMP)-1, MMP-3, and MMP-13 and tissue inhibitor of metalloproternase-1 in osteoarthritis chondrocytes.
Osteoarthritis
Effect of inhibiting MMP13 and ADAMTS5 by intra-articular injection of small interfering RNA in a surgically induced osteoarthritis model of mice.
Osteoarthritis
Effective knock down of matrix metalloproteinase-13 by an intra-articular injection of small interfering RNA (siRNA) in a murine surgically-induced osteoarthritis model.
Osteoarthritis
Effects of an aqueous extract of Eucommia on articular cartilage in a rat model of osteoarthritis of the knee.
Osteoarthritis
Effects of celecoxib on human chondrocytes--enhanced production of chemokines.
Osteoarthritis
Effects of Controlling Abnormal Joint Movement on Expression of MMP13 and TIMP-1 in Osteoarthritis.
Osteoarthritis
Effects of platycodin D on IL-1?-induced inflammatory response in human osteoarthritis chondrocytes.
Osteoarthritis
Effects of ultrasound on estradiol level, bone mineral density, bone biomechanics and matrix metalloproteinase-13 expression in ovariectomized rabbits.
Osteoarthritis
Elf3 Contributes to Cartilage Degradation in vivo in a Surgical Model of Post-Traumatic Osteoarthritis.
Osteoarthritis
Endothelin-1 in osteoarthritic chondrocytes triggers nitric oxide production and upregulates collagenase production.
Osteoarthritis
Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention.
Osteoarthritis
Estrogen receptor alpha regulates matrix metalloproteinase-13 promoter activity primarily through the AP-1 transcriptional regulatory site.
Osteoarthritis
Evidence that estrogen receptor beta enhances MMP-13 promoter activity in HIG-82 cells and that this enhancement can be influenced by ligands and involves specific promoter sites.
Osteoarthritis
Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis.
Osteoarthritis
Expression of collagenases (matrix metalloproteinase-1, 8, 13) and tissue inhibitor of metalloproteinase-1 of retrodiscal tissue in temporomandibular joint disorder patients.
Osteoarthritis
Expression of MMP-13 in human temporomandibular joint disc derangement and osteoarthritis.
Osteoarthritis
Ferulic acid suppresses interleukin-1?-induced degeneration of chondrocytes isolated from patients with osteoarthritis through the SIRT1/AMPK/PGC-1? signaling pathway.
Osteoarthritis
Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug Targets.
Osteoarthritis
Ginsenoside Rb1 inhibits matrix metalloproteinase 13 through down-regulating Notch signaling pathway in osteoarthritis.
Osteoarthritis
Ginsenosides from Korean red ginseng inhibit matrix metalloproteinase-13 expression in articular chondrocytes and prevent cartilage degradation.
Osteoarthritis
Hedgehog signalling does not stimulate cartilage catabolism and is inhibited by Interleukin-1?.
Osteoarthritis
High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.
Osteoarthritis
Histamine stimulates matrix metalloproteinase-3 and -13 production by human articular chondrocytes in vitro.
Osteoarthritis
Histone Methylation and STAT-3 Differentially Regulate Interleukin-6-Induced Matrix Metalloproteinase Gene Activation in Rheumatoid Arthritis Synovial Fibroblasts.
Osteoarthritis
Human osteoarthritis cartilage-derived stromal cells activate joint degeneration through TGF-beta lateral signaling.
Osteoarthritis
Hyaluronic acid alkyl derivative: A novel inhibitor of metalloproteases and hyaluronidases.
Osteoarthritis
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
Osteoarthritis
Identification of opticin, a member of the small leucine-rich repeat proteoglycan family, in human articular tissues: a novel target for MMP-13 in osteoarthritis.
Osteoarthritis
Impairment of the collagenase-3 endocytotic receptor system in cells from patients with osteoarthritis.
Osteoarthritis
In silico study combining docking and QSAR methods on a series of matrix metalloproteinase 13 inhibitors.
Osteoarthritis
In Vivo Dual Fluorescence Imaging to Detect Joint Destruction.
Osteoarthritis
Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans and mice.
Osteoarthritis
Inflammatory markers associated with osteoarthritis after destabilization surgery in young mice with and without Receptor for Advanced Glycation End-products (RAGE).
Osteoarthritis
Inhibition of matrix metalloproteinase-13 expression in IL-1?-treated articular chondrocytes by a steroidal saponin, spicatoside A, and its cellular mechanisms of action.
Osteoarthritis
Interaction of HIF1? and ?-catenin inhibits matrix metalloproteinase 13 expression and prevents cartilage damage in mice.
Osteoarthritis
Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3.
Osteoarthritis
Intra-Articular Injection of (-)-Epigallocatechin 3-Gallate (EGCG) Ameliorates Cartilage Degeneration in Guinea Pigs with Spontaneous Osteoarthritis.
Osteoarthritis
Involvement of SOX-9 and FGF-23 in RUNX-2 regulation in osteoarthritic chondrocytes.
Osteoarthritis
Involvement of SOX9 and FGF23 in RUNX2 regulation in osteoarthritic chondrocytes.
Osteoarthritis
In vivo imaging of MMP-13 activity in the murine destabilised medial meniscus surgical model of osteoarthritis.
Osteoarthritis
LncRNA FAS-AS1 promotes the degradation of extracellular matrix of cartilage in osteoarthritis.
Osteoarthritis
LncRNA TUG1 promotes osteoarthritis-induced degradation of chondrocyte extracellular matrix via miR-195/MMP-13 axis.
Osteoarthritis
Low-Intensity Pulsed Ultrasound Treatment at an Early Osteoarthritis Stage Protects Rabbit Cartilage From Damage via the Integrin/Focal Adhesion Kinase/Mitogen-Activated Protein Kinase Signaling Pathway.
Osteoarthritis
Maresin-1 suppresses IL-1?-induced MMP-13 secretion by activating the PI3K/AKT pathway and inhibiting the NF-?B pathway in synovioblasts of an osteoarthritis rat model with treadmill exercise.
Osteoarthritis
Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium.
Osteoarthritis
Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development.
Osteoarthritis
Matrix metalloproteinase-13 expression in IL-1?-treated chondrocytes by activation of the p38 MAPK/c-Fos/AP-1 and JAK/STAT pathways.
Osteoarthritis
Matrix metalloproteinase-13 influences ERK signalling in articular rabbit chondrocytes.
Osteoarthritis
Matrix metalloproteinase-13 is fully activated by neutrophil elastase and inactivates its serpin inhibitor, alpha-1 antitrypsin: Implications for osteoarthritis.
Osteoarthritis
Mechanical impact induces cartilage degradation via mitogen activated protein kinases.
Osteoarthritis
Mechanism of basic calcium phosphate crystal-stimulated matrix metalloproteinase-13 expression by osteoarthritic synovial fibroblasts: inhibition by prostaglandin E2.
Osteoarthritis
Metabolic reprogramming in chondrocytes to promote mitochondrial respiration reduces downstream features of osteoarthritis.
Osteoarthritis
Metabolic Syndrome Predisposes to Osteoarthritis: Lessons from Model System.
Osteoarthritis
MicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesis.
Osteoarthritis
MicroRNA-27b regulates the expression of MMP-13 in human osteoarthritis chondrocytes.
Osteoarthritis
MicroRNA-381 Regulates Chondrocyte Hypertrophy by Inhibiting Histone Deacetylase 4 Expression.
Osteoarthritis
miR-195 contributes to human osteoarthritis via targeting PTHrP.
Osteoarthritis
MK801 regulates the expression of key osteoarthritis factors in osteoarthritis synovial fibroblasts through complement C5.
Osteoarthritis
MKK3/6-p38 MAPK negatively regulates murine MMP-13 gene expression induced by IL-1beta and TNF-alpha in immortalized periodontal ligament fibroblasts.
Osteoarthritis
MMP-13 enzyme and pH responsive theranostic nanoplatform for osteoarthritis.
Osteoarthritis
MMP13 and TIMP1 are functional markers for two different potential modes of action by mesenchymal stem/stromal cells when treating osteoarthritis.
Osteoarthritis
MMP13 is a critical target gene during the progression of osteoarthritis.
Osteoarthritis
Moderate joint loading reduces degenerative actions of matrix metalloproteinases in the articular cartilage of mouse ulnae.
Osteoarthritis
Molecular changes indicative of cartilage degeneration and osteoarthritis development in patients with anterior cruciate ligament injury.
Osteoarthritis
Molecular modelling studies of quinazolinone derivatives as MMP-13 inhibitors by QSAR, molecular docking and molecular dynamics simulations techniques.
Osteoarthritis
N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.
Osteoarthritis
New Hope for the Treatment of Osteoarthritis Through Selective Inhibition of MMP-13.
Osteoarthritis
New insights on the MMP-13 regulatory network in the pathogenesis of early osteoarthritis.
Osteoarthritis
NF-?B Phosphorylation Inhibition Prevents Articular Cartilage Degradation in Osteoarthritis Rats via 2-Aminoquinoline.
Osteoarthritis
Non-Zinc-Binding Inhibitors of MMP-13: GRID-Based Approaches to Rationalize the Binding Process.
Osteoarthritis
Notch Signaling Regulates MMP-13 Expression via Runx2 in Chondrocytes.
Osteoarthritis
Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants.
Osteoarthritis
Optimization of matrix metalloproteinase fluorogenic probes for osteoarthritis imaging.
Osteoarthritis
Oral administration of N-acetyl cysteine prevents osteoarthritis development and progression in a rat model.
Osteoarthritis
Osteoarthritic lesions: involvement of three different collagenases.
Osteoarthritis
Osteoarthritis patients with high haemoglobin A1c have increased Toll-like receptor 4 and matrix metalloprotease-13 expression in the synovium.
Osteoarthritis
Osteoarthritis treatment with a novel nutraceutical acetylated ligstroside aglycone, a chemically modified extra-virgin olive oil polyphenol.
Osteoarthritis
Osteoarthritis-like changes in the heterozygous sedc mouse associated with the HtrA1-Ddr2-Mmp-13 degradative pathway: a new model of osteoarthritis.
Osteoarthritis
Osteoblasts derived from osteophytes produce interleukin-6, interleukin-8, and matrix metalloproteinase-13 in osteoarthritis.
Osteoarthritis
Osthole ameliorates cartilage degradation by downregulation of NF-?B and HIF-2? pathways in an osteoarthritis murine model.
Osteoarthritis
Overview of MMP-13 as a Promising Target for the Treatment of Osteoarthritis.
Osteoarthritis
Oxidative stress-induced apoptosis and matrix loss of chondrocytes is inhibited by eicosapentaenoic acid.
Osteoarthritis
Phenyl N-tert-butylnitrone down-regulates interleukin-1 beta-stimulated matrix metalloproteinase-13 gene expression in human chondrocytes: suppression of c-Jun NH2-terminal kinase, p38-mitogen-activated protein kinase and activating protein-1.
Osteoarthritis
Phosphorylation of osteopontin in osteoarthritis degenerative cartilage and its effect on matrix metalloprotease 13.
Osteoarthritis
Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs.
Osteoarthritis
Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice.
Osteoarthritis
Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
Osteoarthritis
Potent inhibitors precise to S1' loop of MMP-13, a crucial target for osteoarthritis.
Osteoarthritis
Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
Osteoarthritis
Proline-Serine-Threonine Phosphatase-Interacting Protein 2 Alleviates Diabetes Mellitus-Osteoarthritis in Rats through Attenuating Synovial Inflammation and Cartilage Injury.
Osteoarthritis
Proprotein convertase furin inhibits matrix metalloproteinase 13 in a TGF?-dependent manner and limits osteoarthritis in mice.
Osteoarthritis
Prostaglandin EP2 receptor signalling inhibits the expression of matrix metalloproteinase 13 in human osteoarthritic chondrocytes.
Osteoarthritis
Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13.
Osteoarthritis
Protein expression of MMP-13, uPA, and PAI-1 in pseudocapsular and interface tissue around implants of loose artificial hip joints and in osteoarthritis.
Osteoarthritis
Proteolysis of the collagen fibril in osteoarthritis.
Osteoarthritis
Pyrrolidine dithiocarbamate, a NF-kappaB inhibitor, upregulates MMP-1 and MMP-13 in IL-1beta-stimulated rheumatoid arthritis fibroblast-like synoviocytes.
Osteoarthritis
Quercetin prevent proteoglycan destruction by inhibits matrix metalloproteinase-9, matrix metalloproteinase-13, a disintegrin and metalloproteinase with thrombospondin motifs-5 expressions on osteoarthritis model rats.
Osteoarthritis
Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
Osteoarthritis
Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents.
Osteoarthritis
Regulation of human chondrocyte function through direct inhibition of cartilage master regulator SOX9 by microRNA-145 (miRNA-145).
Osteoarthritis
Regulation of MMP-13 expression by RUNX2 and FGF2 in osteoarthritic cartilage.
Osteoarthritis
Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes.
Osteoarthritis
Rice Porridge Containing Welsh Onion Root Water Extract Alleviates Osteoarthritis-Related Pain Behaviors, Glucose Levels, and Bone Metabolism in Osteoarthritis-Induced Ovariectomized Rats.
Osteoarthritis
Roles of inflammatory and anabolic cytokines in cartilage metabolism: signals and multiple effectors converge upon MMP-13 regulation in osteoarthritis.
Osteoarthritis
Salubrinal reduces expression and activity of MMP13 in chondrocytes.
Osteoarthritis
Salvia miltiorrhiza-asarum ointment combined with Chinese medical massage alleviates symptoms of osteoarthritis in a rat model through the Notch1/ matrix metalloproteinase-13 signaling pathway.
Osteoarthritis
Selective MMP-13 inhibitors: promising agents for the therapy of Osteoarthritis.
Osteoarthritis
Serum and knee synovial fluid matrix metalloproteinase-13 and tumor necrosis factor-alpha levels in patients with late-stage osteoarthritis.
Osteoarthritis
Serum and knee synovial fluid matrixmetalloproteinase-13 and tumor necrosis factor-alpha levels in patients with late stage osteoarthritis.
Osteoarthritis
Single vs. repeated matrix metalloproteinase-13 knockdown with intra-articular short interfering RNA administration in a murine osteoarthritis model.
Osteoarthritis
Suppression of cartilage degeneration by intra-articular injection of heparan sulfate 6-O endosulfatase in a mouse osteoarthritis model.
Osteoarthritis
Targeted inhibition of ?-catenin by miR-320 and decreased MMP-13 expression in suppressing chondrocyte collagen degradation.
Osteoarthritis
The effect of different treatment time of millimeter wave on chondrocyte apoptosis, caspase-3, caspase-8, and MMP-13 expression in rabbit surgically induced model of knee osteoarthritis.
Osteoarthritis
The effects of amphiregulin induced MMP-13 production in human osteoarthritis synovial fibroblast.
Osteoarthritis
The Effects of Laser Moxibustion on Knee Osteoarthritis Pain in Rats.
Osteoarthritis
The effects of low-intensity pulsed ultrasound and nanomagnet applications on the expressions of MMP-13 and MAPKs in rabbit knee osteoarthritis.
Osteoarthritis
The Evaluation of the Effect of Herbal Extract on Osteoarthritis: In Vitro and In Vivo Study.
Osteoarthritis
The Influence of Wharton Jelly Mesenchymal Stem Cell toward Matrix Metalloproteinase-13 and RELA Synoviocyte Gene Expression on Osteoarthritis.
Osteoarthritis
The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K.
Osteoarthritis
The Involvement of Mutual Inhibition of ERK and mTOR in PLC?1-Mediated MMP-13 Expression in Human Osteoarthritis Chondrocytes.
Osteoarthritis
The morphology and histology study on rabbit degenerated medial meniscus after posterior cruciate ligament rupture.
Osteoarthritis
The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis.
Osteoarthritis
The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases.
Osteoarthritis
The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway.
Osteoarthritis
The relationship between abnormal Core binding factor-? expression in human cartilage and osteoarthritis.
Osteoarthritis
Top-Down Fabricated microPlates for Prolonged, Intra-articular Matrix Metalloproteinase 13 siRNA Nanocarrier Delivery to Reduce Post-traumatic Osteoarthritis.
Osteoarthritis
Transcriptional activation of human MMP-13 gene expression by c-Maf in osteoarthritic chondrocyte.
Osteoarthritis
Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors.
Osteoarthritis
Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development.
Osteoarthritis
Upregulated ank expression in osteoarthritis can promote both chondrocyte MMP-13 expression and calcification via chondrocyte extracellular PPi excess.
Osteoarthritis
Virtual screening on MMP-13 led to discovering new inhibitors including a non-zinc binding and a micro molar one: a successful example of receptor selection according to cross-docking results for a flexible enzyme.
Osteoarthritis
Yeast microcapsule-mediated oral delivery of IL-1? shRNA for post-traumatic osteoarthritis therapy.
Osteoarthritis
Zinc: the Other Suspected Environmental Factor in Kashin-Beck Disease in Addition to Selenium.
Osteoarthritis
[Biochemical analysis of the synovial fluid of the shoulder joint in patients with and without rotator cuff tears]
Osteoarthritis
[Changes of six serum biomarkers of rabbits with experimental osteoarthritis].
Osteoarthritis
[Effect of acupotomy lysis on serum matrix metalloproteinase (MMP)-3 and MMP-13 contents in osteoarthritis rabbits]
Osteoarthritis
[Effects of intra-articular injection of p38 mitogen-activated protein kinase inhibitor on matrix metalloproteinase in articular cartilage of a rat model of osteoarthritis]
Osteoarthritis
[Hydrogen sulfide in cartilage and its inhibitory effect on matrix metalloproteinase 13 expression in chondrocytes induced by interlukin-1?].
Osteoarthritis
[Protective effect of LR-90 on articular cartilage in rabbit model of osteoarthritis].
Osteoarthritis
[Regulating effects of transforming growth factor beta on gene expression of matrix metalloproteinase 13 mRNA in human hyaline chondrocytes]
Osteoarthritis
[Transplantation of adipose derived mesenchymal stem cells alleviated osteoarthritis induced with anterior cruciate ligament transection].
Osteoarthritis, Knee
Allogeneic adipose-derived stem cell transplantation on knee osteoarthritis rats and its effect on MMP-13 and DDR2.
Osteoarthritis, Knee
Association of IL-6, IL-8, MMP-13 gene polymorphisms with knee osteoarthritis susceptibility in the Chinese Han population.
Osteoarthritis, Knee
Associations between knee structural measures, circulating inflammatory factors and MMP13 in patients with knee osteoarthritis.
Osteoarthritis, Knee
Chondrocyte calcium-sensing receptor expression is up-regulated in early guinea pig knee osteoarthritis and modulates PTHrP, MMP-13, and TIMP-3 expression.
Osteoarthritis, Knee
Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis.
Osteoarthritis, Knee
Effect of low intensity pulsed ultrasound on expression of TIMP-2 in serum and expression of mmp-13 in articular cartilage of rabbits with knee osteoarthritis.
Osteoarthritis, Knee
Effect of Low-Intensity Pulsed Ultrasound on MMP-13 and MAPKs Signaling Pathway in Rabbit Knee Osteoarthritis.
Osteoarthritis, Knee
Lack of association between MMP13 (rs3819089), ADAM12 (rs3740199-rs1871054) and ADAMTS14 (rs4747096) genotypes and advanced-stage knee osteoarthritis.
Osteoarthritis, Knee
Linking chondrocyte and synovial transcriptional profile to clinical phenotype in osteoarthritis.
Osteoarthritis, Knee
Matrix metalloproteinase-13, NF-?B p65 and interleukin-1? are associated with the severity of knee osteoarthritis.
Osteoarthritis, Knee
Single vs. repeated matrix metalloproteinase-13 knockdown with intra-articular short interfering RNA administration in a murine osteoarthritis model.
Osteoarthritis, Knee
The effect of different treatment time of millimeter wave on chondrocyte apoptosis, caspase-3, caspase-8, and MMP-13 expression in rabbit surgically induced model of knee osteoarthritis.
Osteoarthritis, Knee
The effects of low-intensity pulsed ultrasound and nanomagnet applications on the expressions of MMP-13 and MAPKs in rabbit knee osteoarthritis.
Osteoarthritis, Knee
[Effects of Short Thrust Needing plus Electroacupuncture Intervention on Cartilage Tissue in Rabbits with Knee Osteoarthritis].
Osteoarthritis, Knee
[Roles of biochemical factors in lateral compartment wear from varus knee osteoarthritis].
Osteochondritis Dissecans
Osteochondritis Dissecans (OCD)-Derived Chondrocytes Display Increased Senescence, Oxidative Stress, Chaperone-Mediated Autophagy and, in Co-Culture with Adipose-Derived Stem Cells (ASCs), Enhanced Expression of MMP-13.
Osteochondrodysplasias
Expression of Genes Encoding Extracellular Matrix Macromolecules and Metalloproteinases in Avian Tibial Dyschondroplasia.
Osteochondrodysplasias
Osteoarthritis-like changes in the heterozygous sedc mouse associated with the HtrA1-Ddr2-Mmp-13 degradative pathway: a new model of osteoarthritis.
Osteolysis
Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival.
Osteolysis
Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
Osteolysis
MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-beta1.
Osteolysis
Non-bone metastatic cancers promote osteocyte-induced bone destruction.
Osteolysis
Osteocytes respond to particles of clinically-relevant conventional and cross-linked polyethylene and metal alloys by up-regulation of resorptive and inflammatory pathways.
Osteolysis
PAI-1, a target gene of miR-143, regulates invasion and metastasis by upregulating MMP-13 expression of human osteosarcoma.
Osteolysis
Possible role of matrix metalloproteinases (MMPs) in hyperostosis of intracranial meningiomas.
Osteolysis
Upregulated osterix promotes invasion and bone metastasis and predicts for a poor prognosis in breast cancer.
Osteomyelitis
The N125S polymorphism in the cathepsin G gene (rs45567233) is associated with susceptibility to osteomyelitis in a Spanish population.
Osteophyte
Associations of serum citrate levels with knee structural changes and cartilage enzymes in patients with knee osteoarthritis.
Osteophyte
Contribution of runt-related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability.
Osteophyte
Deletion of JNK Enhances Senescence in Joint Tissues and Increases the Severity of Age-Related Osteoarthritis in Mice.
Osteophyte
Grape seed proanthocyanidin extract (GSPE) ameliorates monosodium iodoacetate-induced osteoarthritis.
Osteophyte
Insulin-Like Growth Factor II (IGF-II) Inhibits IL-1?-Induced Cartilage Matrix Loss and Promotes Cartilage Integrity in Experimental Osteoarthritis.
Osteophyte
Molecular changes in Articular Cartilage and Subchondral Bone in the Rat Anterior Cruciate Ligament Transection and Meniscectomized Models of Osteoarthritis.
Osteophyte
Osteoblasts derived from osteophytes produce interleukin-6, interleukin-8, and matrix metalloproteinase-13 in osteoarthritis.
Osteophyte
Role of the C-C chemokine receptor-2 in a murine model of injury-induced osteoarthritis.
Osteophyte
Suppression of murine osteoarthritis by 4-methylumbelliferone.
Osteophyte
Top-Down Fabricated microPlates for Prolonged, Intra-articular Matrix Metalloproteinase 13 siRNA Nanocarrier Delivery to Reduce Post-traumatic Osteoarthritis.
Osteoporosis
Dynamic expression of matrix metalloproteinases 2, 9 and 13 in ovariectomy-induced osteoporosis rats.
Osteoporosis
Effects of dioxin and estrogen on collagenase-3 in UMR 106-01 osteosarcoma cells.
Osteoporosis
Estrogen receptor alpha regulates matrix metalloproteinase-13 promoter activity primarily through the AP-1 transcriptional regulatory site.
Osteoporosis
[Electroacupuncture Intervention Improves Cartilage Degeneration and Subchondral Bone Osteoporosis of Knee-joint Possibly by Adjusting OPG/RANK/RANKL Signaling in Ovariectomized Rats].
Osteosarcoma
AP-1 and Cbfa/runt physically interact and regulate parathyroid hormone-dependent MMP13 expression in osteoblasts through a new osteoblast-specific element 2/AP-1 composite element.
Osteosarcoma
Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling.
Osteosarcoma
Collagenase-3 binds to a specific receptor and requires the low density lipoprotein receptor-related protein for internalization.
Osteosarcoma
Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-mediated epithelial-mesenchymal transition.
Osteosarcoma
Dissection of Wnt5a-Ror2 signaling leading to matrix metalloproteinase (MMP-13) expression.
Osteosarcoma
Effects of dioxin and estrogen on collagenase-3 in UMR 106-01 osteosarcoma cells.
Osteosarcoma
Expression of collagenase-3 (MMP-13) in c-fos-induced osteosarcomas and chondrosarcomas is restricted to a subset of cells of the osteo-/chondrogenic lineage.
Osteosarcoma
Expression of Tmem41b and MMP13 associated with poor outcome in osteosarcomas.
Osteosarcoma
Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones.
Osteosarcoma
Interleukin-32 stimulates osteosarcoma cell invasion and motility via AKT pathway-mediated MMP-13 expression.
Osteosarcoma
MicroRNA-143 Regulates Human Osteosarcoma Metastasis by Regulating Matrix Metalloprotease-13 Expression.
Osteosarcoma
MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression.
Osteosarcoma
PAI-1, a target gene of miR-143, regulates invasion and metastasis by upregulating MMP-13 expression of human osteosarcoma.
Osteosarcoma
Parathyroid hormone regulation of the rat collagenase-3 promoter by protein kinase A-dependent transactivation of core binding factor alpha1.
Osteosarcoma
Propofol inhibits proliferation and invasion of osteosarcoma cells by regulation of microRNA-143 expression.
Osteosarcoma
Protective effects of acetaminophen on Ibuprofen-induced gastric mucosal damage in rats with associated suppression of matrix metalloproteinase.
Osteosarcoma
Regulation of the collagenase-3 receptor and its role in intracellular ligand processing in rat osteoblastic cells.
Osteosarcoma
Shikonin inhibits invasiveness of osteosarcoma through MMP13 suppression.
Osteosarcoma
TIPE2 Mediates the Suppressive Effects of Shikonin on MMP13 in Osteosarcoma Cells.
Osteosarcoma
Triclosan Blocks Mmp 13 Expression in Hormone-Stimulated Osteoblasts.
Ovarian Neoplasms
Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients.
Ovarian Neoplasms
ETS-1 regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell SKOV-3.
Ovarian Neoplasms
Hypoxia-Inducible Factor-1? (HIF-1?) Promotes Hypoxia-Induced Invasion and Metastasis in Ovarian Cancer by Targeting Matrix Metallopeptidase 13 (MMP13).
Ovarian Neoplasms
The prognostic values of matrix metalloproteinases in ovarian cancer.
Ovarian Neoplasms
[Association of functional polymorphisms on MMP-12 and MMP-13 gene promoter region with epithelial ovarian carcinoma.]
Overweight
Obesity affects the chondrocyte responsiveness to leptin in patients with osteoarthritis.
Pancreatic Neoplasms
Leptin signaling enhances cell invasion and promotes the metastasis of human pancreatic cancer via increasing MMP-13 production.
Pancreatic Neoplasms
The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.
Parkinson Disease
MMP13 Expression Is Increased Following Mutant ?-Synuclein Exposure and Promotes Inflammatory Responses in Microglia.
Patellar Dislocation
Changes in cartilage and subchondral bone in a growing rabbit experimental model of developmental trochlear dysplasia of the knee.
Pemphigoid, Bullous
Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid.
Peri-Implantitis
Histochemical and immunohistochemical evaluation of gingival collagen and metalloproteinases in peri-implantitis.
Peri-Implantitis
MMP13, TIMP2 and TGFB3 Gene Polymorphisms in Brazilian Chronic Periodontitis and Periimplantitis Subjects.
Periapical Granuloma
Collagenase-3 (MMP-13) is expressed in periapical lesions: an immunohistochemical study.
Periapical Granuloma
Collagenase-3 expression in periapical lesions: an immunohistochemical study.
Periapical Granuloma
Expression of matrix metalloproteinase-8 and matrix metalloproteinase-13 in mast cells of human periapical lesions.
Periapical Periodontitis
Expression of matrix metalloproteinase-8 and matrix metalloproteinase-13 in mast cells of human periapical lesions.
Periapical Periodontitis
Sirtuin 1 regulates matrix metalloproteinase-13 expression induced by Porphyromonas endodontalis lipopolysaccharide via targeting nuclear factor-?B in osteoblasts.
Periodontal Diseases
Differential regulation of MMP-13 expression in two models of experimentally induced periodontal disease in rats.
Periodontal Diseases
Fusobacterium nucleatum increases collagenase 3 production and migration of epithelial cells.
Periodontal Diseases
Gingival crevicular fluid matrix metalloproteinase-13 levels and molecular forms in various types of periodontal diseases.
Periodontal Diseases
Matrix metalloproteinase-13 is highly expressed in destructive periodontal disease activity.
Periodontal Diseases
MKK3/6-p38 MAPK negatively regulates murine MMP-13 gene expression induced by IL-1beta and TNF-alpha in immortalized periodontal ligament fibroblasts.
Periodontal Diseases
Silencing matrix metalloproteinase-13 (Mmp-13) reduces inflammatory bone resorption associated with LPS-induced periodontal disease in vivo.
Periodontal Diseases
Triclosan Blocks Mmp 13 Expression in Hormone-Stimulated Osteoblasts.
Periodontal Diseases
[The significance of the expression of matrix metalloproteinases in the differential diagnosis of periodontal diseases].
Periodontal Pocket
Periodontal and endodontic infectious/inflammatory profile in primary periodontal lesions with secondary endodontic involvement after a calcium hydroxide-based intracanal medication.
Periodontitis
Association of Common Variants in MMPs with Periodontitis Risk.
Periodontitis
Collagenase-2 (MMP-8) and collagenase-3 (MMP-13) in adult periodontitis: molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue.
Periodontitis
Effect of Subantimicrobial Dose Doxycycline Treatment on Gingival Crevicular Fluid Levels of MMP-9 and MMP-13 in Periodontitis Stage 2, Grade B in Subjects with Type 2 Diabetes Mellitus.
Periodontitis
Evaluation of collagenase-3 matrix metalloproteinase-13 gene-associated polymorphisms 11A/12A and -77A/G and its associated alleles with and without periodontitis.
Periodontitis
Expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in healthy and diseased human gingiva.
Periodontitis
Interleukin-1 Receptor Antagonist Has a Novel Function in the Regulation of Matrix Metalloproteinase-13 Expression.
Periodontitis
Matrix metalloproteinase-13 is highly expressed in destructive periodontal disease activity.
Periodontitis
MMP-13 and TIMP-1 determinations in progressive chronic periodontitis.
Periodontitis
Non-Surgical Periodontal Therapy Reduces Saliva Adipokines and Matrix Metalloproteinases Levels in Periodontitis.
Periodontitis
Prioritization of Candidate Genes for Periodontitis Using Multiple Computational Tools.
Periodontitis
Salivary MMP-13 gender differences in periodontitis: A cross-sectional study from Sweden.
Periodontitis
Silencing matrix metalloproteinase-13 (Mmp-13) reduces inflammatory bone resorption associated with LPS-induced periodontal disease in vivo.
Periodontitis
Temporal expression of metalloproteinase-8 and -13 and their relationships with extracellular matrix metalloproteinase inducer in the development of ligature-induced periodontitis in rats.
Periodontitis
[Effects of Bushenguchiwan on expression of matrix metalloproteinase-13 in rats' periodontium].
Periodontitis
[The significance of the expression of matrix metalloproteinases in the differential diagnosis of periodontal diseases].
Peripheral Nervous System Diseases
Paclitaxel-induced peripheral neuropathy is caused by epidermal ROS and mitochondrial damage through conserved MMP-13 activation.
Plasmacytoma
Expression and induction of collagenases (MMP-8 and -13) in plasma cells associated with bone-destructive lesions.
Pneumonia
Loss of matrix metalloproteinase-13 attenuates murine radiation-induced pulmonary fibrosis.
Pneumonia
Pathophysiological changes induced by Pseudomonas aeruginosa infection are involved in MMP-12 and MMP-13 upregulation in human carcinoma epithelial cells and a pneumonia mouse model.
Pneumonia
Type III Secretion System of Pseudomonas aeruginosa Affects Matrix Metalloproteinase 12 (MMP-12) and MMP-13 Expression via Nuclear Factor ?B Signaling in Human Carcinoma Epithelial Cells and a Pneumonia Mouse Model.
Pneumoperitoneum
Gas-related impact of pneumoperitoneum on systemic wound healing.
Pneumoperitoneum
Impact of pressure and gas type on anastomotic wound healing in rats.
Pneumoperitoneum
Improved abdominal wall wound healing by helium pneumoperitoneum.
Polyhydramnios
Amniotic fluid concentrations of collagenase-1 and collagenase-3 are increased in polyhydramnios.
Porcine Reproductive and Respiratory Syndrome
Matrix metalloproteinase-13 expression in response to double-stranded RNA in human chondrocytes.
Pre-Eclampsia
Altered Maternal Serum Matrix Metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in Severe Early- and Late-Onset Preeclampsia.
Pre-Eclampsia
Matrix metalloproteinase multiplex screening identifies increased MMP-2 urine concentrations in women predicted to develop preeclampsia.
Premature Birth
Replens Prevents Preterm Birth by Decreasing Type I Interferon Strengthening the Cervical Epithelial Barrier.
Prostatic Hyperplasia
Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer.
Prostatic Intraepithelial Neoplasia
Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer.
Prostatic Neoplasms
Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines.
Prostatic Neoplasms
Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer.
Prostatic Neoplasms
Collagenase-3 expression by tumor cells and gelatinase B expression by stromal fibroblast-like cells are associated with biochemical recurrence after radical prostatectomy in patients with prostate cancer.
Prostatic Neoplasms
CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion.
Prostatic Neoplasms
Expression and functional role of CCR9 in prostate cancer cell migration and invasion.
Prostatic Neoplasms
Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression.
Prostatic Neoplasms
MicroRNA-143 inhibits cell migration and invasion by targeting matrix metalloproteinase 13 in prostate cancer.
Prostatic Neoplasms
Pituitary tumor-transforming gene 1 regulates invasion of prostate cancer cells through MMP13.
Prostatic Neoplasms
Plasma levels of E-cadherin and MMP-13 in prostate cancer patients: correlation with PSA, testosterone and pathological parameters.
Prostatic Neoplasms
Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer.
Prostatic Neoplasms
Small leucine zipper protein promotes the metastasis of castration-resistant prostate cancer through transcriptional regulation of matrix metalloproteinase-13.
Prostatic Neoplasms
The Transcription Factor SPDEF Suppresses Prostate Tumor Metastasis.
Pseudomonas Infections
Matrix Metalloproteinase-13 as a Target for Suppressing Corneal Ulceration Caused by Pseudomonas aeruginosa Infection.
Pseudomonas Infections
Pathophysiological changes induced by Pseudomonas aeruginosa infection are involved in MMP-12 and MMP-13 upregulation in human carcinoma epithelial cells and a pneumonia mouse model.
Psoriasis
Combination of retinoids and narrow-band ultraviolet B inhibits matrix metalloproteinase 13 expression in HaCaT keratinocytes and a mouse model of psoriasis.
Psoriasis
Differences in Osteoimmunological Biomarkers Predictive of Psoriatic Arthritis among a Large Italian Cohort of Psoriatic Patients.
Pterygium
Cyclosporine A Downregulates MMP-3 and MMP-13 Expression in Cultured Pterygium Fibroblasts.
Pterygium
Inhibition of Pterygium Fibroblast Migration and Outgrowth by Bevacizumab and Cyclosporine A Involves Down-Regulation of Matrix Metalloproteinases-3 and -13.
Pulmonary Disease, Chronic Obstructive
Evaluation of collagenase activity, matrix metalloproteinase-8, and matrix metalloproteinase-13 in horses with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Induction of the Matrix Metalloproteinase 13 Gene in Bronchial Epithelial Cells by Interferon and Identification of its Novel Functional Polymorphism.
Pulmonary Disease, Chronic Obstructive
Proteomic Analysis in Lung Tissue of Smokers and COPD Patients.
Pulmonary Disease, Chronic Obstructive
Targeting matrix metalloproteinase-13 in bronchial epithelial repair.
Pulmonary Disease, Chronic Obstructive
Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD.
Pulmonary Fibrosis
Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis.
Pulmonary Fibrosis
Delayed resolution of bleomycin-induced pulmonary fibrosis in absence of MMP13 (collagenase 3).
Pulmonary Fibrosis
Loss of matrix metalloproteinase-13 attenuates murine radiation-induced pulmonary fibrosis.
Pulmonary Fibrosis
Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina.
Radicular Cyst
Collagenase-3 (MMP-13) is expressed in periapical lesions: an immunohistochemical study.
Radicular Cyst
Collagenase-3 expression in periapical lesions: an immunohistochemical study.
Radicular Cyst
Expression of matrix metalloproteinase-8 and matrix metalloproteinase-13 in mast cells of human periapical lesions.
Radicular Cyst
High matrix metalloproteinase activity is a hallmark of periapical granulomas.
receptor protein-tyrosine kinase deficiency
Loss of Fgfr1 in chondrocytes inhibits osteoarthritis by promoting autophagic activity in temporomandibular joint.
Relative Energy Deficiency in Sport
Effect of type II diabetes-induced osteoarthritis on articular cartilage aging in rats: A study in vivo and in vitro.
Retinal Detachment
Retinal MMP-12, MMP-13, TIMP-1, and TIMP-2 Expression in Murine Experimental Retinal Detachment.
Retinoblastoma
HOXB5 promotes retinoblastoma cell migration and invasion via ERK1/2 pathway-mediated MMPs production.
Rickets
Rickets manifestations in a child with metaphyseal anadysplasia, report of a spontaneously resolving case.
Sacroiliitis
Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis.
Sarcoma, Kaposi
MiR99a modulates MMP7 and MMP13 to regulate invasiveness of Kaposi's sarcoma.
Sarcoma, Kaposi
[Let-7 miRNA silencing promotes Kaposi's sarcoma-associated herpesvirus lytic replication via activating mitogen-activated protein kinase kinase kinase kinase 4 and its downstream factors].
Sarcoma, Synovial
Novel p38 MAP kinase inhibitor R-130823 suppresses IL-6, IL-8 and MMP-13 production in spheroid culture of human synovial sarcoma cell line SW 982.
Schistosomiasis
Effective Amelioration of Liver Fibrosis Through Lentiviral Vector Carrying Toxoplasma gondii gra15II in Murine Model.
Scleroderma, Diffuse
Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis.
Scleroderma, Localized
Clinical significance of serum matrix metalloproteinase-13 levels in patients with localized scleroderma.
Scleroderma, Localized
Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis.
Scleroderma, Systemic
Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis.
Scleroderma, Systemic
Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis.
Sepsis
Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF.
Sepsis
Role of plasma matrix-metalloproteases (MMPs) and their polymorphisms (SNPs) in sepsis development and outcome in ICU patients.
Sepsis
TNF? cleavage beyond TACE/ADAM17: matrix metalloproteinase 13 is a potential therapeutic target in sepsis and colitis.
Severe Combined Immunodeficiency
Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of Metalloproteinase (MMP)-13.
Shoulder Dislocation
Factors Expressed in an Animal Model of Anteroinferior Glenohumeral Instability.
Silicosis
Expression and localization of TIMP-1, TIMP-2, MMP-13, MMP-2, and MMP-9 in early and advanced experimental lung silicosis.
Silicosis
Matrix metalloproteinases 2, 9, and 13, and tissue inhibitors of metalloproteinases 1 and 2 in experimental lung silicosis.
Skin Neoplasms
Expression of Matrix Metalloproteinase-13 and Ki-67 in Nonmelanoma Skin Cancer in Xeroderma Pigmentosum and Non-xeroderma Pigmentosum.
Skin Ulcer
Collagenase-3 (MMP-13) enhances remodeling of three-dimensional collagen and promotes survival of human skin fibroblasts.
Spinal Stenosis
The increased expression of matrix metalloproteinases associated with elastin degradation and fibrosis of the ligamentum flavum in patients with lumbar spinal stenosis.
Spondylosis
[Effects of Chiropractics on Intervertebral Disk Extracell Matrix and Metabolic Enzymes in Rats with Cervical Spondylosis].
Squamous Cell Carcinoma of Head and Neck
Alpha v beta 6 integrin down-regulates the MMP-13 expression in oral squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Association of polymorphisms in IL-8, MMP-1 and MMP-13 with the risk and prognosis of oral and oropharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Correlation Between the Expression of Matrix Metalloproteinase-9, Matrix Metalloproteinase-13, Tissue Inhibitor of Metalloproteinases-1, p16 and Differentiation of Head and Neck Squamous Cell Carcinoma: A Prospective Observational Study.
Squamous Cell Carcinoma of Head and Neck
CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway.
Squamous Cell Carcinoma of Head and Neck
Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness.
Squamous Cell Carcinoma of Head and Neck
Evaluation of Collagen in Leukoplakia, Oral Submucous Fibrosis and Oral Squamous Cell Carcinomas Using Polarizing Microscopy and Immunohistochemistry
Squamous Cell Carcinoma of Head and Neck
Identification and analysis of genes associated with head and neck squamous cell carcinoma by integrated bioinformatics methods.
Squamous Cell Carcinoma of Head and Neck
Increase of MMP-13 expression in multi-stage oral carcinogenesis and epigallocatechin-3-gallate suppress MMP-13 expression.
Squamous Cell Carcinoma of Head and Neck
Overexpression of MMP13 is associated with clinical outcomes and poor prognosis in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Prognostic value of matrix metalloproteinases in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Squamous Cell Carcinoma of Head and Neck
Role of matrix metalloproteinase 13 gene expression in the evaluation of radiation response in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Serum and saliva collagenase-3 (MMP-13) in patients with oral lichen planus and oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
The usefulness of new serum tumor markers in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
[Collagenase 3 mRNA expression in squamous epithelial carcinomas of the oropharynx]
Stomach Neoplasms
Correlation of COX-2 and MMP-13 expressions with gastric cancer and their effects on prognosis.
Stomach Neoplasms
Expression analysis of matrix metalloproteinase-13 in human gastric cancer in the presence of Helicobacter Pylori infection.
Stomach Neoplasms
Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer.
Stomach Neoplasms
Inhibition of epidermal growth factor receptor signaling prohibits metastasis of gastric cancer via downregulation of MMP7 and MMP13.
Stomach Neoplasms
Interleukin-11 induces the expression of matrix metalloproteinase 13 in gastric cancer SCH cells partly via the PI3K-AKT and JAK-STAT3 pathways.
Stomach Neoplasms
SIRT1 inhibits gastric cancer proliferation and metastasis via STAT3/MMP-13 signaling.
Stomach Neoplasms
[Expression and clinical significance of collagenase-3 (MMP-13) in gastric cancer]
Stomach Neoplasms
[Retraction] Interleukin-11 induces the expression of matrix metalloproteinase 13 in gastric cancer SCH cells partly via the PI3K-AKT and JAK-STAT3 pathways.
Stomach Ulcer
Spatial and temporal pattern of expression of interstitial collagenase, stromelysin/transin, gelatinase A, and TIMP-1 during experimental gastric ulcer healing.
Stroke
A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke.
Stroke
Cleavage by MMP-13 renders VWF unable to bind to collagen but increases its platelet reactivity.
Stroke
Matrix metalloproteinase-13 is activated and is found in the nucleus of neural cells after cerebral ischemia.
Stroke
Matrix metalloproteinase-13 participates in neuroprotection and neurorepair after cerebral ischemia in mice.
Stroke
Plasma Matrix Metalloproteinases in Patients With Stroke During Intensive Rehabilitation Therapy.
Sunburn
Noninvasive Assessment of UV-induced Skin Damage: Comparison of Optical Measurements to Histology and MMP Expression.
Synovitis
Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators.
Synovitis
Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis.
Synovitis
Baicalin Inhibits Inflammatory Responses to Interleukin-1? Stimulation in Human Chondrocytes.
Synovitis
Curcumin slows osteoarthritis progression and relieves osteoarthritis-associated pain symptoms in a post-traumatic osteoarthritis mouse model.
Synovitis
Elevated expression of ICAM-1 in synovium is associated with early inflammatory response for cartilage degeneration in type 2 diabetes mellitus.
Synovitis
Interleukin-34 overexpression mediated through tumor necrosis factor-alpha reflects severity of synovitis in knee osteoarthritis.
Synovitis
The expression of collagenase 3 (MMP-13) mRNA in the synovial tissue is associated with histopathologic type II synovitis in rheumatoid arthritis.
Synovitis
Transcriptional Profiling of Synovium in a Porcine Model of Early Post-traumatic Osteoarthritis.
Synucleinopathies
MMP13 Expression Is Increased Following Mutant ?-Synuclein Exposure and Promotes Inflammatory Responses in Microglia.
t-plasminogen activator deficiency
Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity.
Temporomandibular Joint Disorders
Activation of ?-catenin signalling leads to temporomandibular joint defects.
Temporomandibular Joint Disorders
Expression of collagenases (matrix metalloproteinase-1, 8, 13) and tissue inhibitor of metalloproteinase-1 of retrodiscal tissue in temporomandibular joint disorder patients.
Tendinopathy
Active expression of matrix metalloproteinase-13 mRNA in the granulation tissue of equine superficial digital flexor tendinitis.
Tendinopathy
Enhanced tendon restoration effects of anti-inflammatory, lactoferrin-immobilized, heparin-polymeric nanoparticles in an Achilles tendinitis rat model.
Tendinopathy
Erratum: Posterior tibial tendinopathy associated with matrix metalloproteinase 13 promoter genotype and haplotype.
Tendinopathy
Posterior tibial tendinopathy associated with matrix metalloproteinase 13 promoter genotype and haplotype.
Tendinopathy
Rapamycin Treatment of Tendon Stem/Progenitor Cells Reduces Cellular Senescence by Upregulating Autophagy.
Tendinopathy
Tendon degeneration is not mediated by regulation of Toll-like receptors 2 and 4 in human tenocytes.
Tenosynovitis
Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis.
Thrombosis
Cleavage by MMP-13 renders VWF unable to bind to collagen but increases its platelet reactivity.
Thrombosis
Expression changes and roles of matrix metalloproteinases in a rat model of traumatic deep vein thrombosis.
Thrombosis
Matrix metalloproteinase-13 unlucky for the forming thrombus.
Thrombosis
MMP-13 binds to platelet receptors ?IIb?3 and GPVI and impairs aggregation and thrombus formation.
Thrombosis
Modified platelet deposition on matrix metalloproteinase 13 digested collagen I.
Thymoma
LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway.
Thyroid Cancer, Papillary
Expression of MMP-13 is associated with invasion and metastasis of papillary thyroid carcinoma.
Thyroid Carcinoma, Anaplastic
Integrated analysis of transcriptome data revealed MMP3 and MMP13 as critical genes in anaplastic thyroid cancer progression.
Thyroid Neoplasms
Relaxin enhances the collagenolytic activity and in vitro invasiveness by upregulating matrix metalloproteinases in human thyroid carcinoma cells.
Tuberculosis
Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis.
Tuberculosis, Spinal
miRNA-155 expression and role in pathogenesis in spinal tuberculosis-induced intervertebral disc destruction.
Ureteral Obstruction
Twist1 in Infiltrating Macrophages Attenuates Kidney Fibrosis via Matrix Metallopeptidase 13-Mediated Matrix Degradation.
Urinary Bladder Neoplasms
microRNA-125b inhibits cell migration and invasion by targeting matrix metallopeptidase 13 in bladder cancer.
Urinary Bladder Neoplasms
PLD1 promotes tumor invasion by regulation of MMP-13 expression via NF-?B signaling in bladder cancer.
Urinary Bladder Neoplasms
Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer.
Urinary Bladder Neoplasms
SENP2 regulates MMP13 expression in a bladder cancer cell line through SUMOylation of TBL1/TBLR1.
Urinary Bladder Neoplasms
Significance of collagenase 3 (matrix metalloproteinase 13) in invasive bladder cancer: correlation with pathological parameters.
Urinary Bladder Neoplasms
SUMO-Specific Protease 2 Suppresses Cell Migration and Invasion through Inhibiting the Expression of MMP13 in Bladder Cancer Cells.
Uterine Cervical Neoplasms
Down-expression of GOLM1 enhances the chemo-sensitivity of cervical cancer to methotrexate through modulation of the MMP13/EMT axis.
Uterine Cervical Neoplasms
Integrated analysis of HPV-mediated immune alterations in cervical cancer.
Vaccinia
Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas.
Varicose Ulcer
Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds.
Varicose Veins
Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target?
Varicose Veins
Metalloproteinase expression in venous aneurysms.
Varicose Veins
Varicose veins possess greater quantities of MMP-1 than normal veins and demonstrate regional variation in MMP-1 and MMP-13.
Vascular Diseases
RECK suppresses interleukin-17/TRAF3IP2-mediated MMP-13 activation and human aortic smooth muscle cell migration and proliferation.
Vascular System Injuries
Cleavage by MMP-13 renders VWF unable to bind to collagen but increases its platelet reactivity.
Vascular System Injuries
Role of the fibrinolytic and matrix metalloproteinase systems in arterial neointima formation after vascular injury.
Virus Diseases
Induction of the Matrix Metalloproteinase 13 Gene in Bronchial Epithelial Cells by Interferon and Identification of its Novel Functional Polymorphism.
Virus Diseases
Matrix Metalloproteinase-13 in Atherosclerotic Plaque Is Increased by Influenza A Virus Infection.
Virus Diseases
Targeting matrix metalloproteinase-13 in bronchial epithelial repair.
Vitamin D Deficiency
Vitamin D Inhibits Activities of Metalloproteinase-9/-13 in Articular Cartilage In Vivo and In Vitro.
Wiskott-Aldrich Syndrome
Differentially up-regulated genes in proliferating porcine neonatal pancreas cells caused by epidermal growth factor.
Xeroderma Pigmentosum
Expression of Matrix Metalloproteinase-13 and Ki-67 in Nonmelanoma Skin Cancer in Xeroderma Pigmentosum and Non-xeroderma Pigmentosum.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.1
(2Z,5E)-2-(1,2-benzothiazol-3-ylimino)-5-(2-methoxybenzylidene)-1,3-thiazolidin-4-one
Homo sapiens
IC50 above 0.1 mM, pH and temperature not specified in the publication
0.1
(2Z,5E)-2-(1,2-benzothiazol-3-ylimino)-5-(3-methoxybenzylidene)-1,3-thiazolidin-4-one
Homo sapiens
IC50 above 0.1 mM, pH and temperature not specified in the publication
0.000041
(E)-2-(4-(2-(biphenyl-4-yl)vinyl)-N-isopropoxyphenylsulfonamido)-N-hydroxyacetamide
Homo sapiens
pH not specified in the publication, 25°C
0.000003
(R)-2-(4'-(4-chlorobenzyloxy)-N-isopropoxybiphenyl-4-ylsulfonamido)-N-hydroxy-3-methylbutanamide
Homo sapiens
pH not specified in the publication, 25°C
0.000019
2-(4'-(4-chlorobenzyloxy)-N-isopropoxybiphenyl-4-ylsulfonamido)-N-hydroxyacetamide
Homo sapiens
pH not specified in the publication, 25°C
0.000015
2-(4'-butoxy-N-isopropoxybiphenyl-4-ylsulfonamido)-N-hydroxyacetamide
Homo sapiens
pH not specified in the publication, 25°C
0.00026
2-(5-((4-butylphenyl)ethynyl)-N-isopropoxythiophene-2-sulfonamido)-N-hydroxyacetamide
Homo sapiens
pH not specified in the publication, 25°C
0.000091
2-(5-(4-ethylphenyl)-N-isopropoxythiophene-2-sulfonamido)-N-hydroxyacetamide
Homo sapiens
pH not specified in the publication, 25°C
0.0006
2-(5-(4-fluorophenyl)-N-isopropoxythiophene-2-sulfonamido)-N-hydroxyacetamide
Homo sapiens
pH not specified in the publication, 25°C
0.000036
2-(benzo[d]isothiazol-3-ylimino)-5-(4-methoxybenzylidene)thiazolidin-4-one
Homo sapiens
pH and temperature not specified in the publication
0.0000000069
4-([(2-([(3-methoxyphenyl)methyl]carbamoyl)-4-oxo-3H,4H-thieno[2,3-d]pyrimidin-5-yl)methoxy]methyl)benzoic acid
Homo sapiens
pH 7.5, 37°C
0.000071
4-oxo-N-[[40-([[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]sulfonyl]methyl)biphenyl-3-yl]methyl]-3,4-dihydroquinazoline-2-carboxamide
Homo sapiens
pH 7.5, 37°C
0.0017
4-[([3-[(3-methoxybenzyl)carbamoyl]benzoyl]amino)methyl]benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00053
4-[([3-[2-(3-methoxybenzyl)-2H-tetrazol-5-yl]benzoyl]amino)methyl]benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00013
4-[([3-[2-(4-methoxybenzyl)-2H-tetrazol-5-yl]benzoyl]amino)methyl]benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0000000039
4-[2-([6-fluoro-2-[([[3-(methyloxy)phenyl]methyl]amino)-carbonyl]-4-oxo-3,4-dihydroquinazolin-5-yl]oxy)ethyl]-benzoic acid
Homo sapiens
pH 7.5, 37°C
0.00000067
4-[[1-methyl-2,4-dioxo-6-(3-phenylprop-1-yn-1-yl)-1,4-dihydroquinazolin-3(2H)-yl]methyl]benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000012
N-(3-methoxybenzyl)-4-oxo-3,4-dihydroquinazoline-2-carboxamide
Homo sapiens
pH 7.5, 37°C
0.0000072
N-hydroxy-2-(N-isopropoxy-4'-(methylthio)biphenyl-4-ylsulfonamido)acetamide
Homo sapiens
pH not specified in the publication, 25°C
0.00001
N-hydroxy-2-(N-isopropoxy-4'-methoxybiphenyl-4-ylsulfonamido)acetamide
Homo sapiens
pH not specified in the publication, 25°C
0.000063
N-hydroxy-2-(N-isopropoxy-4-phenoxyphenylsulfonamido)-acetamide
Homo sapiens
pH not specified in the publication, 25°C
0.000025
N-hydroxy-2-(N-isopropoxy-5-(4-methoxyphenyl)thiophene-2-sulfonamido)acetamide
Homo sapiens
pH not specified in the publication, 25°C
0.000096
N2,N5-bis(3-methylbenzyl)-6-oxo-1,6-dihydropyrimidine-2,5-dicarboxamide
Homo sapiens
pH 7.5, 22°C
0.000068
N2,N5-bis(4-fluoro-3-methylbenzyl)-6-oxo-1,6-dihydropyrimidine-2,5-dicarboxamide
Homo sapiens
pH 7.5, 22°C
0.000039
N2-(biphenyl-4-ylsulfonyl)-N-hydroxy-N2-(2-methylpropyl)glycinamide
Homo sapiens
pH not specified in the publication, 25°C
0.000045
N2-(biphenyl-4-ylsulfonyl)-N-hydroxy-N2-(propan-2-yloxy)glycinamide
Homo sapiens
pH not specified in the publication, 25°C
0.0000028
N2-(biphenyl-4-ylsulfonyl)-N-hydroxyglycinamide
Homo sapiens
pH not specified in the publication, 25°C
0.0000013
(2R)-N,3-dihydroxy-2-[(3-methylbutyl)(naphthalen-2-ylsulfonyl)amino]propanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000012
(2R)-N-hydroxy-2-[(3-methylbutyl)(naphthalen-2-ylsulfonyl)amino]-2-(tetrahydro-2H-pyran-4-yl)ethanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000033
(2R)-N-hydroxy-3-methyl-2-[(naphthalen-2-ylsulfonyl)amino]butanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000029
(2R)-N-hydroxy-3-methyl-2-[methyl(naphthalen-2-ylsulfonyl)amino]butanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000028
(2R)-N-hydroxy-4-(4-hydroxyphenyl)-2-[(3-methylbutyl)(naphthalen-2-ylsulfonyl)amino]butanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000003
(2R)-[1-(tert-butoxycarbonyl)piperidin-4-yl][([5-[4-(dimethylamino)phenyl]thiophen-2-yl]sulfonyl)amino]ethanoic acid
Homo sapiens
-
pH 7.5
0.00000095
(2R,3R)-4-[[4-(2-chloro-4-fluorophenoxy)phenyl]sulfonyl]-N,2-dihydroxy-2-methylmorpholine-3-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000003
(2S,3R)-1-acetyl-N-hydroxy-2-methyl-4-[[4-(2-methylbenzyl)phenyl]sulfonyl]piperidine-3-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000003
(4-[[([5-[2-(ethoxycarbonyl)-1H-indol-5-yl]-1-methyl-1H-pyrazol-3-yl]carbonyl)amino]methyl]phenyl)acetic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.000003
(4R)-1-[4-(4-fluorophenoxy)benzyl]-N-hydroxy-2-oxoimidazolidine-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000007
(4S)-4-[4-(4-fluorophenoxy)phenyl]-N-hydroxy-5-oxo-D-prolinamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000009
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-(1-cyclohexanecarbonyl-piperidin-4-yl)-acetic acid
Homo sapiens
-
pH 7.5
0.0000008
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-(1-iso-propylcarbamoyl-piperidin-4-yl)-acetic acid
Homo sapiens
-
pH 7.5
0.000008
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(2,2-dimethylpropionyl)-piperidin-4-yl]-acetic acid
Homo sapiens
-
pH 7.5
0.000049
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(2,2-dimethylpropyl)-piperidin-4-yl]-acetic acid
Homo sapiens
-
pH 7.5
0.0000055
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(2-methylpropane-1-sulfonyl)-piperidin-4-yl]-acetic acid
Homo sapiens
-
pH 7.5
0.0000036
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(3,3-dimethylbutyryl)-piperidin-4-yl]-acetic acid
Homo sapiens
-
pH 7.5
0.0000007
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(benzenesulfonyl)-piperidin-4-yl]-acetic acid
Homo sapiens
-
pH 7.5
0.0000127
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(methane-1-sulfonyl)-piperidin-4-yl]-acetic acid
Homo sapiens
-
pH 7.5
0.0000007
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(phenylmethanesulfonyl)-piperidin-4-yl]-acetic acid
Homo sapiens
-
pH 7.5
0.0000069
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(propane-1-sulfonyl)-piperidin-4-yl]-acetic acid
Homo sapiens
-
pH 7.5
0.000004
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(propane-2-sulfonyl)-piperidin-4-yl]-acetic acid
Homo sapiens
-
pH 7.5
0.0000017
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(tetrahydropyran-4-carbonyl)-piperidin-4-yl]-acetic acid
Homo sapiens
-
pH 7.5
0.0000076
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-benzylpiperidin-4-yl]-acetic acid
Homo sapiens
-
pH 7.5
0.000028
(R)-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-iso-butylpiperidin-4-yl]-acetic acid
Homo sapiens
-
pH 7.5
0.0000028
(R)-[5-(4'-methoxyphenyl)-thiophene-2-sulfonylamino]-(1-diethylcarbamoylpiperidin-4-yl)-acetic acid
Homo sapiens
-
pH 7.5
0.000016
(R)-[5-(4'-methoxyphenyl)-thiophene-2-sulfonylamino]-(1-iso-butyl-piperidin-4-yl)-acetic acid
Homo sapiens
-
pH 7.5
0.0000016
(R)-[5-(4'-methoxyphenyl)-thiophene-2-sulfonylamino]-(1-isopropylcarbamoyl-piperidin-4-yl)-acetic acid
Homo sapiens
-
pH 7.5
0.0000014
(R)-[5-(4'-methoxyphenyl)-thiophene-2-sulfonylamino]-(1-tertbutylcarbamoyl-piperidin-4-yl)-acetic acid
Homo sapiens
-
pH 7.5
0.0000012
(R)-[5-(4'-methoxyphenyl)-thiophene-2-sulfonylamino]-[1-(benzenesulfonyl)-piperidin-4-yl]-acetic acid
Homo sapiens
-
pH 7.5
0.0000014
(R)-[5-(4'-methoxyphenyl)-thiophene-2-sulfonylamino]-[1-(toluene-4-sulfonyl)-piperidin-4-yl]-acetic acid
Homo sapiens
-
pH 7.5
0.0000047
(R)-[5-(4-ethoxyphenyl)-thiophene-2-sulfonylamino]-[1-(butane-1-sulfonyl)-piperidin-4-yl]-acetic acid
Homo sapiens
-
pH 7.5
0.0000009
1,5-anhydro-2,3-dideoxy-3-[[4-(2,4-dichlorophenoxy)phenyl]sulfonyl]-4-C-(hydroxycarbamoyl)-D-threo-pentitol
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00000033
1-(4-phenoxyphenyl)-1,7,9-triazaspiro[4.5]decane-2,6,8,10-tetrone
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00000036
1-(6-[4-[4-(4-fluorophenyl)-1,3-oxazol-2-yl]phenoxy]pyridin-3-yl)-1,7,9-triazaspiro[4.5]decane-6,8,10-trione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000045
2-(ethyl[[4-(prop-1-yn-1-yloxy)phenyl]sulfonyl]amino)-5-phenylpentane(thioperox)ic O-acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.5
2-butanoyl-1H-indole-5-carboxamide
Homo sapiens
-
IC50 above 0.5 mM, in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.000027
2-chloro-N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]pyridine-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000003
2-chloro-N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]pyrimidine-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000122
2-fluoro-N-hydroxy-6-([4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]sulfonyl)benzamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000015
2-[benzyl[(4-methoxyphenyl)sulfonyl]amino]-N-hydroxy-3,5-dimethylbenzamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000000016
2-[[(4'-chlorobiphenyl-4-yl)oxy]methyl]-N-hydroxy-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000002
2-[[(4'-cyanobiphenyl-4-yl)oxy]methyl]-N-hydroxy-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000018
2-[[(4'-[[(5-bromo-4-methoxy-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]methyl]-3-methylbutanoic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00000008
2-[[[4-(4-chlorophenoxy)phenyl]sulfonyl](methyl)amino]-N-hydroxy-3-[(4-methylpiperazin-1-yl)methyl]benzamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000009
4-((R)-carboxy-[5-[4'-(2-methoxyethoxy)-phenyl]-thiophene-2-sulfonylamino]-methyl)-piperidine-1-carboxylic acid iso-propyl ester
Homo sapiens
-
pH 7.5
0.0000018
4-([4-[(5-[[4-(dimethylamino)phenyl]amino]-5-oxopentyl)oxy]phenyl]sulfonyl)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00000672
4-([6-[(4-methoxybenzyl)carbamoyl]-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl]methyl)benzoic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000003
4-([[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH 7.5
0.0000005 - 0.00000075
4-([[4-(4-fluorophenoxy)phenyl]sulfonyl]amino)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
0.0000082
4-[(4-[3-[(2,2-dimethylpentanoyl)amino]propoxy]phenyl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000008
4-[(4-[3-[(2,4-dimethylbenzoyl)amino]propoxy]phenyl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000082
4-[(4-[3-[(cyclohexylcarbonyl)amino]propoxy]phenyl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000009
4-[(4-[3-[4-(dimethylamino)phenyl]-3-oxopropoxy]phenyl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000008
4-[(4-[4-[4-(dimethylamino)benzoyl]piperidin-1-yl]phenyl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000002
4-[(4-[4-[4-(dimethylamino)phenyl]-4-oxobutoxy]phenyl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.001325
4-[(R)-(benzofuran-2-sulfonylamino)-carboxy-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.000145
4-[(R)-(benzo[b]thiophene-2-sulfonylamino)-carboxy-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.0000003
4-[(R)-carboxy-(4'-dimethylamino-biphenyl-4-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.0000005
4-[(R)-carboxy-(4'-ethoxybiphenyl-4-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.0000024
4-[(R)-carboxy-(4'-fluorobiphenyl-4-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.0000005
4-[(R)-carboxy-(4'-methoxybiphenyl-4-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.0000007
4-[(R)-carboxy-(4'-methylbiphenyl-4-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.0000068
4-[(R)-carboxy-(5-phenylthiophene-2-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.000018
4-[(R)-carboxy-(5-pyridin-2-yl-thiophene-2-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.00009
4-[(R)-carboxy-(5-pyridin-4-yl-thiophene-2-sulfonylamino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.009
4-[(R)-carboxy-[5-(3',4'-difluorophenyl)-furan-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.000197
4-[(R)-carboxy-[5-(3',4'-methylenedioxyphenyl)-furan-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.000575
4-[(R)-carboxy-[5-(3,4-dimethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.001058
4-[(R)-carboxy-[5-(3-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.0000004
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid 1-ethyl-propyl ester
Homo sapiens
-
pH 7.5
0.0000004
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid 4-tetrahydropyranyl ester
Homo sapiens
-
pH 7.5
0.0000008
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid butyl ester
Homo sapiens
-
pH 7.5
0.0000005
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid cyclohexyl ester
Homo sapiens
-
pH 7.5
0.000002
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid ethyl ester
Homo sapiens
-
pH 7.5
0.0000006
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-butyl ester
Homo sapiens
-
pH 7.5
0.0000005
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-propyl ester
Homo sapiens
-
pH 7.5
0.0000035
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid methyl ester
Homo sapiens
-
pH 7.5
0.0000009
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid neopentyl ester
Homo sapiens
-
pH 7.5
0.000001
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid propyl ester
Homo sapiens
-
pH 7.5
0.0000006
4-[(R)-carboxy-[5-(4'-ethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.0000033
4-[(R)-carboxy-[5-(4'-hydroxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-propyl ester
Homo sapiens
-
pH 7.5
0.000004
4-[(R)-carboxy-[5-(4'-iso-propoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-propyl ester
Homo sapiens
-
pH 7.5
0.0000006
4-[(R)-carboxy-[5-(4'-methoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-propyl ester
Homo sapiens
-
pH 7.5
0.0000013
4-[(R)-carboxy-[5-(4'-methylphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-propyl ester
Homo sapiens
-
pH 7.5
0.000011
4-[(R)-carboxy-[5-(4'-N,N-dimethylaminophenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid
Homo sapiens
-
pH 7.5
0.0000008
4-[(R)-carboxy-[5-(4'-n-propoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid
Homo sapiens
-
pH 7.5
0.0000013
4-[(R)-carboxy-[5-(4'-piperidin-1-yl-phenyl)-thiophene-2-sulfonylamino]-methyl]piperidine-1-carboxylic acid iso-propyl ester
Homo sapiens
-
pH 7.5
0.00000075
4-[(R)-carboxy-[5-(4'-piperidin-1-yl-phenyl)-thiophene-2-sulfonylamino]-methyl]piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.0000022
4-[(R)-carboxy-[5-(4'-trifluoromethoxyphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-propyl ester
Homo sapiens
-
pH 7.5
0.0000615
4-[(R)-carboxy-[5-(4'-trifluoromethylphenyl)-furan-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.0000039
4-[(R)-carboxy-[5-(4'-trifluoromethylphenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid iso-propyl ester
Homo sapiens
-
pH 7.5
0.0000121
4-[(R)-carboxy-[5-phenylthiophene-2-sulfonylamino]-methyl]piperidine-1-carboxylic acid iso-propyl ester
Homo sapiens
-
pH 7.5
0.026
4-[([[5-(1H-indol-5-yl)-1-methyl-1H-pyrazol-3-yl]carbonyl]amino)methyl]benzoic acid
Homo sapiens
-
IC50 above 0.026 mM; in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.00000036
4-[2-[4-(4-[[5-(2-ethoxyethyl)-2,4,6-trioxohexahydropyrimidin-5-yl]oxy]phenoxy)phenyl]-1,3-oxazol-4-yl]benzonitrile
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000019
4-[carboxy-[5-(4-N,N-dimethylaminophenyl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.00005
4-[carboxy-[5-(6-methoxy-pyridin-3-yl)-thiophene-2-sulfonylamino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
Homo sapiens
-
pH 7.5
0.000001
4-[[([5-[2-(ethoxycarbonyl)-1H-indol-5-yl]-1-methyl-1H-pyrazol-3-yl]carbonyl)amino]methyl]benzoic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.00025
4-[[([5-[2-(ethoxymethyl)-1H-indol-5-yl]-1-methyl-1H-pyrazol-3-yl]carbonyl)amino]methyl]benzoic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.00000067
4-[[1-methyl-2,4-dioxo-6-(3-phenylprop-1-yn-1-yl)-1,4-dihydroquinazolin-3(2H)-yl]methyl]benzoic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000016
4-[[4-(3-[[4-(dimethylamino)benzoyl]amino]propoxy)phenyl]sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000017
4-[[4-(4-[[4-(dimethylamino)phenyl]amino]-4-oxobutoxy)phenyl]sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000004
4-[[4-([5-[4-(dimethylamino)phenyl]-5-oxopentyl]oxy)phenyl]sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00000154
4-[[4-oxo-6-(3-phenylprop-1-yn-1-yl)quinazolin-3(4H)-yl]methyl]benzoic acid
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00001
5-(2-ethoxyethyl)-5-[4-[4-(1,3,4-oxadiazol-2-yl)phenoxy]phenoxy]pyrimidine-2,4,6(1H,3H,5H)-trione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00039
5-(4-chlorophenoxy)-5-methylpyrimidine-2,4,6(1H,3H,5H)-trione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00043
5-(4-chlorophenyl)-N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000245
5-(5-chloropyridin-2-yl)-N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000078
5-hexyl-5-(4-phenoxyphenoxy)pyrimidine-2,4,6(1H,3H,5H)-trione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000065
5-methyl-5-(4-phenoxyphenoxy)pyrimidine-2,4,6(1H,3H,5H)-trione
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.025
5-[3-[(4-carboxybenzyl)carbamoyl]-1-methyl-1H-pyrazol-5-yl]-1H-indole-2-carboxylic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.0033
5-[3-[(acetylamino)methyl]phenyl]-N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000006
5-[4-(1-benzofuran-2-ylmethoxy)phenyl]-N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00155
5-[4-(acetylamino)phenyl]-N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00003
benzyl 6-benzyl-5,7-dioxo-6,7-dihydro-5H-[1,3]thiazolo[3,2-c]pyrimidine-2-carboxylate
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000012
CGS027023
Homo sapiens
-
pH and temperature not specified in the publication
0.0000035
cipemastat
Homo sapiens
-
pH 7.5
0.0025
ethyl 5-(1-methyl-1H-imidazol-5-yl)-1H-indole-2-carboxylate
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.00012
ethyl 5-(1-methyl-3-[[(6-oxo-1,6-dihydropyridin-3-yl)methyl]carbamoyl]-1H-pyrazol-5-yl)-1H-indole-2-carboxylate
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.0096
ethyl 5-(3-methylpyridin-4-yl)-1H-indole-2-carboxylate
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.031
ethyl 5-(acetylamino)-1H-indole-2-carboxylate
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.5
ethyl 5-(pyridin-2-yl)-1H-indole-2-carboxylate
Homo sapiens
-
IC50 above 0.5 mM, in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.015
ethyl 5-(pyridin-3-yl)-1H-indole-2-carboxylate
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.082
ethyl 5-(pyridin-4-yl)-1H-indole-2-carboxylate
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.039
ethyl 5-carbamoyl-1H-indole-2-carboxylate
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.5
ethyl 5-phenyl-1H-indole-2-carboxylate
Homo sapiens
-
IC50 above 0.5 mM, in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.097
ethyl 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylate
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.00009
ethyl 5-[1-methyl-3-[(pyridin-4-ylmethyl)carbamoyl]-1H-pyrazol-5-yl]-1H-indole-2-carboxylate
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.0024
ethyl 5-[3-(methoxycarbonyl)-1-methyl-1H-pyrazol-5-yl]-1H-indole-2-carboxylate
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.00015
ethyl 5-[5-methyl-2-[(pyridin-4-ylmethyl)carbamoyl]pyridin-4-yl]-1H-indole-2-carboxylate
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.0000066 - 0.000008
N,N'-bis(pyridin-3-ylmethyl)pyrimidine-4,6-dicarboxamide
0.0000012 - 0.000002
N-(4-fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
0.0000013
N-([4'-[(1-benzofuran-2-ylcarbonyl)amino]biphenyl-4-yl]sulfonyl)valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000013
N-([4'-[([3-methyl-4-[(methylsulfonyl)amino]-1-benzofuran-2-yl]carbonyl)amino]biphenyl-4-yl]sulfonyl)-L-threonine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000013
N-([4'-[([3-methyl-4-[(methylsulfonyl)amino]-1-benzofuran-2-yl]carbonyl)amino]biphenyl-4-yl]sulfonyl)-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000025
N-([4'-[([4-[(1-methoxy-2-methyl-1-oxopropan-2-yl)oxy]-3-methyl-1-benzofuran-2-yl]carbonyl)amino]biphenyl-4-yl]sulfonyl)-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000149
N-([4'-[([4-[(2-carboxypropan-2-yl)oxy]-1-benzofuran-2-yl]carbonyl)amino]biphenyl-4-yl]sulfonyl)-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000047
N-hydroxy-2,6-dimethoxy-3-[[(4-methoxyphenyl)sulfonyl](pyridin-3-ylmethyl)amino]pyridine-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000008
N-hydroxy-2-[(2-methylpropyl)(naphthalen-2-ylsulfonyl)amino]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00018
N-hydroxy-2-[(naphthalen-2-ylsulfonyl)amino]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000008
N-hydroxy-2-[[(4-methoxyphenyl)sulfonyl](pyridin-3-ylmethyl)amino]-3-methylbenzamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000004
N-hydroxy-3-methyl-2-(methyl[[4-(pyridin-4-yloxy)phenyl]sulfonyl]amino)benzamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000034
N-hydroxy-3-methyl-N2-(3-methylbutyl)-N2-(naphthalen-2-ylsulfonyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000008
N-hydroxy-4-([4-[(4-hydroxybut-2-yn-1-yl)oxy]phenyl]sulfonyl)-2,2-dimethylthiomorpholine-3-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000009
N-hydroxy-4-([4-[4-(4-methoxyphenoxy)butoxy]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000012
N-hydroxy-4-([4-[4-oxo-4-(piperidin-1-yl)butoxy]phenyl]sulfonyl)tetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000016
N-hydroxy-4-[(4-[3-[(4-methoxybenzoyl)amino]propoxy]phenyl)sulfonyl]tetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000003
N-hydroxy-4-[(4-[4-[(4-methoxyphenyl)amino]-4-oxobutoxy]phenyl)sulfonyl]tetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00000066
N-hydroxy-4-[[4-(3-[[4-(trifluoromethoxy)benzoyl]amino]propoxy)phenyl]sulfonyl]tetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000002
N-hydroxy-4-[[4-(4-oxo-4-[[4-(trifluoromethoxy)phenyl]amino]butoxy)phenyl]sulfonyl]tetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000033
N-hydroxy-4-[[4-(4-[methyl[4-(trifluoromethoxy)phenyl]amino]-4-oxobutoxy)phenyl]sulfonyl]tetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000001
N-hydroxy-4-[[4-(phenylsulfanyl)phenyl]sulfonyl]-1-(prop-2-yn-1-yl)piperidine-4-carboxamide
Homo sapiens
-
IC50 below 1 nM, pH and temperature not specified in the publication
0.000007
N-hydroxy-N2-(2-methylpropyl)-N2-(naphthalen-2-ylsulfonyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000006
N-hydroxy-N2-(3-methylbutyl)-N2-(2,3,3a,7a-tetrahydro-1-benzofuran-5-ylsulfonyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000026
N-hydroxy-N2-(3-methylbutyl)-N2-(naphthalen-2-ylsulfonyl)-5-phenyl-D-norvalinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000006
N-hydroxy-N2-(3-methylbutyl)-N2-(naphthalen-2-ylsulfonyl)-D-leucinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000032
N-hydroxy-N2-(3-methylbutyl)-N2-(naphthalen-2-ylsulfonyl)-D-threoninamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000003
N-hydroxy-N2-(3-methylbutyl)-N2-(naphthalen-2-ylsulfonyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0001
N-hydroxy-N2-(3-methylbutyl)-N2-(quinolin-2-ylsulfonyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000361
N-hydroxy-N2-(3-methylbutyl)-N2-(quinolin-3-ylsulfonyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000012
N-hydroxy-N2-(3-methylbutyl)-N2-(quinolin-6-ylsulfonyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00001
N-hydroxy-N2-(3-methylbutyl)-N2-[(6-propoxynaphthalen-2-yl)sulfonyl]-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000013
N-hydroxy-N2-(3-methylbutyl)-N2-[[6-(2-methylpropoxy)naphthalen-2-yl]sulfonyl]-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000002
N-hydroxy-N2-(naphthalen-2-ylsulfonyl)-N2-(2-phenylethyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000024
N-hydroxy-N2-(naphthalen-2-ylsulfonyl)-N2-(3-phenylpropyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000022
N-hydroxy-N2-(naphthalen-2-ylsulfonyl)-N2-(pyridin-2-ylmethyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000015
N-hydroxy-N2-(naphthalen-2-ylsulfonyl)-N2-(pyridin-3-ylmethyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000007
N-hydroxy-N2-(naphthalen-2-ylsulfonyl)-N2-(pyridin-4-ylmethyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000004
N-hydroxy-N2-methyl-3-[(4-phenoxyphenyl)sulfonyl]-L-alaninamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000001
N-hydroxy-N2-[(6-hydroxynaphthalen-2-yl)sulfonyl]-N2-(3-methylbutyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000013
N-hydroxy-N2-[(6-methoxynaphthalen-2-yl)sulfonyl]-N2-(3-methylbutyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000242
N-hydroxy-N2-[(7-hydroxynaphthalen-2-yl)sulfonyl]-N2-(3-methylbutyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00048
N-hydroxy-N2-[(7-methoxynaphthalen-2-yl)sulfonyl]-N2-(3-methylbutyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000018
N-hydroxy-N2-[2-(morpholin-4-yl)ethyl]-N2-(naphthalen-2-ylsulfonyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000176
N-hydroxy-N2-[[6-(3-methylbutoxy)naphthalen-2-yl]sulfonyl]-N2-(3-methylbutyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000075
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-(3-[[(furan-2-ylcarbonyl)amino]methyl]phenyl)furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000032
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-(4-ethoxyphenyl)furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00022
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-(4-methoxyphenyl)furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00029
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-(4-methylphenyl)furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.05
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-(4-phenoxyphenyl)furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00033
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[3-([[(2-methylfuran-3-yl)carbonyl]amino]methyl)phenyl]furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000006
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-(1H-pyrazol-3-ylmethoxy)phenyl]furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.006
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-(methylcarbamoyl)phenyl]furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00048
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-(methylsulfamoyl)phenyl]furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000004
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-[(1,5-dimethyl-1H-pyrazol-3-yl)methoxy]phenyl]furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000025
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-[(1-methyl-1H-pyrazol-3-yl)methoxy]phenyl]furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000002
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-[(5-methyl-1H-pyrazol-3-yl)methoxy]phenyl]furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00004
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-[(6-methylpyridin-2-yl)methoxy]phenyl]furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00046
N-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-5-[4-[(methylsulfonyl)amino]phenyl]furan-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000048
N-[(4'-[[(3,4-dimethyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000019
N-[(4'-[[(3-methyl-4-phenoxy-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000015
N-[(4'-[[(3-methyl-4-phenyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000043
N-[(4'-[[(4-amino-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000037
N-[(4'-[[(4-cyano-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000061
N-[(4'-[[(4-ethenyl-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000074
N-[(4'-[[(4-ethoxy-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000023
N-[(4'-[[(4-ethyl-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000061
N-[(4'-[[(4-hydroxy-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000095
N-[(4'-[[(4-methoxy-3-methyl-1-benzofuran-2-yl)carbonyl]amino]biphenyl-4-yl)sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000035
N-[(4-[5-[([3-methyl-4-[(methylsulfonyl)amino]-1-benzofuran-2-yl]carbonyl)amino]pyridin-2-yl]phenyl)sulfonyl]-L-threonine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00004
N-[(4-[5-[([3-methyl-4-[(methylsulfonyl)amino]-1-benzofuran-2-yl]carbonyl)amino]pyridin-2-yl]phenyl)sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.22
N-[2-(4,5-dihydro-1,3-oxazol-2-yl)-1H-indol-5-yl]acetamide
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.000017
N-[2-(4-[benzyl[2-(hydroxycarbamoyl)-4,6-dimethylphenyl]sulfamoyl]phenoxy)ethyl]-1-benzofuran-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000072
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-1,5-dimethyl-1H-pyrazole-3-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00031
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-1-methyl-1H-imidazole-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000024
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-1-methyl-1H-pyrazole-3-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00014
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-1-methyl-1H-pyrazole-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000007
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-2-(trifluoromethyl)pyrimidine-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000008
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-2-methyl-1,3-thiazole-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00018
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-3-methylfuran-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0001
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-3-methylpyridine-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000029
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-5-ethylpyridine-3-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000011
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-5-methylfuran-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000009
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-6-(trifluoromethyl)pyridine-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000004
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-6-methylpyridine-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00014
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-7-methylimidazo[1,2-a]pyridine-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00011
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-8-methylimidazo[1,2-a]pyridine-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0001
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]imidazo[1,2-a]pyridine-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000008
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]pyridine-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000042
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]pyridine-3-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000031
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]pyridine-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00001
N-[3-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]pyrimidine-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000036
N-[3-(5-[[1-cyclopropyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-2-(trifluoromethyl)pyrimidine-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000028
N-[3-(5-[[1-cyclopropyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)benzyl]-6-(trifluoromethyl)pyridine-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000002
N-[3-(5-[[2-(methylamino)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl]carbamoyl]furan-2-yl)benzyl]-2-(trifluoromethyl)pyrimidine-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000002
N-[3-(5-[[2-(methylamino)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl]carbamoyl]furan-2-yl)benzyl]-6-(trifluoromethyl)pyridine-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000005
N-[3-(5-[[3-hydroxy-3-methyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl]furan-2-yl)benzyl]-2-(trifluoromethyl)pyrimidine-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000025
N-[3-(5-[[3-hydroxy-3-methyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl]furan-2-yl)benzyl]-6-(trifluoromethyl)pyridine-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000009
N-[3-(5-[[3-methyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl]furan-2-yl)benzyl]-2-(trifluoromethyl)pyrimidine-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000006
N-[3-(5-[[3-methyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl]furan-2-yl)benzyl]-6-(trifluoromethyl)pyridine-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00062
N-[4-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)phenyl]-1-benzofuran-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000031
N-[4-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)phenyl]-1-methyl-1H-pyrazole-3-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000063
N-[4-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)phenyl]-4,5-dimethylfuran-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000088
N-[4-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)phenyl]-5-methyl-1H-pyrazole-3-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000057
N-[4-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)phenyl]-5-methylfuran-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000017
N-[4-(5-[[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl]furan-2-yl)phenyl]-6-methylpyridine-2-carboxamide
Homo sapiens
-
above, pH not specified in the publication, temperature not specified in the publication
0.01
N-[4-(morpholin-4-yl)butyl]-1-benzofuran-2-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000008
N-[[4'-([[3-methyl-4-(methylamino)-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000032
N-[[4'-([[3-methyl-4-(morpholin-4-yl)-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000095
N-[[4'-([[3-methyl-4-(prop-1-yn-1-yl)-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000071
N-[[4'-([[4-(3-hydroxypropyl)-3-methyl-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000011
N-[[4'-([[4-(3-methoxypropyl)-3-methyl-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000025
N-[[4'-([[4-(acetylamino)-3-methyl-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000065
N-[[4'-([[4-(dimethylamino)-3-methyl-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000064
N-[[4'-([[4-(furan-2-yl)-3-methyl-1-benzofuran-2-yl]carbonyl]amino)biphenyl-4-yl]sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000009
N-[[4-(4-fluorophenoxy)phenyl]sulfonyl]-N-[1-(hydroxycarbamoyl)cyclopentyl]-b-alanine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000014
N-[[4-(5-[[(4-cyano-3-methyl-1-benzofuran-2-yl)carbonyl]amino]pyridin-2-yl)phenyl]sulfonyl]-L-valine
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00000005
N2-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-N-hydroxy-N2-(3-methylbutyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000018
N2-(3a,7a-dihydro-1-benzothiophen-5-ylsulfonyl)-N-hydroxy-N2-(3-methylbutyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000038
N2-benzyl-N-hydroxy-N2-(naphthalen-2-ylsulfonyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.5
N2-ethyl-1H-indole-2,5-dicarboxamide
Homo sapiens
-
IC50 above 0.5 mM, in 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% (v/v) Brij 35, and 1% (v/v) DMSO, at 28°C
0.000014
N2-[(2S)-2-[[(4-benzylbenzyl)(hydroxy)phosphoryl]methyl]-4-phenylbutanoyl]-N,3-dimethyl-L-valinamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000021
N2-[(2S)-2-[[(4-benzylbenzyl)(hydroxy)phosphoryl]methyl]-6-phenoxyhexanoyl]-N,3-dimethyl-L-valinamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.003892
N2-[(3,4-dimethoxyphenyl)sulfonyl]-N-hydroxy-N2-(3-methylbutyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000036
N2-[(6-ethoxynaphthalen-2-yl)sulfonyl]-N-hydroxy-N2-(3-methylbutyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000003
N2-[(6-ethylnaphthalen-2-yl)sulfonyl]-N-hydroxy-N2-(3-methylbutyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000603
N2-[(7-ethoxynaphthalen-2-yl)sulfonyl]-N-hydroxy-N2-(3-methylbutyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000032
N2-[2-(dimethylamino)ethyl]-N-hydroxy-N2-(naphthalen-2-ylsulfonyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000165
N2-[[6-(benzyloxy)naphthalen-2-yl]sulfonyl]-N-hydroxy-N2-(3-methylbutyl)-D-valinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0000022
O-tert-butyl-N-hydroxy-N2-(3-methylbutyl)-N2-(naphthalen-2-ylsulfonyl)-D-serinamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000001
SC-276
Homo sapiens
-
IC50 above 1 nM, pH and temperature not specified in the publication
0.0000005
4-([[4-(4-fluorophenoxy)phenyl]sulfonyl]amino)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.00000075
4-([[4-(4-fluorophenoxy)phenyl]sulfonyl]amino)-N-hydroxytetrahydro-2H-pyran-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000066
N,N'-bis(pyridin-3-ylmethyl)pyrimidine-4,6-dicarboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.000008
N,N'-bis(pyridin-3-ylmethyl)pyrimidine-4,6-dicarboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0000012
N-(4-fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, versus full-length bovine type II collagen
0.000002
N-(4-fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication, versus full-length bovine type II gelatin
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Heikkilae, P.; Teronen, O.; Moilanen, M.; Konttinen, Y.T.; Hanemaaijer, R.; Laitinen, M.; Maisi, P.; van der Pluijm, G.; Bartlett, J.D.; Salo, T.; Sorsa, T.
Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines
Anticancer Drugs
13
245-254
2002
Homo sapiens
brenda
Leeman, M.F.; Curran, S.; Murray, G.I.
The structure, regulation, and function of human matrix metalloproteinase-13
Crit. Rev. Biochem. Mol. Biol.
37
149-166
2002
Homo sapiens
brenda
Knaeuper, V.; Lopez-Otin, C.; Smith, B.; Knight, G.; Murphy, G.
Biochemical characterization of human collagenase-3
J. Biol. Chem.
271
1544-1550
1996
Homo sapiens
brenda
Knaeuper, V.; Cowell, S.; Smith, B.; Lopez-Otin, C.; O'Shea, M.; Morris, H.; Zardi, L.; Murphy, G.
The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction
J. Biol. Chem.
272
7608-7616
1997
Homo sapiens
brenda
Deng, S.J.; Bickett, D.M.; Mitchell, J.L.; Lambert, M.H.; Blackburn, R.K.; Carter, H.L., 3rd; Neugebauer, J.; Pahel, G.; Weiner, M.P.; Moss, M.L.
Substrate specificity of human collagenase 3 assessed using a phage-displayed peptide library
J. Biol. Chem.
275
31422-31427
2000
Homo sapiens
brenda
Gomis-Rueth, F.X.; Gohlke, U.; Betz, M.; Knauper, V.; Murphy, G.; Lopez-Otin, C.; Bode, W.
The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexin-like domain
J. Mol. Biol.
264
556-566
1996
Homo sapiens (P45452), Homo sapiens
brenda
Zhang, X.; Gonnella, N.C.; Koehn, J.; Pathak, N.; Ganu, V.; Melton, R.; Parker, D.; Hu, S.I.; Nam, K.Y.
Solution structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent non-peptidic sulfonamide inhibitor: binding comparison with stromelysin-1 and collagenase-1
J. Mol. Biol.
301
513-524
2000
Homo sapiens (P45452), Homo sapiens
brenda
Moy, F.J.; Chanda, P.K.; Chen, J.M.; Cosmi, S.; Edris, W.; Levin, J.I.; Powers, R.
High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor
J. Mol. Biol.
302
671-689
2000
Homo sapiens (P45452), Homo sapiens
brenda
Kohno, T.; Hochigai, H.; Yamashita, E.; Tsukihara, T.; Kanaoka, M.
Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453
Biochem. Biophys. Res. Commun.
344
315-322
2006
Homo sapiens (P45452), Homo sapiens
brenda
Bikadi, Z.; Hazai, E.; Zsila, F.; Lockwood, S.F.
Molecular modeling of non-covalent binding of homochiral (3S,3S)-astaxanthin to matrix metalloproteinase-13 (MMP-13)
Bioorg. Med. Chem.
14
5451-5458
2006
Homo sapiens (P45452), Homo sapiens
brenda
Noe, M.C.; Snow, S.L.; Wolf-Gouveia, L.A.; Mitchell, P.G.; Lopresti-Morrow, L.; Reeves, L.M.; Yocum, S.A.; Liras, J.L.; Vaughn, M.
3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase
Bioorg. Med. Chem. Lett.
14
4727-4730
2004
Homo sapiens
brenda
Kim, S.H.; Pudzianowski, A.T.; Leavitt, K.J.; Barbosa, J.; McDonnell, P.A.; Metzler, W.J.; Rankin, B.M.; Liu, R.; Vaccaro, W.; Pitts, W.
Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13)
Bioorg. Med. Chem. Lett.
15
1101-1106
2005
Homo sapiens
brenda
Engel, C.K.; Pirard, B.; Schimanski, S.; Kirsch, R.; Habermann, J.; Klingler, O.; Schlotte, V.; Weithmann, K.U.; Wendt, K.U.
Structural basis for the highly selective inhibition of MMP-13
Chem. Biol.
12
181-189
2005
Homo sapiens (P45452)
brenda
Sulkala, M.; Paeaekkoenen, V.; Larmas, M.; Salo, T.; Tjaederhane, L.
Matrix metalloproteinase-13 (MMP-13, collagenase-3) is highly expressed in human tooth pulp
Connect. Tissue Res.
45
231-237
2004
Homo sapiens
brenda
Corte, M.D.; Gonzalez, L.O.; Corte, M.G.; Quintela, I.; Pidal, I.; Bongera, M.; Vizoso, F.
Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma
Int. J. Biol. Markers
20
242-248
2006
Homo sapiens
brenda
Toriseva, M.J.; Ala-Aho, R.; Karvinen, J.; Baker, A.H.; Marjomaeki, V.S.; Heino, J.; Kaehaeri, V.M.
Collagenase-3 (MMP-13) enhances remodeling of three-dimensional collagen and promotes survival of human skin fibroblasts
J. Invest. Dermatol.
127
49-59
2006
Homo sapiens
brenda
Kuivanen, T.T.; Jeskanen, L.; Kylloenen, L.; Impola, U.; Saarialho-Kere, U.K.
Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13, are present in epithelial cells of keratoacanthomas
Mod. Pathol.
19
1203-1212
2006
Homo sapiens
brenda
Leonardi, R.; Loreto, C.; Barbato, E.; Caltabiano, R.; Lombardo, C.; Musumeci, G.; Muzio, L.L.
MMP-13 (collagenase 3) localization in human temporomandibular joint discs with internal derangement
Acta Histochem.
110
314-318
2008
Homo sapiens
brenda
Suri, L.; Damoulis, P.D.; Le, T.; Gagari, E.
Expression of MMP-13 (collagenase-3) in long-term cultures of human dental pulp cells
Arch. Oral Biol.
53
791-799
2008
Homo sapiens
brenda
Maskos, K.; Lang, R.; Tschesche, H.; Bode, W.
Flexibility and variability of TIMP binding: X-ray structure of the complex between collagenase-3/MMP-13 and TIMP-2
J. Mol. Biol.
366
1222-1231
2007
Homo sapiens (P45452), Homo sapiens
brenda
Leivonen, S.K.; Ala-Aho, R.; Koli, K.; Grenman, R.; Peltonen, J.; Kaehaeri, V.M.
Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells
Oncogene
25
2588-2600
2006
Homo sapiens
brenda
Rodriguez Faba, O.; Fernandez Gomez, J.M.; Palou Redorta, J.; Escaf Barmadah, S.; Vizoso, F.; Villavicencio Mavrich, H.
Significance of collagenase 3 (matrix metalloproteinase 13) in invasive bladder cancer: correlation with pathological parameters
Urol. Int.
78
140-144
2007
Homo sapiens
brenda
Zhang, B.; Cao, X.; Liu, Y.; Cao, W.; Zhang, F.; Zhang, S.; Li, H.; Ning, L.; Fu, L.; Niu, Y.; Niu, R.; Sun, B.; Hao, X.
Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer
BMC Cancer
8
83
2008
Homo sapiens
brenda
Cuadrado, E.; Rosell, A.; Borrell-Pages, M.; Garcia-Bonilla, L.; Hernandez-Guillamon, M.; Ortega-Aznar, A.; Montaner, J.
Matrix metalloproteinase-13 is activated and is found in the nucleus of neural cells after cerebral ischemia
J. Cereb. Blood Flow Metab.
29
398-410
2009
Homo sapiens, Rattus norvegicus
brenda
Monovich, L.G.; Tommasi, R.A.; Fujimoto, R.A.; Blancuzzi, V.; Clark, K.; Cornell, W.D.; Doti, R.; Doughty, J.; Fang, J.; Farley, D.; Fitt, J.; Ganu, V.; Goldberg, R.; Goldstein, R.; Lavoie, S.; Kulathila, R.; Macchia, W.; Parker, D.T.; Melton, R.; OByrne, E.; Pastor, G.; Pellas, T.; Quadros, E.; Reel, N.
Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13
J. Med. Chem.
52
3523-3538
2009
Homo sapiens, Rattus norvegicus
brenda
Sakao, K.; Takahashi, K.A.; Mazda, O.; Arai, Y.; Tonomura, H.; Inoue, A.; Saito, M.; Fujioka, M.; Takamiya, H.; Imanishi, J.; Kubo, T.
Enhanced expression of interleukin-6, matrix metalloproteinase-13, and receptor activator of NF-kappaB ligand in cells derived from osteoarthritic subchondral bone
J. Orthop. Sci.
13
202-210
2008
Homo sapiens
brenda
Ahmad, R.; Sylvester, J.; Ahmad, M.; Zafarullah, M.
Adaptor proteins and Ras synergistically regulate IL-1-induced ADAMTS-4 expression in human chondrocytes
J. Immunol.
182
5081-5087
2009
Homo sapiens (P45452)
brenda
Kolodziej, S.A.; Hockerman, S.L.; Boehm, T.L.; Carroll, J.N.; DeCrescenzo, G.A.; McDonald, J.J.; Mischke, D.A.; Munie, G.E.; Fletcher, T.R.; Rico, J.G.; Stehle, N.W.; Swearingen, C.; Becker, D.P.
Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates
Bioorg. Med. Chem. Lett.
20
3557-3560
2010
Homo sapiens
brenda
Luukkaa, H.; Klemi, P.; Leivo, I.; Maekitie, A.A.; Irish, J.; Gilbert, R.; Perez-Ordonez, B.; Hirsimaeki, P.; Vahlberg, T.; Kivisaari, A.; Kaehaeri, V.M.; Grenman, R.
Expression of matrix metalloproteinase-1, -7, -9, -13, Ki-67, and HER-2 in epithelial-myoepithelial salivary gland cancer
Head Neck
32
1019-1027
2009
Homo sapiens
brenda
Ansell, A.; Jerhammar, F.; Ceder, R.; Grafstroem, R.; Grenman, R.; Roberg, K.
Matrix metalloproteinase-7 and -13 expression associate to cisplatin resistance in head and neck cancer cell lines
Oral Oncol.
45
866-871
2009
Homo sapiens
brenda
Lausch, E.; Keppler, R.; Hilbert, K.; Cormier-Daire, V.; Nikkel, S.; Nishimura, G.; Unger, S.; Spranger, J.; Superti-Furga, A.; Zabel, B.
Mutations in MMP9 and MMP13 determine the mode of inheritance and the clinical spectrum of metaphyseal anadysplasia
Am. J. Hum. Genet.
85
168-178
2009
Mus musculus, Homo sapiens (P45452), Homo sapiens
brenda
Choi, H.M.; Lee, Y.A.; Lee, S.H.; Hong, S.J.; Hahm, D.H.; Choi, S.Y.; Yang, H.I.; Yoo, M.C.; Kim, K.S.
Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators
Arthritis Res. Ther.
11
R161
2009
Homo sapiens
brenda
Rasheed, Z.; Anbazhagan, A.N.; Akhtar, N.; Ramamurthy, S.; Voss, F.R.; Haqqi, T.M.
Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes
Arthritis Res. Ther.
11
R71
2009
Homo sapiens
brenda
Baragi, V.M.; Becher, G.; Bendele, A.M.; Biesinger, R.; Bluhm, H.; Boer, J.; Deng, H.; Dodd, R.; Essers, M.; Feuerstein, T. et al.
A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models
Arthritis Rheum.
60
2008-2018
2009
Bos taurus, Homo sapiens, Rattus norvegicus
brenda
Hayashida, M.; Okazaki, K.; Fukushi, J.; Sakamoto, A.; Iwamoto, Y.
CCAAT/enhancer binding protein beta mediates expression of matrix metalloproteinase 13 in human articular chondrocytes in inflammatory arthritis
Arthritis Rheum.
60
708-716
2009
Homo sapiens
brenda
Akhtar, N.; Rasheed, Z.; Ramamurthy, S.; Anbazhagan, A.N.; Voss, F.R.; Haqqi, T.M.
MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes
Arthritis Rheum.
62
1361-1371
2010
Homo sapiens
brenda
Borzi, R.M.; Olivotto, E.; Pagani, S.; Vitellozzi, R.; Neri, S.; Battistelli, M.; Falcieri, E.; Facchini, A.; Flamigni, F.; Penzo, M.; Platano, D.; Santi, S.; Facchini, A.; Marcu, K.B.
Matrix metalloproteinase 13 loss associated with impaired extracellular matrix remodeling disrupts chondrocyte differentiation by concerted effects on multiple regulatory factors
Arthritis Rheum.
62
2370-2381
2010
Homo sapiens
brenda
Settle, S.; Vickery, L.; Nemirovskiy, O.; Vidmar, T.; Bendele, A.; Messing, D.; Ruminski, P.; Schnute, M.; Sunyer, T.
Cartilage degradation biomarkers predict efficacy of a novel highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: Multivariate analysis confirmed that modulation of type II collagen aggrecan degradation peptides paralle
Arthritis Rheum.
62
3006-3015
2010
Canis lupus familiaris, Homo sapiens
brenda
Lu, D.Y.; Leung, Y.M.; Cheung, C.W.; Chen, Y.R.; Wong, K.L.
Glial cell line-derived neurotrophic factor induces cell migration and matrix metalloproteinase-13 expression in glioma cells
Biochem. Pharmacol.
80
1201-1209
2010
Homo sapiens
brenda
Li, W.; Hu, Y.; Li, J.; Thomason, J.R.; DeVincentis, D.; Du, X.; Wu, J.; Hotchandani, R.; Rush, T.S.; Skotnicki, J.S.; Tam, S.; Chockalingam, P.S.; Morris, E.A.; Levin, J.I.
3,4-Disubstituted benzofuran P1 MMP-13 inhibitors: optimization of selectivity and reduction of protein binding
Bioorg. Med. Chem. Lett.
19
4546-4550
2009
Homo sapiens
brenda
Heim-Riether, A.; Taylor, S.J.; Liang, S.; Gao, D.A.; Xiong, Z.; Michael August, E.; Collins, B.K.; Farmer, B.T.; Haverty, K.; Hill-Drzewi, M.; Junker, H.D.; Mariana Margarit, S.; Moss, N.; Neumann, T.; Proudfoot, J.R.; Keenan, L.S.; Sekul, R.; Zhang, Q.; Li, J.; Farrow, N.A.
Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors
Bioorg. Med. Chem. Lett.
19
5321-5324
2009
Homo sapiens
brenda
Kolodziej, S.A.; Hockerman, S.L.; DeCrescenzo, G.A.; McDonald, J.J.; Mischke, D.A.; Munie, G.E.; Fletcher, T.R.; Stehle, N.; Swearingen, C.; Becker, D.P.
MMP-13 selective isonipecotamide alpha-sulfone hydroxamates
Bioorg. Med. Chem. Lett.
20
3561-3564
2010
Homo sapiens
brenda
Gao, D.A.; Xiong, Z.; Heim-Riether, A.; Amodeo, L.; August, E.M.; Cao, X.; Ciccarelli, L.; Collins, B.K.; Harrington, K.; Haverty, K.; Hill-Drzewi, M.; Li, X.; Liang, S.; Margarit, S.M.; Moss, N.; Nagaraja, N.; Proudfoot, J.; Roman, R.; Schlyer, S.; Keenan, L.S.; Taylor, S.; Wellenzohn, B.; Wiedenmayer, D.; Li, J.; Farrow, N.A.
SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability
Bioorg. Med. Chem. Lett.
20
5039-5043
2010
Homo sapiens
brenda
Schnute, M.E.; OBrien, P.M.; Nahra, J.; Morris, M.; Howard Roark, W.; Hanau, C.E.; Ruminski, P.G.; Scholten, J.A.; Fletcher, T.R.; Hamper, B.C.; Carroll, J.N.; Patt, W.C.; Shieh, H.S.; Collins, B.; Pavlovsky, A.G.; Palmquist, K.E.; Aston, K.W.; Hitchcock, J.; Rogers, M.D.; McDonald, J.; Johnson, A.R.; Munie, G.E.
Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis
Bioorg. Med. Chem. Lett.
20
576-580
2010
Homo sapiens (P45452)
brenda
Ziegler, N.; Alonso, A.; Steinberg, T.; Woodnutt, D.; Kohl, A.; Muessig, E.; Schulz, S.; Tomakidi, P.
Mechano-transduction in periodontal ligament cells identifies activated states of MAP-kinases p42/44 and p38-stress kinase as a mechanism for MMP-13 expression
BMC Cell Biol.
11
10
2010
Homo sapiens
brenda
Tardif, G.; Hum, D.; Pelletier, J.; Duval, N.; Martel-Pelletier, J.
Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes
BMC Musculoskelet. Disord.
10
148
2009
Homo sapiens
brenda
Mak, I.W.; Cowan, R.W.; Popovic, S.; Colterjohn, N.; Singh, G.; Ghert, M.
Upregulation of MMP-13 via Runx2 in the stromal cell of Giant Cell Tumor of bone
Bone
45
377-386
2009
Homo sapiens (P45452)
brenda
Ma, O.; Cai, W.W.; Zender, L.; Dayaram, T.; Shen, J.; Herron, A.J.; Lowe, S.W.; Man, T.K.; Lau, C.C.; Donehower, L.A.
MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression
Cancer Res.
69
2559-2567
2009
Homo sapiens, Mus musculus
brenda
Tan, T.W.; Yang, W.H.; Lin, Y.T.; Hsu, S.F.; Li, T.M.; Kao, S.T.; Chen, W.C.; Fong, Y.C.; Tang, C.H.
Cyr61 increases migration and MMP-13 expression via alphavbeta3 integrin, FAK, ERK and AP-1-dependent pathway in human chondrosarcoma cells
Carcinogenesis
30
258-268
2009
Homo sapiens
brenda
Lecomte, J.; Louis, K.; Detry, B.; Blacher, S.; Lambert, V.; Bekaert, S.; Munaut, C.; Paupert, J.; Blaise, P.; Foidart, J.M.; Rakic, J.M.; Krane, S.M.; Noel, A.
Bone marrow-derived mesenchymal cells and MMP13 contribute to experimental choroidal neovascularization
Cell. Mol. Life Sci.
68
677-686
2011
Homo sapiens (P45452), Homo sapiens, Mus musculus, Mus musculus C57BL/6
brenda
Kim, K.S.; Oh, d.a..H.; Choi, H.M.; Bang, J.S.; Ryu, C.J.; Kim, J.H.; Yoo, M.C.; Yang, H.I.
Pyrrolidine dithiocarbamate, a NF-kappaB inhibitor, upregulates MMP-1 and MMP-13 in IL-1beta-stimulated rheumatoid arthritis fibroblast-like synoviocytes
Eur. J. Pharmacol.
613
167-175
2009
Homo sapiens
brenda
Mak, I.W.; Seidlitz, E.P.; Cowan, R.W.; Turcotte, R.E.; Popovic, S.; Wu, W.C.; Singh, G.; Ghert, M.
Evidence for the role of matrix metalloproteinase-13 in bone resorption by giant cell tumor of bone
Hum. Pathol.
41
1320-1329
2010
Homo sapiens, Mus musculus
brenda
Kumamoto, K.; Fujita, K.; Kurotani, R.; Saito, M.; Unoki, M.; Hagiwara, N.; Shiga, H.; Bowman, E.D.; Yanaihara, N.; Okamura, S.; Nagashima, M.; Miyamoto, K.; Takenoshita, S.; Yokota, J.; Harris, C.C.
ING2 is upregulated in colon cancer and increases invasion by enhanced MMP13 expression
Int. J. Cancer
125
1306-1315
2009
Homo sapiens
brenda
Yang, L.; Guo, A.; Gu, J.C.
c-Jun N-terminal kinase and nuclear factor kappaB mediate nitric oxide-induced expression of matrix metalloproteinase-13
Int. Orthop.
35
1261-1266
2011
Homo sapiens
brenda
Tan, T.W.; Lai, C.H.; Huang, C.Y.; Yang, W.H.; Chen, H.T.; Hsu, H.C.; Fong, Y.C.; Tang, C.H.
CTGF enhances migration and MMP-13 up-regulation via alphanybeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells
J. Cell. Biochem.
107
345-356
2009
Homo sapiens
brenda
Hernandez Rios, M.; Sorsa, T.; Obregon, F.; Tervahartiala, T.; Valenzuela, M.A.; Pozo, P.; Dutzan, N.; Lesaffre, E.; Molas, M.; Gamonal, J.
Proteolytic roles of matrix metalloproteinase (MMP)-13 during progression of chronic periodontitis: initial evidence for MMP-13/MMP-9 activation cascade
J. Clin. Periodontol.
36
1011-1017
2009
Homo sapiens
brenda
Pirhan, D.; Atilla, G.; Emingil, G.; Tervahartiala, T.; Sorsa, T.; Berdeli, A.
MMP-13 promoter polymorphisms in patients with chronic periodontitis: effects on GCF MMP-13 levels and outcome of periodontal therapy
J. Clin. Periodontol.
36
474-481
2009
Homo sapiens
brenda
Hong, H.; Park, Y.K.; Choi, M.S.; Ryu, N.H.; Song, D.K.; Suh, S.I.; Nam, K.Y.; Park, G.Y.; Jang, B.C.
Differential down-regulation of COX-2 and MMP-13 in human skin fibroblasts by glucosamine-hydrochloride
J. Dermatol. Sci.
56
43-50
2009
Homo sapiens
brenda
Blaney Davidson, E.N.; Remst, D.F.; Vitters, E.L.; van Beuningen, H.M.; Blom, A.B.; Goumans, M.J.; van den Berg, W.B.; van der Kraan, P.M.
Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans and mice
J. Immunol.
182
7937-7945
2009
Homo sapiens, Mus musculus
brenda
Nuti, E.; Casalini, F.; Avramova, S.I.; Santamaria, S.; Cercignani, G.; Marinelli, L.; La Pietra, V.; Novellino, E.; Orlandini, E.; Nencetti, S.; Tuccinardi, T.; Martinelli, A.; Lim, N.H.; Visse, R.; Nagase, H.; Rossello, A.
N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis
J. Med. Chem.
52
4757-4773
2009
Homo sapiens (P45452)
brenda
Fortier, L.A.; Motta, T.; Greenwald, R.A.; Divers, T.J.; Mayr, K.G.
Synoviocytes are more sensitive than cartilage to the effects of minocycline and doxycycline on IL-1alpha and MMP-13-induced catabolic gene responses
J. Orthop. Res.
28
522-528
2010
Homo sapiens
brenda
Julovi, S.M.; Ito, H.; Nishitani, K.; Jackson, C.J.; Nakamura, T.
Hyaluronan inhibits matrix metalloproteinase-13 in human arthritic chondrocytes via CD44 and P38
J. Orthop. Res.
29
258-264
2010
Homo sapiens
brenda
Tabuchi, S.; Sakuta, T.; Oyama, T.; Tokuda, M.; Tatsuyama, S.; Kajihara, T.; Nagaoka, S.; Beppu, M.; Sugihara, K.; Ikebe, T.; Shirasuna, K.; Torii, M.
Runt-related gene 2 is involved in the inhibition of matrix metalloproteinase-13 expression by roxithromycin in human gingival epithelial cell cultures
J. Periodontal Res.
44
283-288
2009
Homo sapiens
brenda
Kimura, H.; Yukitake, H.; Suzuki, H.; Tajima, Y.; Gomaibashi, K.; Morimoto, S.; Funabashi, Y.; Yamada, K.; Takizawa, M.
The chondroprotective agent ITZ-1 inhibits interleukin-1beta-induced matrix metalloproteinase-13 production and suppresses nitric oxide-induced chondrocyte death
J. Pharmacol. Sci.
110
201-211
2009
Homo sapiens, Rattus norvegicus
brenda
Li, J.J.; Johnson, A.R.
Selective MMP13 inhibitors
Med. Res. Rev.
31
863-894
2011
Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Im, H.; Sharrocks, A.; Lin, X.; Yan, D.; Kim, J.; Van Wijnen, A.; Hipskind, R.
Basic fibroblast growth factor induces matrix metalloproteinase-13 via eRK MAP kinase-altered phosphorylation and sumoylation of Elk-1 in human adult articular chondrocytes
Open Access Rheumatol.
1
151-161
2009
Homo sapiens
brenda
Kardesler, L.; Biyikoglu, B.; Cetinkalp, S.; Pitkala, M.; Sorsa, T.; Buduneli, N.
Crevicular fluid matrix metalloproteinase-8, -13, and TIMP-1 levels in type 2 diabetics
Oral Dis.
16
476-481
2010
Homo sapiens
brenda
Leonardi, R.; Matthews, J.B.; Caltabiano, R.; Greco, M.; Lombardo, C.; Loreto, C.; Santarelli, A.; Muzio, L.L.
MMP-13 expression in keratocyst odontogenic tumour associated with NBCCS and sporadic keratocysts
Oral Dis.
16
795-800
2010
Homo sapiens
brenda
Ahmad, R.; El Mabrouk, M.; Sylvester, J.; Zafarullah, M.
Human osteoarthritic chondrocytes are impaired in matrix metalloproteinase-13 inhibition by IFN-gamma due to reduced IFN-gamma receptor levels
Osteoarthritis Cartilage
17
1049-1055
2009
Homo sapiens
brenda
Long, D.L.; Loeser, R.F.
p38gamma mitogen-activated protein kinase suppresses chondrocyte production of MMP-13 in response to catabolic stimulation
Osteoarthritis Cartilage
18
1203-1210
2010
Homo sapiens
brenda
Kothapalli, R.; Khan, A.M.; Basappa, A.M.; Gopalsamy, A.; Chong, Y.S.; Annamalai, L.
Cheminformatics-based drug design approach for identification of inhibitors targeting the characteristic residues of MMP-13 hemopexin domain
PLoS ONE
5
e12494
2010
Homo sapiens
brenda
Kim, K.S.; Choi, H.M.; Lee, Y.A.; Choi, I.A.; Lee, S.H.; Hong, S.J.; Yang, H.I.; Yoo, M.C.
Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis
Rheumatol. Int.
31
543-547
2010
Homo sapiens
brenda
Li, C.H.; Cheng, Y.W.; Liao, P.L.; Yang, Y.T.; Kang, J.J.
Chloramphenicol causes mitochondrial stress, decreases ATP biosynthesis, induces matrix metalloproteinase-13 expression, and solid-tumor cell invasion
Toxicol. Sci.
116
140-150
2010
Homo sapiens
brenda
Giano, M.C.; Pochan, D.J.; Schneider, J.P.
Controlled biodegradation of self-assembling beta-hairpin peptide hydrogels by proteolysis with matrix metalloproteinase-13
Biomaterials
32
6471-6477
2011
Homo sapiens
brenda
Fobian, Y.M.; Freskos, J.N.; Barta, T.E.; Bedell, L.J.; Heintz, R.; Kassab, D.J.; Kiefer, J.R.; Mischke, B.V.; Molyneaux, J.M.; Mullins, P.; Munie, G.E.; Becker, D.P.
MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1 amides
Bioorg. Med. Chem. Lett.
21
2823-2825
2011
Homo sapiens
brenda
De Savi, C.; Morley, A.D.; Ting, A.; Nash, I.; Karabelas, K.; Wood, C.M.; James, M.; Norris, S.J.; Karoutchi, G.; Rankine, N.; Hamlin, G.; Macfaul, P.A.; Ryan, D.; Baker, S.V.; Hargreaves, D.; Gerhardt, S.
Selective non zinc binding inhibitors of MMP13
Bioorg. Med. Chem. Lett.
21
4215-4219
2011
Homo sapiens
brenda
Tommasi, R.A.; Weiler, S.; McQuire, L.W.; Rogel, O.; Chambers, M.; Clark, K.; Doughty, J.; Fang, J.; Ganu, V.; Grob, J.; Goldberg, R.; Goldstein, R.; Lavoie, S.; Kulathila, R.; Macchia, W.; Melton, R.; Springer, C.; Walker, M.; Zhang, J.; Zhu, L.; Shultz, M.
Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13
Bioorg. Med. Chem. Lett.
21
6440-6445
2011
Homo sapiens
brenda
Vicini, P.; Crasc, L.; Incerti, M.; Ronsisvalle, S.; Cardile, V.; Panico, A.
Benzisothiazolyliminothiazolidin-4-ones with chondroprotective properties: Searching for potent and selective inhibitors of MMP-13
ChemMedChem
6
1199-1202
2011
Homo sapiens (P45452)
brenda
Zhang, L.; Yang, M.; Yang, D.; Cavey, G.; Davidson, P.; Gibson, G.
Molecular interactions of MMP-13 C-terminal domain with chondrocyte proteins
Connect. Tissue Res.
51
230-239
2010
Homo sapiens
brenda
Taylor, S.J.; Abeywardane, A.; Liang, S.; Muegge, I.; Padyana, A.K.; Xiong, Z.; Hill-Drzewi, M.; Farmer, B.; Li, X.; Collins, B.; Li, J.X.; Heim-Riether, A.; Proudfoot, J.; Zhang, Q.; Goldberg, D.; Zuvela-Jelaska, L.; Zaher, H.; Li, J.; Farrow, N.A.
Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13
J. Med. Chem.
54
8174-8187
2011
Homo sapiens
brenda
Meierjohann, S.; Hufnagel, A.; Wende, E.; Kleinschmidt, M.A.; Wolf, K.; Friedl, P.; Gaubatz, S.; Schartl, M.
MMP13 mediates cell cycle progression in melanocytes and melanoma cells: in vitro studies of migration and proliferation
Mol. Cancer
9
201
2010
Homo sapiens, Mus musculus
brenda
Naito, S.; Takahashi, T.; Onoda, J.; Yamauchi, A.; Kawai, T.; Kishino, J.; Yamane, S.; Fujii, I.; Fukui, N.; Numata, Y.
Development of a neutralizing antibody specific for the active form of matrix metalloproteinase-13
Biochemistry
51
8877-8884
2012
Homo sapiens (P45452), Homo sapiens
brenda
Nara, H.; Sato, K.; Naito, T.; Mototani, H.; Oki, H.; Yamamoto, Y.; Kuno, H.; Santou, T.; Kanzaki, N.; Terauchi, J.; Uchikawa, O.; Kori, M.
Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: Highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1'' binding site
Bioorg. Med. Chem.
22
5487-5505
2014
Homo sapiens (P45452)
brenda
Lu, H.; Wang, S.; Li, Q.; Wang, Y.
Design, synthesis and evaluation of 6-oxo-1, 6-dihydropyrimidine-2,5-dicarboxamide derivatives as MMP 13 inhibitors
Chem. Res. Chin. Univ.
29
67-70
2013
Homo sapiens (P45452)
-
brenda
Stura, E.A.; Visse, R.; Cuniasse, P.; Dive, V.; Nagase, H.
Crystal structure of full-length human collagenase 3 (MMP-13) with peptides in the active site defines exosites in the catalytic domain
FASEB J.
27
4395-4405
2013
Homo sapiens (P45452), Homo sapiens
brenda
Howes, J.M.; Bihan, D.; Slatter, D.A.; Hamaia, S.W.; Packman, L.C.; Knauper, V.; Visse, R.; Farndale, R.W.
The recognition of collagen and triple-helical toolkit peptides by MMP-13: sequence specificity for binding and cleavage
J. Biol. Chem.
289
24091-24101
2014
Homo sapiens (P45452)
brenda
Nara, H.; Sato, K.; Naito, T.; Mototani, H.; Oki, H.; Yamamoto, Y.; Kuno, H.; Santou, T.; Kanzaki, N.; Terauchi, J.; Uchikawa, O.; Kori, M.
Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach
J. Med. Chem.
57
8886-8902
2014
Homo sapiens (P45452)
brenda
Filomia, F.; Saxena, P.; Durante, C.; De Rienzo, F.; Cocchi, M.; Menziani, M.
Computational insights into ADAMTS4, ADAMTS5 and MMP13 inhibitor selectivity
Mol. Inform.
31
421-430
2012
Homo sapiens (P45452)
brenda
Nara, H.; Sato, K.; Kaieda, A.; Oki, H.; Kuno, H.; Santou, T.; Kanzaki, N.; Terauchi, J.; Uchikawa, O.; Kori, M.
Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors
Bioorg. Med. Chem.
24
6149-6165
2016
Homo sapiens (P45452)
brenda
Satish Kumar, K.; Velayutham, R.; Roy, K.K.
A systematic computational analysis of human matrix metalloproteinase 13 (MMP-13) crystal structures and structure-based identification of prospective drug candidates as MMP-13 inhibitors repurposable for osteoarthritis
J. Biomol. Struct. Dyn.
12
1-13
2019
Homo sapiens (P45452), Homo sapiens
brenda
Zhang, R.; Zhang, L.; Li, C.; Chen, B.; Li, Q.; Fang, X.; Shen, Y.
Refolding of recombinant histidine-tagged catalytic domain of MMP-13 from escherichia coli with ion-exchange chromatography for higher bioactivity
J. Liq. Chromatogr. Relat. Technol.
38
561-568
2015
Homo sapiens
-
brenda
Prystupa, A.; Szpetnar, M.; Boguszewska-Czubara, A.; Grzybowski, A.; Sak, J.; Zaluska, W.
Activity of MMP1 and MMP13 and amino acid metabolism in patients with alcoholic liver cirrhosis
Med. Sci. Monit.
21
1008-1014
2015
Homo sapiens (P45452), Homo sapiens
brenda